Professor Eugene McCloskey

MD, FRCPI

Clinical Medicine, School of Medicine and Population Health

Professor in Adult Bone Disease

Honorary Consultant

E.V.McCloskey@sheffield.ac.uk
+44 114 215 9695

+44 114 215 9236

+44 114 261 8775 (fax)

Metabolic Bone Centre, Sorby Wing, Northern General Hospital

Office EU14 at the Medical School

Full contact details

Professor Eugene McCloskey
Clinical Medicine, School of Medicine and Population Health
Metabolic Bone Centre, Sorby Wing
Northern General Hospital
Herries Road
Sheffield
S5 7AU

Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

Born in Loughgiel, Northern Ireland, I studied medicine at Trinity College Dublin before arriving in Sheffield in 1985 via house officer posts in Ayrshire.

Research interests

I developed my longstanding interest in metabolic bone diseases via an MRC Training Fellowship. My initial interests were in the field of malignant bone disease, but subsequently focussed on osteoporosis. I have been the principal investigator in a number of MRC and pharmaceutical industry-funded studies.

I am an acknowledged expert in the fields of vertebral fracture definition, osteoporosis epidemiology as well as non-invasive assessments of bone strength and fracture risk. I have published over 150 peer-reviewed articles, book chapters, guidelines, and reviews.

Current Projects

FRAX and fracture risk assessment
Interaction between physical and pharmaceutical interventions

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R, Gittoes N, Harvey I, Harvey N, Heawood A , Holland R et al (2018) Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. The Lancet, 391(10122), 741-747. View this article in WRRO
Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C & IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide.. Osteoporos Int, 23(9), 2239-2256.
Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G , Johansson H et al (2011) Interpretation and use of FRAX in clinical practice.. Osteoporos Int, 22(9), 2395-2411.
McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T & Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study.. Osteoporos Int, 20(5), 811-817.
Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A & National Osteoporosis Guideline Group (2008) Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.. Osteoporos Int, 19(10), 1395-1408.
Kanis JA, Johnell O, Oden A, Johansson H & McCloskey E (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporosis International, 19(4), 385-397.
Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ & Khaltaev N (2008) A reference standard for the description of osteoporosis.. Bone, 42(3), 467-475.
McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, Orgee J, Ashford R, Forster M, Cliffe J , Kersh L et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study.. J Bone Miner Res, 22(1), 135-141.
Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H , McCloskey EV et al (2004) A meta-analysis of previous fracture and subsequent fracture risk.. Bone, 35(2), 375-382.
Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S , Pajunen M et al (2002) Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer. Journal of Clinical Oncology, 20(15), 3219-3224.
McCloskey EV, Dunn JA, Kanis JA, MacLennan IC & Drayson MT (2001) Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma.. Br J Haematol, 113(4), 1035-1043.
McCloskey EV, MacLennan ICM, Drayson MT, Chapman C, Dunn J, Kanis JA & MRC Working Party Leukaemia Adults (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. BRIT J HAEMATOL, 100(2), 317-325.
McCloskey EV, Spector TD, Eyres KS, Fern ED, O'Rourke N, Vasikaran S & Kanis JA (1993) The assessment of vertebral deformity: a method for use in population studies and clinical trials.. Osteoporos Int, 3(3), 138-147.

All publications

Journal articles

Gandham A, Gregori G, Johansson L, Larsson BAM, Johansson H, Harvey NC, Vandenput L, McCloskey E, Kanis JA, Litsne H , Axelsson K et al (2024) Sarcopenia definitions and their association with injurious falls in older Swedish women from the Sahlgrenska University Hospital Prospective Evaluation of Risk of Bone fractures (SUPERB) study. Osteoporosis International, 1-10.
Kistler-Fischbacher M, Armbrecht G, Gängler S, Theiler R, Rizzoli R, Dawson-Hughes B, Kanis JA, Hofbauer LC, Schimmer RC, Vellas B , Da Silva JAP et al (2024) Effects of vitamin D3, omega-3s, and a simple strength training exercise program on bone health: the DO-HEALTH randomized controlled trial. Journal of Bone and Mineral Research, 39(6), 661-671.
Tai T-W, Chen H-Y, Shih C-A, Huang C-F, McCloskey E, Lee J-K, Yeap SS, Cheung C-L, Charatcharoenwitthaya N, Jaisamrarn U , Kuptniratsaikul V et al (2024) Asia-Pacific consensus on long-term and sequential therapy for osteoporosis. Osteoporosis and Sarcopenia.
Jones C, Gray S, Brown M, Brown J, McCloskey E, Rai BP, Clarke N & Sachdeva A (2024) Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled Trials. European Urology Oncology.
Goel H, Binkley N, Boggild M, Chan WP, Leslie WD, McCloskey E, Morgan SL, Silva BC & Cheung AM (2024) Clinical Use of Trabecular Bone Score: The 2023 ISCD Official Positions. Journal of Clinical Densitometry, 27(1), 101452-101452.
Johansson H, Pandey D, Lorentzon M, Harvey NC, McCloskey EV & Kanis JA (2023) A surrogate FRAX model for Nepal. Archives of Osteoporosis, 19(1), S269-S269.
Albergaria BH, Zerbini CAF, Lazaretti-Castro M, Eis SR, Vilaca T, Johansson H, Harvey NC, Liu E, Vandenput L, Lorentzon M , Schini M et al (2023) A new FRAX model for Brazil. Archives of Osteoporosis, 18(1). View this article in WRRO
Leslie WD, Binkley N, Goel H, Hans D & McCloskey EV (2023) Adjusting Trabecular Bone Score (TBS) for Level-specific Differences Reduces FRAX®-based Treatment Reclassification in Patients with Vertebral Exclusions: The Manitoba BMD Registry. Journal of Clinical Densitometry, 101429-101429.
Leslie WD, Binkley N, Goel H, McCloskey EV & Hans D (2023) FRAX® adjustment using renormalized trabecular bone score (TBS) from L1 alone may be optimal for fracture prediction: The Manitoba BMD registry. Journal of Clinical Densitometry, 26(4), 101430-101430.
López Gavilánez E, Johansson H, Harvey N, Lorentzon M, McCloskey E, Valdivieso Jara J & Kanis JA (2023) The application of FRAX in Ecuador. Revista Colombiana de Reumatología (English Edition), 30(3), 199-206.
Leslie WD, Binkley N, Goel H, Hans D & McCloskey EV (2023) Trabecular Bone Score Vertebral Exclusions Affect Risk Classification and Treatment Recommendations: The Manitoba BMD Registry. Journal of Clinical Densitometry, 101415-101415.
Yeh EJ, Gitlin M, Sorio F & McCloskey E (2023) Estimating the future clinical and economic benefits of improving osteoporosis diagnosis and treatment among postmenopausal women across eight European countries. Archives of Osteoporosis, 18.
Ye C, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC, Kanis JA & Leslie WD (2023) Performance of FRAX in men with prostate cancer: a registry-based cohort study. Journal of Bone and Mineral Research.
Leslie WD, Binkley N, Hans D & McCloskey EV (2023) Vertebral Level Variations in Trabecular Bone Score and Effect on Fracture Prediction: The Manitoba BMD Registry. Journal of Clinical Densitometry.
Leslie WD, Goel H, Binkley N, McCloskey EV & Hans D (2023) Contributions of clinical and technical factors to longitudinal change in trabecular bone score and bone density: a registry‐based individual‐level analysis. Journal of Bone and Mineral Research.
Westbury LD, Beaudart C, Bruyère O, Cauley JA, Cawthon P, Cruz‐Jentoft AJ, Curtis EM, Ensrud K, Fielding RA, Johansson H , Kanis JA et al (2023) Recent sarcopenia definitions—prevalence, agreement and mortality associations among men: findings from population‐based cohorts. Journal of Cachexia, Sarcopenia and Muscle.
Payer J, Vyskočil V & McCloskey E (2023) Award of top experts and collaborators of the Society for Metabolic Diseases of the Skeleton ČLS JEP. Clinical Osteology(3), 49.
Leslie WD, Binkley N, McCloskey EV, Johansson H, Harvey NC, Lorentzon M, Kanis JA & Hans D (2023) FRAX Adjustment by Trabecular Bone Score with or Without Bone Mineral Density: The Manitoba BMD Registry. Journal of Clinical Densitometry, 101378-101378.
Haarhaus M, Aaltonen L, Cejka D, Cozzolino M, de Jong RT, D'Haese P, Evenepoel P, Lafage-Proust M-H, Mazzaferro S, McCloskey E , Salam S et al (2023) Management of fracture risk in CKD—traditional and novel approaches. Clinical Kidney Journal, 16(3), 456-472.
Schini M, Bhatia P, Shreef H, Johansson H, Harvey NC, Lorentzon M, Kanis JA, Bandman O & McCloskey EV (2022) Increased fracture risk in Parkinson's disease – An exploration of mechanisms and consequences for fracture prediction with FRAX. Bone, 116651-116651.
Harvey NC, Clegg PD, Dennison EM, Greenhaff P, Griffin SJ, Gregson CL, Jackson MJ, Lord JM, McCloskey EV, Stevenson E , Tobias JH et al (2022) UKRI MRC National Musculoskeletal Ageing Network: strategic prioritisation to increase healthy lifespan and minimise physical frailty. Archives of Osteoporosis, 17(1).
Dimai HP, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, Fahrleitner-Pammer A, Pietschmann P, Muschitz C, McCloskey EV & Kanis JA (2022) Osteoporosis treatment in Austria—assessment of FRAX-based intervention thresholds for high and very high fracture risk. Archives of Osteoporosis, 17(1).
Harvey NC, Orwoll E, Cauley JA, Kwok T, Karlsson MK, Rosengren BE, Ribom E, Cawthon PM, Ensrud K, Liu E , Laskou F et al (2022) Greater pQCT calf muscle density is associated with lower fracture risk, independent of FRAX, falls and BMD: a meta-analysis in the osteoporotic fractures in men (MrOS) study. JBMR Plus.
Kanis JA, McCloskey EV, Harvey NC, Cooper C, Rizzoli R, Dawson-Hughes B, Maggi S & Reginster J-Y (2022) Intervention thresholds and diagnostic thresholds in the management of osteoporosis. Aging Clinical and Experimental Research, 34(12), 3155-3157.
Albergaria B-H, Zerbini CAF, Szejnfeld VL, Eis SR, Silva DMW, de Fatima Lobato da Cunha M, McClung MR, Kanis JA, McCloskey EV, Vilaca T & Lazaretti-Castro M (2022) An updated hip fracture incidence rate for Brazil: the Brazilian Validation Osteoporosis Study (BRAVOS). Archives of Osteoporosis, 17(1).
Chotiyarnwong P, McCloskey EV, Harvey NC, Lorentzon M, Prieto-Alhambra D, Abrahamsen B, Adachi JD, Borgström F, Bruyere O, Carey JJ , Clark P et al (2022) Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Archives of Osteoporosis, 17(1).
McCloskey E, Harvey NC, Lorentzon M, Johansson H, Hans D & Kanis JA (2022) Trabecular Bone Score Adjustment for the Fracture Risk Assessment Tool (FRAX®).. Calcif Tissue Int.
Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N, Kanis J, Leyland S, Low R , McCloskey E et al (2022) Correction: UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis, 17(1).
Zheng Z, Johansson H, Harvey NC, Lorentzon M, Vandenput L, Liu E, Kanis JA & McCloskey EV (2022) Potential Adverse Effect of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) on Bisphosphonate Efficacy: An Exploratory Post Hoc Analysis From a Randomized Controlled Trial of Clodronate.. J Bone Miner Res.
Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N, Kanis J, Leyland S, Low R , McCloskey E et al (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis, 17(1).
Saleh YAL, Sulimani RA, Alomary S, Alnajjar YI, Vandenput L, Liu E, Lorentzon M, Harvey NC, McCloskey EV, Johansson H , Kanis JA et al (2022) Incidence of hip fracture in Saudi Arabia and the development of a FRAX model. Archives of Osteoporosis, 17(1).
Gupta A, Maslen C, Vindlacheruvu M, Abel RL, Bhattacharya P, Bromiley PA, Clark EM, Compston JE, Crabtree N, Gregory JS , Kariki EP et al (2022) Digital health interventions for osteoporosis and post-fragility fracture care. Therapeutic Advances in Musculoskeletal Disease, 14. View this article in WRRO
Abdulla N, Alsaed OS, Lutf A, Alam F, Abdulmomen I, Al Emadi S, Harvey NC, Liu E, Vandenput L, Lorentzon M , McCloskey E et al (2022) Epidemiology of hip fracture in Qatar and development of a country specific FRAX model. Archives of Osteoporosis, 17(1).
Willers C, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Borgström F & Kanis JA (2022) Osteoporosis in Europe: a compendium of country-specific reports. Archives of Osteoporosis, 17(1).
McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E, Hadji P, Payer J, Palmer K, Stad R , O’Kelly J et al (2022) Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe. Archives of Osteoporosis, 17(1).
Harvey NC, Poole KE, Ralston SH, McCloskey EV, Sangan CB, Wiggins L, Jones C, Gittoes N, Compston J, Abrahamsen B , Gregson C et al (2022) Towards a cure for osteoporosis: the UK Royal Osteoporosis Society (ROS) Osteoporosis Research Roadmap. Archives of Osteoporosis, 17(1).
Johansson L, Johansson H, Axelsson KF, Litsne H, Harvey NC, Liu E, Leslie WD, Vandenput L, McCloskey E, Kanis JA & Lorentzon M (2022) Improved fracture risk prediction by adding VFA-identified vertebral fracture data to BMD by DXA and clinical risk factors used in FRAX. Osteoporosis International.
Vandenput L, Johansson H, McCloskey EV, Liu E, Åkesson KE, Anderson FA, Azagra R, Bager CL, Beaudart C, Bischoff-Ferrari HA , Biver E et al (2022) Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis International.
Al-Daghri NM, Sabico S, Al-Saleh Y, Sulimani R, Aljohani NJ, Sheshah E, Alodhayani A, Harvey NC, Liu E, Lorentzon M , McCloskey EV et al (2021) The application of FRAX in Saudi Arabia. Archives of Osteoporosis, 16(1).
Möller S, Skjødt MK, Yan L, Abrahamsen B, Lix LM, McCloskey EV, Johansson H, Harvey NC, Kanis JA, Rubin KH & Leslie WD (2021) Prediction of imminent fracture risk in Canadian women and men aged 45 years or older: external validation of the Fracture Risk Evaluation Model (FREM).. Osteoporos Int.
Soriano-Arroquia A, Gostage J, Xia Q, Bardell D, McCormick R, McCloskey E, Bellantuono I, Clegg P, McDonagh B & Goljanek-Whysall K (2021) miR-24 and its target gene Prdx6 regulate viability and senescence of myogenic progenitors during aging. Aging Cell.
Johansson H, Naureen G, Iqbal R, Jafri L, Khan AH, Umer M, Liu E, Vandenput L, Lorentzon M, McCloskey EV , Kanis JA et al (2021) FRAX-based intervention thresholds for Pakistan. Osteoporosis International.
Lorentzon M, Johansson H, Harvey NC, Liu E, Vandenput L, McCloskey EV & Kanis JA (2021) Osteoporosis and fractures in women: the burden of disease.. Climacteric, 1-7.
Povoroznyuk V, Grygorieva N, Johansson H, Lorentzon M, Harvey NC, McCloskey EV, Musienko A, Liu E, Kanis JA, Zaverukha N & Ivanyk O (2021) FRAX-based intervention thresholds for osteoporosis treatment in Ukraine. Journal of Osteoporosis, 2021, 1-7.
Kebaetse M, Nkhwa S, Mogodi M, Masunge J, Gureja YP, Ramabu M, Mmopelwa T, Sharif I, Orford A, Harvey NC , McCloskey EV et al (2021) A country-specific FRAX model for Botswana. Archives of Osteoporosis, 16(1). View this article in WRRO
Lesnyak O, Zakroyeva A, Babalyan V, Cazac V, Gabdulina G, Ismailov S, Lobanchenko O, Rudenka E, Tsagareli M, Johansson H , Harvey NC et al (2021) FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan. Archives of Osteoporosis, 16(1).
Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C & Borgström F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe.. Arch Osteoporos, 16(1), 82.
McCloskey EV, Borgstrom F, Cooper C, Harvey NC, Javaid MK, Lorentzon M & Kanis JA (2021) Short time horizons for fracture prediction tools : time for a rethink. Osteoporosis International. View this article in WRRO
Papaioannou A, McCloskey E, Bell A, Ngui D, Mehan U, Tan M, Goldin L & Langer A (2021) Use of an electronic medical record dashboard to identify gaps in osteoporosis care. Archives of Osteoporosis, 16. View this article in WRRO
Harvey NC, Orwoll E, Kwok T, Karlsson MK, Rosengren BE, Ribom E, Cauley JA, Cawthon PM, Ensrud K, Liu E , Cruz-Jentoft AJ et al (2021) Sarcopenia definitions as predictors of fracture risk independent of FRAX®, falls, and BMD in the osteoporotic fractures in men (MrOS) study: a meta‐analysis. Journal of Bone and Mineral Research. View this article in WRRO
Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L & McCloskey EV (2021) An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: A report for the National Osteoporosis Guideline Group (NOGG). Osteoporosis International.
(2021) Corrigendum to: “Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF”. The Journal of Clinical Endocrinology & Metabolism, 106(4), e1931-e1931.
Harvey NC, Kanis JA, Liu E, Vandenput L, Lorentzon M, Cooper C, McCloskey E & Johansson H (2021) Impact of population-based or targeted BMD interventions on fracture incidence. Osteoporosis International, 32(10), 1973-1979.
Johansson H, Dela SS, Cassim B, Paruk F, Brown SL, Conradie M, Harvey NC, Jordaan JD, Kalla AA, Liu E , Lorentzon M et al (2021) FRAX-based fracture probabilities in South Africa. Archives of Osteoporosis, 16(1).
Naureen G, Johansson H, Iqbal R, Jafri L, Khan AH, Umer M, Liu E, Vandenput L, Lorentzon M, Harvey NC , McCloskey EV et al (2021) A surrogate FRAX model for Pakistan. Archives of Osteoporosis, 16. View this article in WRRO
Kebaetse M, Nkhwa S, Mogodi M, Masunge J, Gureja YP, Ramabu M, Mmopelwa T, Sharif I, Orford A, Johansson H , Harvey NC et al (2021) Epidemiology of hip fracture in Botswana. Archives of Osteoporosis, 16. View this article in WRRO
Lu T, Forgetta V, Keller-Baruch J, Nethander M, Bennett D, Forest M, Bhatnagar S, Walters RG, Lin K, Chen Z , Li L et al (2021) Improved prediction of fracture risk leveraging a genome-wide polygenic risk score. Genome Medicine, 13(1). View this article in WRRO
McCloskey EV, Johansson H, Harvey NC, Lorentzon M, Shi Y & Kanis JA (2021) Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporosis International. View this article in WRRO
Altai Z, Montefiori E, van Veen B, A. Paggiosi M, McCloskey EV, Viceconti M, Mazzà C & Li X (2021) Femoral neck strain prediction during level walking using a combined musculoskeletal and finite element model approach. PLoS ONE, 16(2). View this article in WRRO
Harvey NC, Kanis JA, Liu E, Cooper C, Lorentzon M, Bea JW, Carbone L, Cespedes Feliciano EM, Laddu DR, Schnatz PF , Shadyab AH et al (2021) Predictive value of DXA appendicular lean mass for incident fractures, falls, and mortality, independent of prior falls, FRAX, and BMD: Findings from the Women's Health Initiative (WHI). Journal of Bone and Mineral Research. View this article in WRRO
Hartley A, Hardcastle SA, Frysz M, Parkinson J, Paternoster L, McCloskey E, Poole KES, Javaid MK, Aye M, Moss K , Williams M et al (2021) Increased development of radiographic hip osteoarthritis in individuals with high bone mass : a prospective cohort study. Arthritis Research & Therapy, 23(1). View this article in WRRO
Larsson BAM, Johansson L, Johansson H, Axelsson KF, Harvey N, Vandenput L, Magnusson P, McCloskey E, Liu E, Kanis JA , Sundh D et al (2021) The timed up and go test predicts fracture risk in older women independently of clinical risk factors and bone mineral density. Osteoporosis International, 32(1), 75-84. View this article in WRRO
Leslie WD, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC & Kanis JA (2021) Fracture prediction from FRAX for Canadian ethnic groups: a registry-based cohort study. Osteoporosis International, 32(1), 113-122. View this article in WRRO
Duerksen DR, Lix LM, Johansson H, McCloskey EV, Harvey NC, Kanis JA & Leslie WD (2021) Fracture risk assessment in celiac disease: a registry-based cohort study. Osteoporosis International, 32(1), 93-99. View this article in WRRO
López Gavilánez E, Johansson H, Harvey N, Lorentzon M, McCloskey E, Valdivieso Jara J & Kanis JA (2021) The application of FRAX in Ecuador. Revista Colombiana de Reumatologia.
Burden AM, Tanaka Y, Xu L, Ha YC, McCloskey E, Cummings SR & Glüer CC (2021) Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. Osteoporosis International, 32(5), 817-829.
Kanis JA, Harvey NC, Lorentzon M, Liu E, Vandenput L, McCloskey EV & Johansson H (2021) Combining fracture outcomes in phase 3 trials of osteoporosis: an analysis of the effects of denosumab in postmenopausal women. Osteoporosis International, 32(1), 165-171.
Tsourdi E, Zillikens MC, Meier C, Body J-J, Gonzalez Rodriguez E, Anastasilakis AD, Abrahamsen B, McCloskey E, Hofbauer LC, Guañabens N , Obermayer-Pietsch B et al (2021) Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. The Journal of Clinical Endocrinology & Metabolism, 106(1), 264-281.
Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L, Leslie WD & McCloskey EV (2021) The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture. Osteoporosis International, 32(1), 47-54.
McCloskey E, Paterson AH, Powles T & Kanis JA (2021) Clodronate. Bone, 143, 115715-115715.
Spain L, Yang L, Wilkinson JM & McCloskey E (2020) Transmission of whole body vibration – comparison of three vibration platforms in healthy subjects. Bone, 144. View this article in WRRO
Montefiori E, Kalkman B, Henson W, Paggiosi M, McCloskey E & Mazza C (2020) MRI-based anatomical characterisation of lower-limb muscles in older women. PLoS ONE, 15(12). View this article in WRRO
Wu C-H, Hung W-C, Chang I-L, Tsai T-T, Chang Y-F, McCloskey EV, Watts NB, McClung MR, Huang C-F, Chen C-H , Wu K-L et al (2020) Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis. Bone Reports, 13. View this article in WRRO
Brown JE, Handforth C, Compston JE, Cross W, Parr N, Selby P, Wood S, Drudge-Coates L, Walsh JS, Mitchell C , Collinson FJ et al (2020) Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone Oncology, 25. View this article in WRRO
Lesnyak O, Ismailov S, Shakirova M, Alikhanova N, Zakroyeva A, Abboskhujaeva L, Johansson H, Harvey NC, McCloskey E & Kanis JA (2020) Epidemiology of hip fracture and the development of a FRAX model for Uzbekistan. Archives of Osteoporosis, 15(1).
Leslie WD, Schousboe JT, Morin SN, Martineau P, Lix LM, Johansson H, McCloskey EV, Harvey NC & Kanis JA (2020) Loss in DXA-estimated total body lean mass but not fat mass predicts incident major osteoporotic fracture and hip fracture independently from FRAX: a registry-based cohort study. Archives of Osteoporosis, 15(1).
Borgström F, Karlsson L, Ortsäter G, Norton N, Halbout P, Cooper C, Lorentzon M, McCloskey EV, Harvey NC, Javaid MK & Kanis JA (2020) Fragility fractures in Europe : burden, management and opportunities. Archives of Osteoporosis, 15(1). View this article in WRRO
Kirilova E, Johansson H, Kirilov N, Vladeva S, Petranova T, Kolarov Z, Liu E, Lorentzon M, Vandenput L, Harvey NC , McCloskey E et al (2020) Epidemiology of hip fractures in Bulgaria : development of a country-specific FRAX model. Archives of Osteoporosis, 15(1). View this article in WRRO
Issayeva S, Lesnyak O, Zakroyeva A, Issayeva B, Dilmanova D, Johansson H, Liu E, Lorentzon M, Harvey NC, McCloskey E & Kanis JA (2020) Epidemiology of osteoporotic fracture in Kazakhstan and development of a country specific FRAX model. Archives of Osteoporosis, 15(1). View this article in WRRO
Zakroyeva A, Lesnyak O, Cazac V, Groppa L, Russu E, Chislari L, Rotaru L, Johansson H, Harvey NC, McCloskey E , Lorentzon M et al (2020) Epidemiology of osteoporotic fracture in Moldova and development of a country-specific FRAX model. Archives of Osteoporosis, 15(1). View this article in WRRO
Bischoff-Ferrari HA, Vellas B, Rizzoli R, Kressig RW, da Silva JAP, Blauth M, Felson DT, McCloskey EV, Watzl B, Hofbauer LC , Felsenberg D et al (2020) Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. JAMA, 324(18), 1855-1855.
Trela-Larsen L, Kroken G, Bartz-Johannessen C, Sayers A, Aram P, McCloskey E, Kadirkamanathan V, Blom AW, Lie SA, Furnes ON & Wilkinson JM (2020) Personalized estimation of one-year mortality risk after elective hip or knee arthroplasty for osteoarthritis. Bone & Joint Research, 9(11), 808-820. View this article in WRRO
Almog YA, Rai A, Zhang P, Moulaison A, Powell R, Mishra A, Weinberg K, Hamilton C, Oates M, McCloskey E & Cummings SR (2020) Deep learning with electronic health records for short-term fracture risk identification : crystal bone algorithm development and validation. Journal of Medical Internet Research, 22(10). View this article in WRRO
McCloskey EV, Harvey NC, Johansson H, Lorentzon M, Vandenput L, Liu E & Kanis JA (2020) Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures. Osteoporosis International. View this article in WRRO
Miller PD, Bilezikian JP, Fitzpatrick LA, Mitlak B, McCloskey EV, Cosman F & Bone HG (2020) Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Current Medical Research and Opinion. View this article in WRRO
Paggiosi MA, Peel N, McCloskey E, Walsh JS & Eastell R (2020) Comparison of treatment responder rates for three oral bisphosphonates: The TRIO study. Bone Reports, 13, 100677-100677.
Zotov E, Hills AF, de Mello FL, Aram P, Sayers A, Blom AW, McCloskey EV, Wilkinson JM & Kadirkamanathan V (2020) JointCalc: A web-based personalised patient decision support tool for joint replacement. International Journal of Medical Informatics, 142. View this article in WRRO
Kanis JA, Cooper C, Dawson-Hughes B, Harvey NC, Johansson H, Lorentzon M, McCloskey EV, Reginster J-Y & Rizzoli R (2020) FRAX and ethnicity. Osteoporosis International, 31(11), 2063-2067.
McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E, Hadji P, Payer J, Palmer K, Stad R , O’Kelly J et al (2020) The osteoporosis treatment gap in patients at risk of fracture in European primary care : a multi-country cross-sectional observational study. Osteoporosis International. View this article in WRRO
Kanis JA, Chandran M, Chionh SB, Ganeson G, Harvey NC, Koh W-P, Kwok T, Lau TC, Liu E, Lorentzon M , McCloskey EV et al (2020) Use of age-dependent FRAX-based intervention thresholds for Singapore. Archives of Osteoporosis, 15(1). View this article in WRRO
Forgetta V, Keller-Baruch J, Forest M, Durand A, Bhatnagar S, Kemp JP, Nethander M, Evans D, Morris JA, Kiel DP , Rivadeneira F et al (2020) Development of a polygenic risk score to improve screening for fracture risk: A genetic risk prediction study. PLoS Medicine, 17(7). View this article in WRRO
Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L & McCloskey EV (2020) Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporosis International, 31(10), 1817-1828.
Pepe J, Body J-J, Hadji P, McCloskey E, Meier C, Obermayer-Pietsch B, Palermo A, Tsourdi E, Zillikens MC, Langdahl B & Ferrari S (2020) Osteoporosis in premenopausal women: a clinical narrative review by the ECTS and the IOF. The Journal of Clinical Endocrinology & Metabolism. View this article in WRRO
Almog Y, Rai A, Mishra A, Moulaison A, Powell R, Weinberg K, Hamilton C, Oates M, McCloskey E & Cummings SR (2020) OR13-07 Crystal Bone: Personalized, Short-Term Fracture Risk Prediction with Natural Language Processing Methods. Journal of the Endocrine Society, 4(Supplement_1).
Lesnyak O, Zakroyeva A, Lobanchenko O, Johansson H, Liu E, Lorentzon M, Harvey NC, McCloskey E & Kanis JA (2020) A surrogate FRAX model for the Kyrgyz Republic. Archives of Osteoporosis, 15(1). View this article in WRRO
Hartley A, Hardcastle SA, Paternoster L, McCloskey E, Poole KES, Javaid MK, Aye M, Moss K, Granell R, Gregory J , Williams M et al (2020) Individuals with high bone mass have increased progression of radiographic and clinical features of knee osteoarthritis. Osteoarthritis and Cartilage, 28(9), 1180-1190.
Chotiyarnwong P & McCloskey EV (2020) Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nature Reviews Endocrinology, 16(8), 437-447.
Leslie WD, Schousboe JT, Morin SN, Martineau P, Lix LM, Johansson H, McCloskey EV, Harvey NC & Kanis JA (2020) Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study. Osteoporosis International, 31(6), 1059-1067.
Condurache CI, Chiu S, Chotiyarnwong P, Johansson H, Shepstone L, Lenaghan E, Cooper C, Clarke S, Khioe RFS, Fordham R , Gittoes N et al (2020) Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study. Osteoporosis International, 31(3), 457-464.
Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N , Campusano C et al (2020) Correction to: Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis International, 31(4), 797-798.
Kanis JA, Harvey NC, Johansson H, Liu E, Vandenput L, Lorentzon M, Leslie WD & McCloskey EV (2020) A decade of FRAX: how has it changed the management of osteoporosis?. Aging Clinical and Experimental Research, 32(2), 187-196.
Leslie WD, Schousboe JT, Morin SN, Martineau P, Lix LM, Johansson H, McCloskey EV, Harvey NC & Kanis JA (2020) Measured height loss predicts incident clinical fractures independently from FRAX: a registry-based cohort study. Osteoporosis International, 31(6), 1079-1087.
Chotiyarnwong P, McCloskey E, Eastell R, McClung MR, Gielen E, Gostage J, McDermott M, Chines A, Huang S & Cummings SR (2020) A pooled analysis of fall incidence from placebo‐controlled trials of denosumab. Journal of Bone and Mineral Research. View this article in WRRO
Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, Brandi M-L, Cano A, Collins P, Cooper C, Genazzani AR, Hillard T, Kanis JA , Kaufman J-M et al (2020) Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?. Osteoporosis International, 31(12), 2271-2286.
McCloskey E, Harvey N, Johansson H, Lorentzon M, Vandenput L & Kanis JA (2020) Screening for high fracture risk. Osteoporosis International, 31(6), 1179-1180.
Koromani F, Oei L, Shevroja E, Trajanoska K, Schoufour J, Muka T, Franco OH, Ikram MA, Zillikens MC, Uitterlinden AG , Krestin GP et al (2020) Vertebral Fractures in Individuals With Type 2 Diabetes: More Than Skeletal Complications Alone. Diabetes Care, 43(1), 137-144.
Leslie WD, Morin SN, Lix LM, Martineau P, Bryanton M, McCloskey EV, Johansson H, Harvey NC & Kanis JA (2020) Reassessment intervals for transition from low to high fracture risk among adults older than 50 years. JAMA Network Open, 3(1). View this article in WRRO
Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N , Campusano C et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis International, 31(1), 1-12.
Harvey NC, Lorentzon M, Kanis JA, McCloskey E & Johansson H (2020) Incidence of myocardial infarction and associated mortality varies by latitude and season: findings from a Swedish Registry Study. Journal of Public Health, 42(4), e440-e448.
Gossiel F, Paggiosi MA, Naylor KE, McCloskey EV, Walsh J, Peel N & Eastell R (2020) The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. Bone, 131.
Chotiyarnwong P, Harvey NC, Johansson H, Liu E, Lorentzen M, Kanis JA & McCloskey EV (2019) Temporal changes in access to FRAX® in Thailand between 2010 and 2018. Archives of Osteoporosis, 14(1). View this article in WRRO
McCloskey EV, Fitzpatrick LA, Hu M-Y, Williams G & Kanis JA (2019) Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Archives of Osteoporosis, 14(1).
Lopez Gavilanez E, Johansson H, McCloskey E, Harvey NC, Segale Bajana A, Marriott Blum D, Navarro Grijalva M, Diaz Curiel M & Kanis JA (2019) Assessing the risk of osteoporotic fractures: the Ecuadorian FRAX model. Archives of Osteoporosis, 14(1).
Fathi Kazerooni A, Pozo JM, McCloskey EV, Saligheh Rad H & Frangi AF (2019) Diffusion MRI for assessment of bone quality; A review of findings in healthy aging and osteoporosis. Journal of Magnetic Resonance Imaging. View this article in WRRO
Svedbom A, Borgstrom F, Hernlund E, Alekna V, Bianchi ML, Clark P, Diaz Curiel M, Dimai HP, Jurisson M, Olga L , McCloskey E et al (2019) PMS67 EXPERIENCE AND PREFERENCE-BASED EQ-5D-3L VALUE SET DERIVED FROM LONGITUDINAL DATA: RESULTS FROM THE INTERNATIONAL COSTS AND UTILITIES OF OSTEOPOROTIC FRACTURES STUDY (ICUROS). Value in Health, 22, S705-S706.
Anastasilakis AD, Tsourdi E, Makras P, Polyzos SA, Meier C, McCloskey EV, Pepe J & Zillikens MC (2019) Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society. Bone, 127, 401-418.
Farzi M, Pozo JM, McCloskey E, Eastell R, Harvey N, Wilkinson JM & Frangi AF (2019) A spatio-temporal ageing atlas of the proximal femur. IEEE Transactions on Medical Imaging. View this article in WRRO
Lorentzon M, Branco J, Brandi ML, Bruyère O, Chapurlat R, Cooper C, Cortet B, Diez-Perez A, Ferrari S, Gasparik A , Herrmann M et al (2019) Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Advances in Therapy, 36(10), 2811-2824. View this article in WRRO
Bauer JM, Cruz-Jentoft AJ, Fielding RA, Kanis JA, Reginster J-Y, Bruyère O, Cesari M, Chapurlat R, Al-Daghri N, Dennison E , Kaufman J-M et al (2019) Correction to: Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. Calcified Tissue International, 105(2), 125-126.
Leslie WD, Morin SN, Lix LM, Martineau P, Bryanton M, McCloskey EV, Johansson H, Harvey NC & Kanis JA (2019) Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study. Osteoporosis International, 30(11), 2195-2203.
Beaudart C, Rolland Y, Cruz-Jentoft AJ, Bauer JM, Sieber C, Cooper C, Al-Daghri N, Araujo de Carvalho I, Bautmans I, Bernabei R , Bruyère O et al (2019) Assessment of Muscle Function and Physical Performance in Daily Clinical Practice. Calcified Tissue International, 105(1), 1-14.
Leslie WD, Morin SN, Lix LM, Niraula S, McCloskey EV, Johansson H, Harvey NC & Kanis JA (2019) Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry‐Based Cohort Study. The Oncologist, 24(11), 1432-1438.
Dennison EM, Cooper C, Kanis JA, Bruyère O, Silverman S, McCloskey E, Abrahamsen B, Prieto-Alhambra D & Ferrari S (2019) Fracture risk following intermission of osteoporosis therapy. Osteoporosis International, 30(9), 1733-1743.
Leslie WD, Morin SN, Lix LM, Niraula S, McCloskey EV, Johansson H, Harvey NC & Kanis JA (2019) Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry‐Based Cohort Study. Journal of Bone and Mineral Research, 34(8), 1428-1435.
Wilkinson JM, Trela-Larsen L, Bartz-Johannessen C, Sayers A, Aram P, McCloskey E, Kadirkamanathan V, Blom A, Lie S & Furnes O (2019) Estimating patient-specific mortality after joint replacement: algorithm development and validation using national audit datasets. Osteoarthritis and Cartilage, 27, S229-S229.
Harvey NC, Kanis JA, Liu E, Johansson H, Lorentzon M & McCloskey E (2019) Appendicular lean mass and fracture risk assessment: implications for FRAX® and sarcopenia. Osteoporosis International, 30(3), 537-539.
Naylor KE, McCloskey EV, Jacques RM, Peel NFA, Paggiosi MA, Gossiel F, Walsh JS & Eastell R (2019) Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis. Osteoporosis International. View this article in WRRO
Bauer JM, Cruz-Jentoft AJ, Fielding RA, Kanis JA, Reginster J-Y, Bruyère O, Cesari M, Chapurlat R, Al-Daghri N, Dennison E , Kaufman J-M et al (2019) Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. Calcified Tissue International, 105(2), 109-124.
Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Borgström F & McCloskey EV (2019) Correspondence in response to OSIN-D-18-00831 quantifying imminent risk. Osteoporosis International, 30(2), 525-526. View this article in WRRO
Khashayar P, Keshtkar A, Ostovar A, Larijani B, Johansson H, Harvey NC, Lorentzon M, McCloskey E & Kanis JA (2019) FRAX-based intervention and assessment thresholds for osteoporosis in Iran. Osteoporosis International, 30(11), 2225-2230.
Svedbom A, Hadji P, Hernlund E, Thoren R, McCloskey E, Stad R & Stollenwerk B (2019) Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom. Osteoporosis International, 30(9), 1745-1754.
Harvey NC, Odén A, Orwoll E, Lapidus J, Kwok T, Karlsson MK, Rosengren BE, Ribom E, Cooper C, Cawthon PM , Kanis JA et al (2018) Measures of Physical Performance and Muscle Strength as Predictors of Fracture Risk Independent of FRAX, Falls, and aBMD: A Meta‐Analysis of the Osteoporotic Fractures in Men (MrOS) Study. Journal of Bone and Mineral Research, 33(12), 2150-2157. View this article in WRRO
Buckinx F, Landi F, Cesari M, Fieding RA, Visser M, Engelke K, Maggi S, Dennison E, Al-Daghri NM, Allepaerts S , Bauer J et al (2018) The authors reply: Letter on: “Pitfalls in the measurement of muscle mass: a need for a reference standard” by Clark et al.. Journal of Cachexia, Sarcopenia and Muscle, 9(7), 1272-1274.
Alsayednoor J, Metcalf L, Rochester J, Dall’Ara E, McCloskey E & Lacroix D (2018) Comparison of HR-pQCT- and microCT-based finite element models for the estimation of the mechanical properties of the calcaneus trabecular bone. Biomechanics and Modeling in Mechanobiology, 17(6), 1715-1730. View this article in WRRO
Ramanau H, Chernyanin I, Rudenka E, Lesnyak O, Zakroyeva A, Bilezikian JP, Johansson H, Harvey NC, McCloskey EV & Kanis JA (2018) Epidemiology of hip fracture in Belarus: development of a country-specific FRAX model and its comparison to neighboring country models. Archives of Osteoporosis, 13(1). View this article in WRRO
Chandran M, McCloskey EV, Thu WPP, Logan S, Hao Y, Tay D, Ang WC, Aung TKK, Choo KS, Ali A , Yan SX et al (2018) FRAX® based intervention thresholds for management of osteoporosis in Singaporean women. Archives of Osteoporosis, 13(1).
Kanis JA, Johansson H, Harvey NC & McCloskey EV (2018) A brief history of FRAX. Archives of Osteoporosis, 13(1).
Povoroznyuk VV, Grygorieva NV, Korzh MO, Strafun SS, Vaida VM, Klymovytsky FV, Vlasenko RO, Kanis JA, Johansson H & McCloskey EV (2018) Epidemiology Of Hip Fractures In Ukraine: Results Of STOP-Study. Journal of Clinical Densitometry, 21(4), 603-603.
Aram P, Trela-Larsen L, Sayers A, Hills AF, Blom AW, McCloskey EV, Kadirkamanathan V & Wilkinson JM (2018) Estimating an Individual's Probability of Revision Surgery After Knee Replacement: A Comparison of Modeling Approaches Using a National Dataset. American Journal of Epidemiology, 187(10), 2252-2262. View this article in WRRO
Kemp GJ, Jackson MJ, McCloskey EV, Mathers JC & CIMA Toolkit Working Group (2018) Towards a toolkit for the assessment and monitoring of musculoskeletal ageing.. Age and Ageing, 47(6), 774-777. View this article in WRRO
Kemp GJ, Birrell F, Clegg PD, Cuthbertson DJ, De Vito G, Van Dieën JH, Del Din S, Eastell R, Garnero P, Goljanek-Whysall K , Hackl M et al (2018) Developing a toolkit for the assessment and monitoring of musculoskeletal ageing. Age and Ageing, 47, iv1-iv19. View this article in WRRO
Buckinx F, Landi F, Cesari M, Fieding RA, Visser M, Engelke K, Maggi S, Dennison E, Al-Daghri NM, Allepaerts S , Bauer J et al (2018) The Authors reply: “Dual energy X-ray absorptiometry: gold standard for muscle mass?” by Scafoglieri et al.. Journal of Cachexia, Sarcopenia and Muscle, 9(4), 788-790. View this article in WRRO
Shepstone L & McCloskey E (2018) A closer look at SCOOP: screening for fracture prevention – Authors' reply. The Lancet, 392(10147), 552-553.
Martineau P, Leslie WD, Johansson H, Harvey NC, McCloskey EV, Hans D & Kanis JA (2018) In which patients does lumbar spine trabecular bone score (TBS) have the largest effect?. Bone, 113, 161-168.
Leslie WD, Johansson H, McCloskey EV, Harvey NC, Kanis JA & Hans D (2018) Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. Journal of Bone and Mineral Research, 33(11), 1923-1930.
McCloskey E, Johansson H, Harvey NC, Shepstone L, Lenaghan E, Fordham R, Harvey I, Howe A, Cooper C, Clarke S , Gittoes N et al (2018) Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study. Journal of Bone and Mineral Research, 33(6), 1020-1026. View this article in WRRO
Kanis JA, Johansson H, Odén A, Harvey NC, Gudnason V, Sanders KM, Sigurdsson G, Siggeirsdottir K, Fitzpatrick LA, Borgström F & McCloskey EV (2018) Characteristics of recurrent fractures. Osteoporosis International, 29(8), 1747-1757.
Harvey NC, McCloskey E, Kanis JA, Compston J & Cooper C (2018) Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464). Osteoporosis International, 29(7), 1511-1513.
Povoroznyuk VV, Grygorieva NV, Kanis JA, McCloskey EV, Johansson H, Strafun SS, Korzh MO, Vaida VM, Klymovytsky FV, Forosenko VS & Vlasenko RO (2018) Epidemiology of Hip Fractures in Two Regions of Ukraine. Journal of Osteoporosis, 2018. View this article in WRRO
Paggiosi MA, Yang L, Blackwell D, Walsh JS, McCloskey E, Peel N & Eastell R (2018) Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study. Osteoporosis International, 29(6), 1367-1378. View this article in WRRO
Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS & Eastell R (2018) Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporosis International, 29(6), 1407-1417. View this article in WRRO
Turner DA, Khioe RFS, Shepstone L, Lenaghan E, Cooper C, Gittoes N, Harvey NC, Holland R, Howe A, McCloskey E , O'Neill TW et al (2018) The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. Journal of Bone and Mineral Research, 33(5), 845-851.
Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, Maggi S, Dennison E, Al-Daghri NM, Allepaerts S , Bauer J et al (2018) Pitfalls in the measurement of muscle mass: a need for a reference standard. Journal of Cachexia, Sarcopenia and Muscle, 9(2), 269-278. View this article in WRRO
Gossiel F, Scott JR, Paggiosi MA, Naylor KE, McCloskey EV, Peel NFA, Walsh JS & Eastell R (2018) The effect of teriparatide treatment on circulating periostin and its relationship to regulators of bone formation and BMD in postmenopausal women with osteoporosis.. Journal of Clinical Endocrinology and Metabolism, 103(4), 1302-1309. View this article in WRRO
Yang S, Luo Y, Yang L, Dall'Ara E, Eastell R, Goertzen AL, McCloskey EV, Leslie WD & Lix LM (2018) Comparison of femoral strength and fracture risk index derived from DXA-based finite element analysis for stratifying hip fracture risk: A cross-sectional study. Bone, 110, 386-391.
Harvey NC, Odén A, Orwoll E, Lapidus J, Kwok T, Karlsson MK, Rosengren BE, Ljunggren Ö, Cooper C, McCloskey E , Kanis JA et al (2018) Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. Journal of Bone and Mineral Research, 33(3), 510-516. View this article in WRRO
Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R, Gittoes N, Harvey I, Harvey N, Heawood A , Holland R et al (2018) Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. The Lancet, 391(10122), 741-747. View this article in WRRO
Leslie WD, Majumdar SR, Morin SN, Lix LM, Schousboe JT, Ensrud KE, Johansson H, McCloskey EV & Kanis JA (2018) Performance of FRAX in clinical practice according to sex and osteoporosis definitions: the Manitoba BMD registry. Osteoporosis International, 29(3), 759-767.
Leslie WD, Shevroja E, Johansson H, McCloskey EV, Harvey NC, Kanis JA & Hans D (2018) Risk-equivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry. Osteoporosis International, 29(3), 751-758.
Johansson H, Hongslo Vala C, Odén A, Lorentzon M, McCloskey E, Kanis JA, Harvey NC, Ohlsson C, Stefan Lohmander L, Kärrholm J & Mellström D (2018) Low risk for hip fracture and high risk for hip arthroplasty due to osteoarthritis among Swedish farmers. Osteoporosis International, 29(3), 741-749.
Metcalf LM, Dall'Ara E, Paggiosi MA, Rochester JR, Vilayphiou N, Kemp GJ & McCloskey EV (2018) Validation of calcaneus trabecular microstructure measurements by HR-pQCT. Bone, 106, 69-77. View this article in WRRO
Svedbom A, Borgström F, Hernlund E, Ström O, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jürisson M , Uusküla A et al (2018) Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. Quality of Life Research, 27(3), 707-716.
Svedbom A, Borgstöm F, Hernlund E, Ström O, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jürisson M , Kallikorm R et al (2018) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures—results from the ICUROS. Osteoporosis International, 29(3), 557-566.
Robinson SM, Reginster JY, Rizzoli R, Shaw SC, Kanis JA, Bautmans I, Bischoff-Ferrari H, Bruyère O, Cesari M, Dawson-Hughes B , Fielding RA et al (2018) Does nutrition play a role in the prevention and management of sarcopenia?. Clinical Nutrition, 37(4), 1121-1132.
Povoroznyu VV, Grygorieva NV, McCloskey EV, Johansson H & Kanis JA (2017) Application of FRAX to Determine the Risk of Osteoporotic Fractures in the Ukrainian Population. International Journal of Osteoporosis and Metabolic Disorders, 11(1), 7-13.
Lesnyak O, Sahakyan S, Zakroyeva A, Bilezikian JP, Hutchings N, Babalyan V, Galstyan R, Lebedev A, Johansson H, Harvey NC , McCloskey E et al (2017) Epidemiology of fractures in Armenia: development of a country-specific FRAX model and comparison to its surrogate. Archives of Osteoporosis, 12(1). View this article in WRRO
Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES , Reid DM et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Archives of Osteoporosis, 12(1), 43-43. View this article in WRRO
Harvey NC, McCloskey E, Kanis JA, Compston J & Cooper C (2017) Bisphosphonates in osteoporosis: NICE and easy?. The Lancet, 390(10109), 2243-2244.
Leslie WD, Lix LM, Majumdar SR, Morin SN, Johansson H, Odén A, McCloskey EV & Kanis JA (2017) Total Hip Bone Area Affects Fracture Prediction With FRAX® in Canadian White Women. The Journal of Clinical Endocrinology & Metabolism, 102(11), 4242-4249.
Johansson H, Azizieh F, al Ali N, Alessa T, Harvey NC, McCloskey E & Kanis JA (2017) FRAX- vs. T-score-based intervention thresholds for osteoporosis. Osteoporosis International, 28(11), 3099-3105. View this article in WRRO
Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM, Brandi ML, Cannata-Andia J, Cortet B, Dimai HP, Ferrari S , Hadji P et al (2017) Erratum to: Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporosis International, 28(11), 3285-3286.
Kanis JA, Harvey NC, Johansson H, Odén A, Leslie WD & McCloskey EV (2017) FRAX Update. Journal of Clinical Densitometry, 20(3), 360-367.
McCloskey E, Kanis J, Reginster J, Cooper C, Rizzoli R, Cruz Jentoft A & Landi F (2017) DETERMINING THE ROLE OF SARCOPENIA IN THE DECLINE OF INTRINSIC CAPACITY IN ELDERLY SUBJECTS. Innovation in Aging, 1(suppl_1), 693-693.
Kanis JA, Harvey NC, Johansson H, Odén A, McCloskey EV & Leslie WD (2017) Overview of fracture prediction tools. Journal of Clinical Densitometry, 20(3), 444-450. View this article in WRRO
Leslie WD, Majumdar SR, Morin SN, Lix LM, Johansson H, Oden A, McCloskey EV & Kanis JA (2017) FRAX for fracture prediction shorter and longer than 10 years: the Manitoba BMD registry. Osteoporosis International.
Bolton JM, Morin SN, Majumdar SR, Sareen J, Lix LM, Johansson H, Odén A, McCloskey EV, Kanis JA & Leslie WD (2017) Association of Mental Disorders and Related Medication Use With Risk for Major Osteoporotic Fractures. JAMA Psychiatry, 74(6), 641-648.
Metcalf LM, Aspray TJ & McCloskey EV (2017) The effects of parathyroid hormone peptides on the peripheral skeleton of postmenopausal women. A systematic review.. Bone, 99, 39-46. View this article in WRRO
Povoroznyuk VV, Grygorieva NV, Kanis JA, McCloskey EV, Johansson H, Harvey NC, Korzh MO, Strafun SS, Vaida VM, Klymovytsky FV , Vlasenko RO et al (2017) Epidemiology of hip fracture and the development of FRAX in Ukraine. Archives of Osteoporosis, 12. View this article in WRRO
McCloskey EV, Johansson H, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick L & Kanis JA (2017) The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study. Journal of Bone and Mineral Research, 32(8), 1625-1631. View this article in WRRO
Harvey NC, McCloskey E & Kanis JA (2017) Utilisation du FRAX ® chez l’homme. Revue du Rhumatisme, 84(3), 196-198.
Harvey NCW, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster J-Y, Rizzoli R, Cooper C & Kanis JA (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporosis International, 28(5), 1507-1529. View this article in WRRO
Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM, Brandi ML, Cannata-Andia J, Cortet B, Dimai HP, Ferrari S , Hadji P et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporosis International, 28(7), 2023-2034. View this article in WRRO
McCloskey EV (2017) Identification of vertebral fractures: a moderately severe solution?. Osteoporos Int.
(2017) Addendum. American Journal of Gastroenterology, 112(6), 974-974.
Martineau P, Leslie WD, Johansson H, Oden A, McCloskey EV, Hans D & Kanis JA (2017) Clinical Utility of Using Lumbar Spine Trabecular Bone Score to Adjust Fracture Probability: The Manitoba BMD Cohort. Journal of Bone and Mineral Research.
Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G & Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporosis International, 28(3), 775-780. View this article in WRRO
Beaudart C, Dawson A, Shaw SC, Harvey NC, Kanis JA, Binkley N, Reginster JY, Chapurlat R, Chan DC, Bruyère O , Rizzoli R et al (2017) Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporosis International, 28(6), 1817-1833. View this article in WRRO
Chan D-C, McCloskey EV, Chang C-B, Lin K-P, Lim LC, Tsai K-S & Yang R-S (2017) Establishing and evaluating FRAX® probability thresholds in Taiwan. Journal of the Formosan Medical Association, 116(3), 161-168. View this article in WRRO
McCloskey EV, Johansson H, Harvey NC, Compston J & Kanis JA (2017) Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK—an analysis of anonymous website activity. Osteoporosis International, 28(1), 71-76. View this article in WRRO
Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A & McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX. Archives of Osteoporosis, 11(1).
Majumdar SR, Leslie WD, Lix LM, Morin SN, Johansson H, Oden A, McCloskey EV & Kanis JA (2016) Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort. The Journal of Clinical Endocrinology & Metabolism, 101(11), 4489-4496. View this article in WRRO
Beaudart C, McCloskey E, Bruyère O, Cesari M, Rolland Y, Rizzoli R, Araujo de Carvalho I, Amuthavalli Thiyagarajan J, Bautmans I, Bertière M-C , Brandi ML et al (2016) Sarcopenia in daily practice: assessment and management. BMC Geriatrics, 16(1). View this article in WRRO
Harvey NC, McCloskey E & Kanis JA (2016) Use of FRAX® in men. Joint Bone Spine, 83(5), 477-478.
Leslie WD, Majumdar SR, Lix LM, Josse RG, Johansson H, Oden A, McCloskey EV & Kanis JA (2016) Direct comparison of FRAX® and a simplified fracture risk assessment tool in routine clinical practice: a registry-based cohort study. Osteoporosis International, 27(9), 2689-2695.
Gossiel F, Hoyle C, McCloskey EV, Naylor KE, Walsh J, Peel N & Eastell R (2016) The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study. Bone, 92, 94-99. View this article in WRRO
Leslie WD, Lix LM, Morin SN, Johansson H, Odén A, McCloskey EV & Kanis JA (2016) Adjusting Hip Fracture Probability in Men and Women Using Hip Axis Length: the Manitoba Bone Density Database. Journal of Clinical Densitometry, 19(3), 326-331.
Bruyère O, Beaudart C, Reginster J-Y, Buckinx F, Schoene D, Hirani V, Cooper C, Kanis JA, Rizzoli R, McCloskey E , Cederholm T et al (2016) Assessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey. European Geriatric Medicine, 7(3), 243-246.
McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H, Barkmann R, Boutroy S, Brown J, Chapurlat R , Elders PJM et al (2016) A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. Journal of Bone and Mineral Research, 31(5), 940-948.
McCloskey EV, Harvey NC, Johansson H & Kanis JA (2016) FRAX updates 2016. Current Opinion in Rheumatology, 28(4), 433-441.
Robinson PC, Leo PJ, Pointon JJ, Harris J, Cremin K, Bradbury LA, Stebbings S, Harrison AA, Duncan EL, Evans DM , Wordsworth PB et al (2016) Exome-wide study of ankylosing spondylitis demonstrates additional shared genetic background with inflammatory bowel disease. npj Genomic Medicine, 1(1).
Gregson CL, Wheeler L, Hardcastle SA, Appleton LH, Addison KA, Brugmans M, Clark GR, Ward KA, Paggiosi M, Stone M , Thomas J et al (2016) Mutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass Cases. Journal of Bone and Mineral Research, 31(3), 640-649. View this article in WRRO
Reginster J-Y, Cooper C, Rizzoli R, Kanis JA, Appelboom G, Bautmans I, Bischoff-Ferrari HA, Boers M, Brandi ML, Bruyère O , Cherubini A et al (2016) Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research, 28(1), 47-58. View this article in WRRO
Cooper C, Bardin T, Brandi M-L, Cacoub P, Caminis J, Civitelli R, Cutolo M, Dere W, Devogelaer J-P, Diez-Perez A , Einhorn TA et al (2016) Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clinical and Experimental Research, 28(1), 1-16.
Harvey NC, Johansson H, Odén A, Karlsson MK, Rosengren BE, Ljunggren Ö, Cooper C, McCloskey E, Kanis JA, Ohlsson C & Mellström D (2016) FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporosis International, 27(1), 267-274.
McCloskey E (2016) A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base. Osteoporosis International, 27(1), 417-419.
Robinson PC, Leo PJ, Pointon JJ, Harris J, Cremin K, Bradbury LA, Stebbings S, Harrison AA, Evans DM, Duncan EL , Wordsworth BP et al (2016) The genetic associations of acute anterior uveitis and their overlap with the genetics of ankylosing spondylitis. Genes & Immunity, 17(1), 46-51.
Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NFA, McCloskey EV, Walsh JS & Eastell R (2016) Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporosis International, 27(1), 21-31. View this article in WRRO
Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS & Eastell R (2016) Bone turnover markers: response to comments by Seeman and Nguyen. Osteoporosis International, 27(1), 37-37. View this article in WRRO
Reppe S, Wang Y, Thompson WK, McEvoy LK, Schork AJ, Zuber V, LeBlanc M, Bettella F, Mills IG, Desikan RS , Djurovic S et al (2015) Genetic Sharing with Cardiovascular Disease Risk Factors and Diabetes Reveals Novel Bone Mineral Density Loci. PLoS ONE, 10(12). View this article in WRRO
Kanis JA, Compston J, Cooper C, Harvey NC, Johansson H, Odén A & McCloskey EV (2015) SIGN Guidelines for Scotland: BMD Versus FRAX Versus QFracture. Calcified Tissue International, 98(5), 417-425.
Zerbini CAF, Szejnfeld VL, Abergaria BH, McCloskey EV, Johansson H & Kanis JA (2015) Incidence of hip fracture in Brazil and the development of a FRAX model. Archives of Osteoporosis, 10(1).
Johansson H, Odén A, Lorentzon M, McCloskey E, Kanis JA, Harvey NC, Karlsson MK & Mellström D (2015) Is the Swedish FRAX model appropriate for Swedish immigrants?. Osteoporosis International, 26(11), 2617-2622.
Kanis JA, Harvey NC, Johansson H, Odén A, Leslie WD & McCloskey EV (2015) FRAX and fracture prediction without bone mineral density. Climacteric, 18(sup2), 2-9.
Harvey NC, Kanis JA, Odén A, Nakamura T, Shiraki M, Sugimoto T, Kuroda T, Johansson H & McCloskey EV (2015) Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporosis International, 26(9), 2347-2353. View this article in WRRO
Odén A, McCloskey EV, Kanis JA, Harvey NC & Johansson H (2015) Burden of high fracture probability worldwide: secular increases 2010–2040. Osteoporosis International, 26(9), 2243-2248.
Harvey NC, Kanis JA, Odén A, Burge RT, Mitlak BH, Johansson H & McCloskey EV (2015) FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. Osteoporosis International, 26(11), 2677-2684.
McCloskey E, Kanis JA, Johansson H, Harvey N, Odén A, Cooper A, Cooper C, Francis RM, Reid DM, Marsh D , Selby P et al (2015) FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK. Osteoporosis International, 26(8), 2091-2099.
Harvey NC, Glüer CC, Binkley N, McCloskey EV, Brandi M-L, Cooper C, Kendler D, Lamy O, Laslop A, Camargos BM , Reginster J-Y et al (2015) Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone, 78, 216-224.
Leslie WD, Lix LM, Morin SN, Johansson H, Odén A, McCloskey EV & Kanis JA (2015) Hip Axis Length Is a FRAX- and Bone Density-Independent Risk Factor for Hip Fracture in Women. The Journal of Clinical Endocrinology & Metabolism, 100(5), 2063-2070.
Alonso N, Soares DC, V McCloskey E, Summers GD, Ralston SH & Gregson CL (2015) Atypical Femoral Fracture in Osteoporosis Pseudoglioma Syndrome Associated with Two Novel Compound Heterozygous Mutations inLRP5. Journal of Bone and Mineral Research, 30(4), 615-620.
McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H & Kanis JA (2015) Adjusting Fracture Probability by Trabecular Bone Score. Calcified Tissue International, 96(6), 500-509.
McCloskey EV, Kanis JA, Odén A, Harvey NC, Bauer D, González-Macias J, Hans D, Kaptoge S, Krieg MA, Kwok T , Marin F et al (2015) Predictive ability of heel quantitative ultrasound for incident fractures: an individual-level meta-analysis. Osteoporosis International, 26(7), 1979-1987.
McCloskey EV, Harvey NC & Kanis JA (2015) Can we treat to target in osteoporosis?. International Journal of Clinical Rheumatology, 10(1), 1-4.
(2015) CORRIGENDA. The Journal of Clinical Endocrinology & Metabolism, 100(8), 3219-3219.
Kanis JA, McCloskey EV, Harvey NC, Johansson H & Leslie WD (2015) Intervention Thresholds and the Diagnosis of Osteoporosis. Journal of Bone and Mineral Research, 30(10), 1747-1753.
Duncan R, Francis RM, Jagger C, Kingston A, McCloskey E, Collerton J, Robinson L, Kirkwood TBL & Birrell F (2015) Magnitude of fragility fracture risk in the very old—are we meeting their needs? The Newcastle 85+ Study. Osteoporosis International, 26(1), 123-130.
(2015) CORRIGENDA. The Journal of Clinical Endocrinology & Metabolism, 100(8), 3219-3219.
Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV & Epidemiology and Quality of Life Working Group of IOF (2014) Worldwide uptake of FRAX.. Arch Osteoporos, 9, 166.
Leslie WD, Orwoll ES, Nielson CM, Morin SN, Majumdar SR, Johansson H, Odén A, McCloskey EV & Kanis JA (2014) Estimated Lean Mass and Fat Mass Differentially Affect Femoral Bone Density and Strength Index but Are Not FRAX Independent Risk Factors for Fracture. Journal of Bone and Mineral Research, 29(11), 2511-2519.
Johansson H, Kanis JA, Odén A, Leslie WD, Fujiwara S, Glüer CC, Kroger H, LaCroix AZ, Lau E, Melton LJ , Eisman JA et al (2014) Impact of Femoral Neck and Lumbar Spine BMD Discordances on FRAX Probabilities in Women: A Meta-analysis of International Cohorts. Calcified Tissue International, 95(5), 428-435.
Paggiosi MA, Peel N, McCloskey E, Walsh JS & Eastell R (2014) Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporosis International, 25(12), 2729-2741.
Kanis JA, Svedbom A, Harvey N & McCloskey EV (2014) The osteoporosis treatment gap.. J Bone Miner Res, 29(9), 1926-1928.
Leslie WD, Johansson H, Kanis JA, Oden A, McCloskey EV, Lamy O & Hans D (2014) Lumbar spine texture enhances 10-year fracture probability assessment. Osteoporosis International.
Kanis JA, Harvey NC & McCloskey E (2014) Pre-screening young postmenopausal women for BMD testing. BoneKEy Reports, 3.
Svedbom A, Wintzell V, Alekna V, Bianchi ML, Clark P, Díaz-Curiel M, Dimai HP, Lesnyak O, McCloskey E, Sanders KM , Tamulaitiene M et al (2014) Resource Use Related To Vertebral Fractures Based On Data From Icuros. Value in Health, 17(3), A48-A49.
Leslie WD, Majumdar SR, Lix LM, Morin SN, Johansson H, Oden A, McCloskey EV & Kanis JA (2014) Can Change in FRAX Score Be Used to " Treat to Target"? A Population- Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, 29(5), 1074-1080.
Odén A, Kanis JA, McCloskey EV & Johansson H (2014) The effect of latitude on the risk and seasonal variation in hip fracture in Sweden.. J Bone Miner Res, 29(10), 2217-2223.
Zhang L, Choi HJ, Estrada K, Leo PJ, Li J, Pei Y-F, Zhang Y, Lin Y, Shen H, Liu Y-Z , Liu Y et al (2014) Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Human Molecular Genetics, 23(7), 1923-1933.
Johansson H, Odén A, Kanis JA, McCloskey EV, Morris HA, Cooper C, Vasikaran S & IFCC-IOF Joint Working Group on Standardisation of Biochemical Markers of Bone Turnover (2014) A meta-analysis of reference markers of bone turnover for prediction of fracture.. Calcif Tissue Int, 94(5), 560-567.
Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA & Bilezikian JP (2014) Trabecular bone score: A noninvasive analytical method based upon the DXA image. Journal of Bone and Mineral Research, 29(3), 518-530.
Oei L, Estrada K, Duncan EL, Christiansen C, Liu C-T, Langdahl BL, Obermayer-Pietsch B, Riancho JA, Prince RL, van Schoor NM , McCloskey E et al (2014) Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus.. Bone, 59, 20-27.
Oei L, Estrada K, Duncan EL, Christiansen C, Liu C-T, Langdahl BL, Obermayer-Pietsch B, Riancho JA, Prince RL, van Schoor NM , McCloskey E et al (2014) Genome-wide association study for radiographic vertebral fractures: A potential role for the 16q24 BMD locus. Bone, 59, 20-27.
Johansson H, Kanis JA, Odén A, McCloskey E, Chapurlat RD, Christiansen C, Cummings SR, Diez-Perez A, Eisman JA, Fujiwara S , Glüer C-C et al (2014) A Meta-Analysis of the Association of Fracture Risk and Body Mass Index in Women. Journal of Bone and Mineral Research, 29(1), 223-233.
Sund R, Honkanen R, Johansson H, Odén A, McCloskey E, Kanis J & Kröger H (2014) Evaluation of the FRAX Model for Hip Fracture Predictions in the Population-based Kuopio Osteoporosis Risk Factor and Prevention Study (OSTPRE). Calcified Tissue International, 95(1), 39-45.
Johansson H, Odén A, Karlsson MK, McCloskey E, Kanis JA, Ohlsson C & Mellström D (2014) Waning predictive value of serum adiponectin for fracture risk in elderly men: MrOS Sweden. Osteoporosis International, 25(7), 1831-1836.
Siggeirsdottir K, Aspelund T, Johansson H, Gudmundsson EF, Mogensen B, Jonsson BY, Gudnason V, McCloskey E, Oden A, Sigurdsson G & Kanis JA (2014) The incidence of a first major osteoporotic fracture in Iceland and implications for FRAX. Osteoporosis International, 25(10), 2445-2451.
Piscitelli P, Brandi M, Cawston H, Gauthier A, Kanis JA, Compston J, Borgström F, Cooper C & McCloskey E (2014) Epidemiological Burden of Postmenopausal Osteoporosis in Italy from 2010 to 2020: Estimations from a Disease Model. Calcified Tissue International, 95(5), 419-427.
Brennan SL, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E & Kanis JA (2014) FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporosis International, 25(1), 61-69.
Kanis JA, McCloskey E, Branco J, Brandi M-L, Dennison E, Devogelaer J-P, Ferrari S, Kaufman J-M, Papapoulos S, Reginster J-Y & Rizzoli R (2014) Goal-directed treatment of osteoporosis in Europe. Osteoporosis International, 25(11), 2533-2543.
Johansson H, Odén A, McCloskey EV & Kanis JA (2014) Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures.. Osteoporos Int, 25(1), 235-241.
Yang L, Udall WJM, McCloskey EV & Eastell R (2014) Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study.. Osteoporos Int, 25(1), 251-263.
Moayyeri A, Hsu Y-H, Karasik D, Estrada K, Xiao S-M, Nielson C, Srikanth P, Giroux S, Wilson SG, Zheng H-F , Smith AV et al (2014) Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. Human Molecular Genetics, 23(11), 3054-3068.
Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B & Kanis JA (2013) Osteoporosis in the European Union: A compendium of country-specific reports. Archives of Osteoporosis, 8(1-2). View this article in WRRO
Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B & Kanis JA (2013) Osteoporosis in the European Union: Medical management, epidemiology and economic burden: A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Archives of Osteoporosis, 8(1-2). View this article in WRRO
Kanis JA, Borgström F, Compston J, Dreinhöfer K, Nolte E, Jonsson L, Lems WF, McCloskey EV, Rizzoli R & Stenmark J (2013) SCOPE: a scorecard for osteoporosis in Europe.. Archives of osteoporosis, 8(1-2), 144.
Kanis JA, Borgström F, Compston J, Dreinhöfer K, Nolte E, Jonsson L, Lems WF, McCloskey EV, Rizzoli R & Stenmark J (2013) SCOPE: A scorecard for osteoporosis in Europe. Archives of Osteoporosis, 8(1-2). View this article in WRRO
Grigorie D, Sucaliuc A, Johansson H, Kanis JA & McCloskey E (2013) Incidence of Hip Fracture in Romania and the Development of a Romanian FRAX Model. Calcified Tissue International, 92(5), 429-436.
Grigorie D, Sucaliuc A, Johansson H, Kanis JA & McCloskey E (2013) FRAX-based intervention and assessment thresholds for osteoporosis in Romania. Archives of Osteoporosis, 8(1-2).
Leslie WD, Brennan SL, Lix LM, Johansson H, Oden A, McCloskey E & Kanis JA (2013) Direct comparison of eight national FRAX® tools for fracture prediction and treatment qualification in Canadian women. Archives of Osteoporosis, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Masaryk P, Payer J , Jackuliak P et al (2013) Epidemiology and Economic Burden of Osteoporosis in Slovakia. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Lyritis GP, Makras P & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Greece. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in UK. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Alekna V, Tamulaitiene M & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Lithuania. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Hirsch M & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Luxembourg. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Dreinhoefer K & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Germany. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Abrahamsen B & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Denmark. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Georgiades GL & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Cyprus. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Bayer M & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in the Czech Republic. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Diez-Perez A & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Spain. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Brandi ML, Silveri F , Rossini M et al (2013) Epidemiology and Economic Burden of Osteoporosis in Italy. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Akesson K & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Sweden. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Papapoulos S & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in the Netherlands. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kocjan T & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Slovenia. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Borissova A-M, Kovacheva R , Shinkov A et al (2013) Epidemiology and Economic Burden of Osteoporosis in Bulgaria. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Monteiro J & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Portugal. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Dimai HP & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Austria A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kroger H & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Finland. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Hiligsmann M, Goemaere S , Reginster J-Y et al (2013) Epidemiology and Economic Burden of Osteoporosis in Belgium. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, O'Brien M & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Ireland. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in France. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Czerwinski E, Badurski JE , Lorene RS et al (2013) Epidemiology and Economic Burden of Osteoporosis in Poland. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Rasa I, Pavlina I , Berza S et al (2013) Epidemiology and Economic Burden of Osteoporosis in Latvia. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Grigorie D & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Romania. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Lakatos P, Szekeres L , Marton I et al (2013) Epidemiology and Economic Burden of Osteoporosis in Hungary. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Ivergard M, Svedbom A, Hernlund E, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Galea RP & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Malta. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Maasalu K & Kanis JA (2013) Epidemiology and Economic Burden of Osteoporosis in Estonia. ARCHIVES OF OSTEOPOROSIS, 8(1-2).
McCloskey E (2013) Assessing fracture risk in patients with osteoporosis. Practitioner, 257(1765), 19-21.
Wintzell V, Ivergård M, Tankó LB, Barghout V, Svedbom A, Alekna V, Bianchi ML, Clark P, Díaz Curiel M, Dimai HP , Jürisson M et al (2013) The Resource Use Related to Hip Fractures Based on Data from ICUROS. Value in Health, 16(7), A573-A574.
Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E & Kanis JA (2013) Selection of Women Aged 50–64Yr for Bone Density Measurement. Journal of Clinical Densitometry, 16(4), 570-578.
Leslie W, Kanis JA, Lamy O, Johansson H, McCloskey EV & Hans D (2013) Adjustment of FRAX probability according to lumbar spine Trabecular Bone Score (TBS): The Manitoba BMD Cohort. Journal of Clinical Densitometry, 16(3), 267-268.
Targownik LE, Bernstein CN, Nugent Z, Johansson H, Oden A, McCloskey E, Kanis JA & Leslie WD (2013) Inflammatory bowel disease and the risk of fracture after controlling for FRAX. Journal of Bone and Mineral Research, 28(5), 1007-1013.
McCloskey E, Compston J & Kanis J (2013) Confused thinking about discrepancies in predicted fracture risk in older people. BMJ, 346(mar12 3), f1427-f1427.
Goodyear SR, Barr RJ, McCloskey E, Alesci S, Aspden RM, Reid DM & Gregory JS (2013) Can we improve the prediction of hip fracture by assessing bone structure using shape and appearance modelling?. Bone, 53(1), 188-193.
Kaufman J-M, Reginster J-Y, Boonen S, Brandi ML, Cooper C, Dere W, Devogelaer J-P, Diez-Perez A, Kanis JA, McCloskey E , Mitlak B et al (2013) Treatment of osteoporosis in men. Bone, 53(1), 134-144.
McCloskey E & Leslie WD (2013) Goal-directed therapy in osteoporosis. Journal of Bone and Mineral Research, 28(3), 439-441.
Borgström F, Lekander I, Ivergård M, Ström O, Svedbom A, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP , Jürisson M et al (2013) The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)—quality of life during the first 4 months after fracture. Osteoporosis International, 24(3), 811-823.
Gregson CL, Paggiosi MA, Crabtree N, Steel SA, McCloskey E, Duncan EL, Fan B, Shepherd JA, Fraser WD, Smith GD & Tobias JH (2013) Analysis of Body Composition in Individuals With High Bone Mass Reveals a Marked Increase in Fat Mass in Women But Not Men. The Journal of Clinical Endocrinology & Metabolism, 98(2), 818-828.
Francis R, Reid DM, Cooper A, McCloskey EV, Cooper C, Kanis JA, Compston J, Bowring C, Davies C, Marsh D & Selby P (2013) Corrigendum to "Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013" [Maturitas 75 (2013) 392-396] (DOI:10.1016/j.maturitas.2013.08.006). Maturitas.
Francis R, Reid DM, Cooper A, McCloskey EV, Cooper C, Kanis JA, Compston J, Bowring C, Davies C, Marsh D & Selby P (2013) Erratum to "Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013" [Maturitas 75 (2013) 392-396] (DOI:10.1016/j.maturitas.2013.05.013). Maturitas.
Wu C-H, Chang Y-F, McCloskey EV, Lee JK, Itabashi A, Prince R, Yu W, Li-Yu J, Chionh SB, Zhao Y , Shin CS et al (2013) Consensus of Official Position of IOF/ISCD FRAX Initiatives in Asia-Pacific Region. Journal of Clinical Densitometry.
Francis R, Reid DM, Cooper A, McCloskey EV, Cooper C, Kanis JA, Compston J, Bowring C, Davies C, Marsh D & Selby P (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas.
Audran M, Jakob FJ, Palacios S, Brandi M-L, Bröll H, Hamdy NAT & Mccloskey EV (2013) A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatology International, 1-9.
Peters B, Post F, Wierzbicki AS, Phillips A, Power L, Das S, Johnson M, Moyle G, Hughes L, Wilkins E , McCloskey E et al (2013) Screening for chronic comorbid diseases in people with HIV: the need for a strategic approach. HIV Medicine, 14, 1-11.
Kanis JA, Oden A, Johansson H & McCloskey E (2013) Pitfalls in the external validation of FRAX: response to Bolland et al.. Osteoporosis International, 24(1), 391-392.
Naylor KE, McCloskey EV, Eastell R & Yang L (2013) Use of DXA-based finite element analysis of the proximal femur in a longitudinal study of hip fracture.. J Bone Miner Res, 28(5), 1014-1021.
Odén A, McCloskey EV, Johansson H & Kanis JA (2013) Assessing the impact of osteoporosis on the burden of hip fractures.. Calcif Tissue Int, 92(1), 42-49.
Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y & Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women.. Osteoporos Int, 24(1), 23-57.
Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Johansson H, McCloskey E & Kanis JA (2012) The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study. Archives of Osteoporosis, 7(1-2), 229-235.
Lesnyak O, Ershova O, Belova K, Gladkova E, Sinitsina O, Ganert O, Romanova M, Khodirev V, Johansson H, McCloskey E & Kanis JA (2012) Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Archives of Osteoporosis, 7(1-2), 67-73.
Shepstone L, Fordham R, Lenaghan E, Harvey I, Cooper C, Gittoes N, Heawood A, Peters TJ, O’Neill T, Torgerson D , Holland R et al (2012) A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporosis International, 23(10), 2507-2515.
McCloskey E & Kanis JA (2012) FRAX updates 2012. Current Opinion in Rheumatology, 24(5), 554-560.
Kanis JA, Johansson H, Odén A & McCloskey EV (2012) The distribution of FRAX(®)-based probabilities in women from Japan.. J Bone Miner Metab, 30(6), 700-705.
McCloskey E, Johansson H, Oden A & Kanis JA (2012) Fracture risk assessment. Clinical Biochemistry, 45(12), 887-893.
Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA & Cooper C (2012) Variations in latitude may or may not explain the worldwide variation in hip fracture incidence.. Osteoporos Int, 23(9), 2401-2402.
Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E & Kanis JA (2012) Does osteoporosis therapy invalidate FRAX for fracture prediction?. Journal of Bone and Mineral Research, 27(6), 1243-1251.
Johansson H, Odén A, Lerner UH, Jutberger H, Lorentzon M, Barrett-Connor E, Karlsson MK, Ljunggren Ö, Smith U, McCloskey E , Kanis JA et al (2012) High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden. Journal of Bone and Mineral Research, 27(6), 1390-1396.
Johansson H, McCloskey E, Odén A & Kanis JA (2012) Risk evaluation and treatment decisions. Bone, 50, S14-S14.
McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C & Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.. J Bone Miner Res, 27(7), 1480-1486.
Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C & IOF Working Group on Epidemiology and Quality of Life (2012) A systematic review of hip fracture incidence and probability of fracture worldwide.. Osteoporos Int, 23(9), 2239-2256.
Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E & Kanis JA (2012) A comparative study of using non-hip bone density inputs with FRAX®. Osteoporosis International, 23(3), 853-860.
Johansson H, Kanis JA, Oden A, Compston J & McCloskey E (2012) A comparison of case-finding strategies in the UK for the management of hip fractures. Osteoporosis International, 23(3), 907-915.
Johansson H, Odén A, Kanis J, McCloskey E, Lorentzon M, Ljunggren Ö, Karlsson MK, Thorsby PM, Tivesten Å, Barrett-Connor E , Ohlsson C et al (2012) Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden. Osteoporosis International, 23(3), 991-999.
Gregson CL, Steel SA, O’Rourke KP, Allan K, Ayuk J, Bhalla A, Clunie G, Crabtree N, Fogelman I, Goodby A , Langman CM et al (2012) ‘Sink or swim’: an evaluation of the clinical characteristics of individuals with high bone mass. Osteoporosis International, 23(2), 643-654. View this article in WRRO
Kanis JA, Oden A, Johansson H & McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporosis International, 23(2), 423-431.
Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E & Kanis JA (2012) FRAX underestimates fracture risk in patients with diabetes. Journal of Bone and Mineral Research, 27(2), 301-308.
Gauthier A, Kanis JA, Jiang Y, Dreinhöfer K, Martin M, Compston J, Borgström F, Cooper C & McCloskey E (2012) Burden of postmenopausal osteoporosis in Germany: estimations from a disease model. Archives of Osteoporosis, 7(1-2), 209-218.
Cawston H, Maravic M, Fardellone P, Gauthier A, Kanis JA, Compston J, Borgström F, Cooper C & McCloskey E (2012) Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. Archives of Osteoporosis, 7(1-2), 237-246.
Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Perez AD, Eastell R, Hofbauer LC , Kanis JA et al (2012) An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Archives of Osteoporosis, 7(1-2), 25-30.
Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC , Kanis JA et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporosis International, 23(9), 2257-2276.
Estrada K, Styrkarsdottir U, Evangelou E, Hsu Y-H, Duncan EL, Ntzani EE, Oei L, Albagha OME, Amin N, Kemp JP , Koller DL et al (2012) Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature Genetics, 44(5), 491-501. View this article in WRRO
Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA & Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporosis International, 1-18.
Lewiecki EM, Bilezikian JP, Jankowski LG, McCloskey EV, Miller PD, Morgan SL, Orwoll ES & Potts JT (2012) Proceedings of the 2011 Santa Fe Bone Symposium. Journal of Clinical Densitometry, 15(1), 1-20.
Kanis JA, McCloskey E, Johansson H, Oden A & Leslie WD (2012) FRAX® with and without Bone Mineral Density. Calcified Tissue International, 90(1), 1-13.
Leslie WD, Majumdar SR, Lix LM, Johansson H, Oden A, McCloskey E & Kanis JA (2012) High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporosis International, 23(1), 391-397.
Leslie WD, Morin S, Lix LM, Johansson H, Oden A, McCloskey E & Kanis JA (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporosis International, 23(1), 75-85.
Stone B, McCloskey E, Bowman C & Dockrell D (2011) Is FRAX® a valid screening tool for fragility fracture risk assessment in HIV-positive individuals?. Journal of Infection, 63(6), e39-e40.
Czerwinski E, Kanis JA, Osieleniec J, Kumorek A, Milert A, Johansson H, McCloskey EV & Gorkiewicz M (2011) Evaluation of FRAX to characterise fracture risk in Poland. OSTEOPOROSIS INT, 22(9), 2507-2512.
Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G , Johansson H et al (2011) Interpretation and use of FRAX in clinical practice.. Osteoporos Int, 22(9), 2395-2411.
McCloskey EV, Vasikaran S, Cooper C & FRAX(®) Position Development Conference Members (2011) Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.. J Clin Densitom, 14(3), 220-222.
McCloskey EV, Binkley N & FRAX(®) Position Development Conference Members (2011) FRAX(®) Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.. J Clin Densitom, 14(3), 181-183.
Kanis JA, Johansson H, Oden A & McCloskey EV (2011) Erratum to: A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).. Osteoporos Int, 22(8), 2357-2358.
Johansson H, Odén A, Kanis J, McCloskey E, Lorentzon M, Ljunggren Ö, Karlsson MK, Orwoll E, Tivesten Å, Ohlsson C & Mellström D (2011) Low bone mineral density is associated with increased mortality in elderly men: MrOS Sweden. Osteoporosis International, 22(5), 1411-1418.
Duncan EL, Danoy P, Kemp JP, Leo PJ, McCloskey E, Nicholson GC, Eastell R, Prince RL, Eisman JA, Jones G , Sambrook PN et al (2011) Genome-Wide Association Study Using Extreme Truncate Selection Identifies Novel Genes Affecting Bone Mineral Density and Fracture Risk. PLoS Genetics, 7(4). View this article in WRRO
Leslie W, Lix L, Johansson H, McCloskey E & Kanis J (2011) A Helping of Hip and a Sprinkling of Spine: The Blended T-score is Equivalent to the Offset Enhancement for Fracture Prediction with FRAX. Journal of Clinical Densitometry, 14(2), 161-161.
Fraser L-A, Langsetmo L, Berger C, Ioannidis G, Goltzman D, Adachi JD, Papaioannou A, Josse R, Kovacs CS, Olszynski WP , Towheed T et al (2011) Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporosis International, 22(3), 829-837.
Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E & Kanis JA (2011) Spine–hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporosis International, 22(3), 839-847.
Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA, Adachi JD, Johansson H, Oden A, McCloskey E & Kanis JA (2011) Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporosis International, 22(3), 817-827.
Borgström F, Ström O, Kleman M, McCloskey E, Johansson H, Odén A & Kanis JA (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporosis International, 22(3), 955-965.
Coleman RE & McCloskey EV (2011) Bisphosphonates in oncology.. Bone, 49(1), 71-76.
Kanis JA, Johansson H, Oden A & McCloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).. Osteoporos Int, 22(8), 2347-2355.
McCloskey E (2011) Use of FRAX® to target BMD in women <65 years of age. Nature Reviews Endocrinology, 7(7), 383-384.
Kanis JA, Johansson H, Oden A & McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids.. Osteoporos Int, 22(3), 809-816.
Gauthier A, Kanis JA, Jiang Y, Martin M, Compston JE, Borgström F, Cooper C & McCloskey EV (2011) Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: Estimations from a disease model. Archives of Osteoporosis, 6(1-2), 179-188.
Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV & Jönsson B (2011) Osteoporosis: Burden, health care provision and opportunities in the EU. Archives of Osteoporosis, 6(1-2), 59-155.
MacKey DC, Black DM, Bauer DC, McCloskey EV, Eastell R, Mesenbrink P, Thompson JR & Cummings SR (2011) Effects of antiresorptive treatment on nonvertebral fracture outcomes. Journal of Bone and Mineral Research, 26(10), 2411-2418.
Leib ES, Saag KG, Adachi JD, Geusens PP, Binkley N, McCloskey EV & Hans DB (2011) Official Positions for FRAX^® Clinical Regarding Glucocorticoids: The impact of the Use of Glucocorticoids on the Estimate by FRAX^® of the 10 Year Risk of Fracture. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX^®M. Journal of Clinical Densitometry, 14(3), 212-219.
Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Cooper C, Dawson-Hughes B, El-Hajj Fuleihan G , Leslie WD et al (2011) Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX^®. Executive Summary of the 2010 Position Development Conference on Interpretation and Use of FRAX^® in Clinical Practice. Journal of Clinical Densitometry, 14(3), 171-180.
Gauthier A, Kanis JA, Jiang Y, Martin M, Compston JE, Borgström F, Cooper C & McCloskey EV (2011) Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. Archives of Osteoporosis, 1-10.
Post FA, McCloskey EV, Compston JE, Bowman CA, Hay PE, Johnson MA, Mallon PWG, Peters BS, Samarawickrama A & Tudor-Williams G (2011) Prevention of bone loss and management of fracture risk in HIV-infected individuals: Case studies and recommendations for different patient subgroups. Future Virology, 6(6), 769-782.
Kanis JA, Johansson H, Oden A & McCloskey EV (2011) Adjustment of the FRAX (R) for the Glucocorticoid Dosis. OSTEOLOGIE, 20(1), 82-83.
Johansson H, Clark P, Carlos F, Oden A, McCloskey EV & Kanis JA (2011) Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican Institute of Social Security.. Osteoporos Int, 22(8), 2359-2364.
Johansson H, Kanis JA, McCloskey EV, Odén A, Devogelaer J-P, Kaufman J-M, Neuprez A, Hiligsmann M, Bruyere O & Reginster J-Y (2011) A FRAX® model for the assessment of fracture probability in Belgium.. Osteoporos Int, 22(2), 453-461.
Gauthier A, Kanis JA, Martin M, Compston J, Borgström F, Cooper C & McCloskey E (2011) Development and validation of a disease model for postmenopausal osteoporosis. Osteoporosis International, 22(3), 771-780.
McCloskey E (2010) Calculating fracture risk in primary care. Practitioner, 254(1725), 7.
Kanis JA, McCloskey EV, Jonsson B, Cooper A, Ström O & Borgström F (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Archives of Osteoporosis, 5(1-2), 19-48.
Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E & Kanis JA (2010) Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration. Journal of Bone and Mineral Research, 25(11), 2350-2358.
Ström O, Borgström F, Kleman M, McCloskey E, Odén A, Johansson H & Kanis JA (2010) FRAX® and its applications in health economics—Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone, 47(2), 430-437.
Stone B, Dockrell D, Bowman C & McCloskey E (2010) HIV and bone disease. Archives of Biochemistry and Biophysics.
Kanis JA, Johansson H, Oden A & McCloskey EV (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.. Bone, 47(4), 729-735.
Gregson C, Crabtree N, Steel S, Poole K, McCloskey E & Tobias JH (2010) Identification of high bone mass; a syndrome characterised by mandible enlargement, an inability to float and increased total body fat mass. Bone, 47, S227-S227.
Johansson H, Oden A, Chines A, Kanis J & Mccloskey E (2010) Non-vertebral fracture risk reduction by bazedoxifene. Bone, 47, S211-S211.
Goodyear SR, Gregory JS, Barr RJ, McCloskey EV, Alesci S, Lee JH, Aspden RM & Reid DM (2010) Can active shape and appearance modelling be used to generate risk factors for hip fracture?. Bone, 47, S163-S163.
Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O & Borgström F (2010) Development and use of FRAX in osteoporosis.. Osteoporos Int, 21 Suppl 2, S407-S413.
McCloskey E, Compston J & Cooper C (2010) The US FRAX® filter: avoiding confusion or hindering progress?. Osteoporosis International, 21(5), 885-885.
Clark EM, Hutchinson AP, McCloskey EV, Stone MD, Martin JC, Bhalla AK & Tobias JH (2010) Lateral back pain identifies prevalent vertebral fractures in post-menopausal women: cross-sectional analysis of a primary care-based cohort. RHEUMATOLOGY, 49(3), 505-512.
Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV & Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAXA (R). OSTEOPOROSIS INT, 21(3), 495-505.
McCloskey E, Paterson A, Kanis J, Tähtelä R & Powles T (2010) Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. European Journal of Cancer, 46(3), 558-565.
Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey E & Kanis JA (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporosis International, 21(2), 339-349.
Kanis JA, McCloskey EV, Johansson H & Oden A (2010) Diagnostic Thresholds for Osteoporosis in Men, 605-611.
Stone B, Dockrell D, Bowman C & McCloskey E (2010) HIV and bone disease. Archives of Biochemistry and Biophysics, 503(1), 66-77.
Kanis JA, McCloskey EV, Jonsson B, Cooper A, Ström O & Borgström F (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Archives of Osteoporosis, 1-30.
Kanis JA, Johansson H, Oden A, Dawson-Hughes B, Melton LJ & McCloskey EV (2010) The effects of a FRAX revision for the USA.. Osteoporos Int, 21(1), 35-40.
Epstein S, Jeglitsch M & McCloskey E (2009) Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Current Medical Research and Opinion, 25(12), 2951-2960.
Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F & Oden A (2009) How to decide who to treat.. Best Pract Res Clin Rheumatol, 23(6), 711-726.
Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, Belleli R, Wright TM & John MR (2009) Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.. Bone, 45(6), 1053-1058.
Kayan K, Johansson H, Oden A, Vasireddy S, Pande K, Orgee J, Kanis JA & McCloskey EV (2009) Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate.. Osteoporos Int, 20(12), 2055-2061.
Stevenson MD, Oakley JE, Lloyd Jones M, Brennan A, Compston JE, McCloskey EV & Selby PL (2009) The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture.. Med Decis Making, 29(6), 678-689. View this article in WRRO
Johansson H, Kanis JA, Oden A, Johnell O & McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporosis International, 20(10), 1675-1682.
McCloskey EV, Johansson H, Oden A & Kanis JA (2009) From relative risk to absolute fracture risk calculation: the FRAX algorithm.. Curr Osteoporos Rep, 7(3), 77-83.
Kanis JA, Johansson H, Oden A & McCloskey EV (2009) Assessment of fracture risk.. Eur J Radiol, 71(3), 392-397.
Kanis JA, McCloskey EV, Johansson H & Oden A (2009) Approaches to the targeting of treatment for osteoporosis.. Nat Rev Rheumatol, 5(8), 425-431.
Kanis JA, Johansson H, Oden A & McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.. Bone, 44(6), 1049-1054.
Borgström F, Coelho J, Ström O, McCloskey E, Odén A, Johansson H & Kanis JA (2009) PMS20 A COMPARISON OF DIFFERENT METHODS OF ESTIMATING FRACTURE RISK AND FRACTURE RISK REDUCTION IN COST-EFFECTIVENESS ANALYSES OF THE OSTEOPOROSIS TREATMENT BAZEDOXIFENE. Value in Health, 12(3), A67-A67.
Goodman K, Fraser WD, Selby P, McCloskey E, Hampson G, Gennari L, Brandi M, Del Pino J, Brown J, Hooper M , Walsh J et al (2009) Design of an international, randomised trial of genetic testing and targeted zoledronic acid therapy to prevent sqstm1 mediated Paget's disease: the Zipp trial. Bone, 44, S123-S124.
McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T & Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study.. Osteoporos Int, 20(5), 811-817.
Kanis JA, Oden A, Johansson H, Borgström F, Ström O & McCloskey E (2009) FRAX® and its applications to clinical practice. Bone, 44(5), 734-743.
Aloumanis K, Murphy E, Williams G, Eastell R & McCloskey E (2009) A history of thyroid disease and body composition in elderly women. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 39, 4-4.
Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P & Wilkins M (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas, 62(2), 105-108.
Neuprez A, Johansson H, Kanis JA, McCloskey EV, Odén A, Bruyère O, Hiligsmann M, Devogelaer JP, Kaufman JM & Reginster JY (2009) A FRAX® model for the assessment of fracture probability in belgium. Revue Medicale de Liege, 64(12), 612-619.
Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F & Oden A (2009) Case finding for the management of osteoporosis with FRAX®-assessment and intervention thresholds for the UK (Osteoporosis International DOI: 10.1007/s00198-008-0712-1). Osteoporosis International, 20(3), 499-502.
Yang L, Peel N, Clowes JA, McCloskey EV & Eastell R (2009) Use of DXA-based structural engineering models of the proximal femur to discriminate hip fracture.. J Bone Miner Res, 24(1), 33-42.
Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body J-J, Boyce BF, Calvi LM, Hadji P, McCloskey EV , Saad F et al (2008) Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.. Clin Cancer Res, 14(20), 6387-6395.
Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A & National Osteoporosis Guideline Group (2008) Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.. Osteoporos Int, 19(10), 1395-1408.
Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD , Nickelsen T et al (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J BONE MINER RES, 23(10), 1591-1600.
McCloskey EV, Vasireddy S, Threlkeld J, Eastaugh J, Parry A, Bonnet N, Beneton M, Kanis JA & Charlesworth D (2008) Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis.. J Bone Miner Res, 23(10), 1561-1568.
Kanis JA & Compston JE (2008) NICE continues to muddy the waters of osteoporosis. Osteoporosis International, 19(8), 1105-1107.
Yang L, Maric I, McCloskey EV & Eastell R (2008) Shape, structural properties, and cortical stability along the femoral neck: a study using clinical QCT.. J Clin Densitom, 11(3), 373-382.
Kanis JA, Johnell O, Oden A, Johansson H & McCloskey E (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporosis International, 19(4), 385-397.
Kanis JA, Oden A, Johansson H & McCloskey EV (2008) Expressing fracture risk. OSTEOPOROSIS INT, 19(4), 593-594.
Kanis JA, Oden A, Johansson H & McCloskey E (2008) FRAX™ and the assessment of fracture probability: An introduction. IBMS BoneKEy, 5(3), 114-117.
Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ & Khaltaev N (2008) A reference standard for the description of osteoporosis.. Bone, 42(3), 467-475.
Schousboe JT, Taylor BC, Kiel DP, Ensrud KE, Wilson KE & McCloskey EV (2008) Abdominal aortic calcification detected on lateral spine images from a bone densitometer predicts incident myocardial infarction or stroke in older women. J BONE MINER RES, 23(3), 409-416.
Paterson A, McCloskey E, Redzepovic J, Ott I & Gust R (2008) Cost-effectiveness of Oral Clodronate Compared with Oral Ibandronate, Intravenous Zoledronate or Intravenous Pamidronate in Breast Cancer Patients. Journal of International Medical Research, 36(3), 400-413.
Powles TJ, Howell A, Evans DG, McCloskey EV, Ashley S, Greenhalgh R, Affen J, Flook LA & Tidy A (2008) Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause International, 14(1), 6-12.
Yang L, Prevrhal S, McCloskey EV & Eastell R (2008) A method to estimate femoral neck cortical thickness from clinical QCT scans. CALCIFIED TISSUE INT, 82, S181-S182.
Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P & Coleman RE (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.. Cancer Treat Rev, 34 Suppl 1, S3-18.
McCloskey E (2007) The potential impact of modern treatments for breast cancer on bone health. Menopause International, 13(4), 197-197.
McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, Finkelman RD & Eastell R (2007) Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.. Eur J Cancer, 43(17), 2523-2531.
Brown JE, McCloskey EV, Dewar JA, Body JJ, Cameron DA, Harnett AN, Ruutu M, Purohit OP, Tähtelä R & Coleman RE (2007) The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.. Calcif Tissue Int, 81(5), 341-351.
Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit O-P, McCloskey E & Coleman RE (2007) Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid. Clinical Cancer Research, 13(18), 5406-5410.
Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S , Eisman JA et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporosis International, 18(8), 1033-1046.
Johansson H, Oden A, McCloskey E & Kanis J (2007) Estimates of fracture probability in Denmark. Osteoporosis International, 18(8), 1141-1143.
McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A & Eastell R (2007) Interaction between body mass index and bone turnover during aromatase inhibition: Evidence from the letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial. Journal of Clinical Oncology, 25(18_suppl), 560-560.
Bonnet N, Gadois C, McCloskey E, Lemineur G, Lespessailles E, Courteix D & Benhamou CL (2007) Protective effect of β blockers in postmenopausal women: Influence on fractures, bone density, micro and macroarchitecture. Bone, 40(5), 1209-1216.
Kanis JA, Stevenson M, McCloskey EV, Davis S & Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.. Health technology assessment (Winchester, England), 11(7).
Souberbielle B, Williams R & McCloskey E (2007) The cost-effectiveness of bisphosphonates in metastatic breast cancer: letter to the editor in response to Botteman et al. 2006. Annals of Oncology, 18(2), 393-393.
McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, Orgee J, Ashford R, Forster M, Cliffe J , Kersh L et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study.. J Bone Miner Res, 22(1), 135-141.
Kanis JA, Stevenson M, McCloskey EV, Davis S & Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.. Health Technol Assess, 11(7), iii-231.
Obermaier-Pietsch GB, Marin F, McCloskey EV, Hadji P, Simoes ME, Barker C, Oertel H, Nickelsen TN & Boonen S (2007) Effects of prior antiresorptive therapy on markers of bone formation after 6 months of teriparatide treatment in postmenopausal women with osteoporosis: Results from the eurofors trial. CALCIFIED TISSUE INT, 80, S137-S137.
McCloskey EV, Marin F, Obermayer-Pietsch GB, Simoes ME, Barker C, Lyritis G, Oertel H, Nickelsen TN & Boonen S (2007) Effects of prior antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis: Final results from the EUROFORS trial. CALCIFIED TISSUE INT, 80, S30-S30.
Johansson H, McCloskey EV, Oden A, Johnell O, De Laet C, Brow J, Eisman J, Fujiwara S, Goltzman D, Mellstrom D , Melton J et al (2007) Clinical risk factors enhance the performance of BMD in the prediction of fractures. CALCIFIED TISSUE INT, 80, S29-S29.
Yang L, Peel N, Clowes J, Wilson K, McCloskey EV & Eastell R (2007) Use of DXA-based structural engineering models of the proximal femur to predict hip fracture. CALCIFIED TISSUE INT, 80, S25-S26.
Tobias JH, Hutchinson AP, Hunt LP, McCloskey EV, Stone MD, Martin JC, Thompson PW, Palferman TG & Bhalla AK (2007) Use of clinical risk factors to identify postmenopausal women with vertebral fractures. OSTEOPOROSIS INT, 18(1), 35-43.
McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A & Eastell R (2006) The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial: A direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women. Journal of Clinical Oncology, 24(18_suppl), 555-555.
McCloskey E (2006) Current status and future prospects in the management of bone disease. Future Rheumatology, 1(3), 289-291.
McCloskey EV (2006) Aromatase inhibitors and bone health. BoneKEy-Osteovision, 3(6), 5-13.
Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L & Kanis J (2006) Erratum to: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Research, 8(3).
McCloskey E (2006) Effects of third-generation aromatase inhibitors on bone. European Journal of Cancer, 42(8), 1044-1051.
van Hogezand RA, Banffer D, Zwinderman AH, McCloskey EV, Griffioen G & Hamdy NAT (2006) Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. OSTEOPOROSIS INT, 17(4), 535-542.
Coleman RE, Mccloskey EV, Guest JF, Ashford RU & Kanis JA (2006) Cost Implications of Bisphosphonates, 415-426.
Coleman RE, Ashford RU, Mccloskey EV & Kanis JA (2006) Prevention of Bone Loss, 399-414.
Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L & Kanis J (2006) Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Research, 8(2). View this article in WRRO
De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P , McCloskey EV et al (2005) Body mass index as a predictor of fracture risk: A meta-analysis. OSTEOPOROSIS INT, 16(11), 1330-1338.
Kanis JA, Johansson H, Oden A, De Laet C, Johnell O, Eisman JA, McCloskey E, Mellstrom D, Pols H, Reeve J , Silman A et al (2005) A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporosis International, 16(7), 799-804.
McCloskey E, Paterson AHG & Powles TJ (2005) Oral clodronate maintains bone mass in women with primary breast cancer. Journal of Clinical Oncology, 23(16_suppl), 535-535.
Guest JF, Clegg JP, Davie AM & McCloskey E (2005) Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK. Current Medical Research and Opinion, 21(5), 805-815.
LESTER J, DODWELL D, MCCLOSKEY E & COLEMAN R (2005) The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treatment Reviews, 31(2), 115-142.
Pande KC, Pande SK, de Takats D & McCloskey EV (2005) Modified Calcaneal Index: A New Screening Tool for Osteoporosis Based on Plain Radiographs of the Calcaneum. Journal of Orthopaedic Surgery, 13(1), 27-33.
Sanders DS, Patel D, Khan FB, Westbrook RH, Webber CV, Milford-Ward A & McCloskey EV (2005) Case-finding for adult celiac disease in patients with reduced bone mineral density.. Dig Dis Sci, 50(3), 587-592.
Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D , Melton LJ et al (2005) Smoking and fracture risk: a meta-analysis.. Osteoporos Int, 16(2), 155-162.
Toth E, Csupor E, Meszaros S, Ferencz V, Nemeth L, McCloskey EV & Horvath C (2005) The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures - An open label study. BONE, 36(1), 47-51.
Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman JA, McCloskey EV, Mellstrom D, Melton LJ, Pols HAP , Reeve J et al (2004) A family history of fracture and fracture risk: a meta-analysis.. Bone, 35(5), 1029-1037.
Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H , McCloskey EV et al (2004) A meta-analysis of previous fracture and subsequent fracture risk.. Bone, 35(2), 375-382.
Powles T, Paterson A, McCloskey E, Kurkilahti M & Kanis J (2004) Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. Journal of Clinical Oncology, 22(14_suppl), 528-528.
Brown JE, McCloskey E, Dewar JA, Body J-J, Cameron DA, Purohit OP-K, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption. Journal of Clinical Oncology, 22(14_suppl), 8056-8056.
Powles T, Paterson A, McCloskey E, Kurkilahti M & Kanis J (2004) Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. Journal of Clinical Oncology, 22(14_suppl), 528-528.
Brown JE, McCloskey E, Dewar JA, Body J-J, Cameron DA, Purohit OP-K, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption. Journal of Clinical Oncology, 22(14_suppl), 8056-8056.
van der Klift M, de Laet CEDH, McCloskey EV, Johnell O, Kanis JA, Hofman A & Pols HAP (2004) Risk factors for incident vertebral fractures in men and women: The Rotterdam study. J BONE MINER RES, 19(7), 1172-1180.
Pande KC & McCloskey EV (2004) An Age- and Sex-Controlled Matched Pair Analysis of T Scores in Ethnic Indians with Hip Fractures. Journal of Orthopaedic Surgery, 12(1), 133-133.
Johansson H, Oden A, Johnell O, Jonsson B, de Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T & Kanis JA (2004) Optimization of BMD measurements to identify high risk groups for treatment - A test analysis. J BONE MINER RES, 19(6), 906-913.
Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton III LJ, Tenenhouse A, Reeve J, Silman AJ, Pols HAP , Eisman JA et al (2004) A meta-analysis of prior corticosteroid use and fracture risk.. J Bone Miner Res, 19(6), 893-899.
Vasireddy S, Reaney L, Charlesworth D, Kanis JA & McCloskey EV (2004) EFFECT OF MEDICAL RISK FACTORS ON DXA MEASUREMENTS AND METACARPAL RADIOGRAPHIC INDICES. RHEUMATOLOGY, 43, 56-56.
Ørstavik RE, Haugeberg G, Mowinckel P, Høiseth A, Uhlig T, Falch JA, Halse JI, McCloskey E & Kvien TK (2004) Vertebral Deformities in Rheumatoid Arthritis. Archives of Internal Medicine, 164(4), 420-420.
McCloskey EV, Dey A, Parr RM, Aras N, Balogh A, Bostock J, Borelli A, Krishnan S, Lobo G, Qin LL , Zhang Y et al (2004) Global variations in peak bone mass as studied by dual-energy X-ray absorptiometry. J RADIOANAL NUCL CH, 259(2), 341-345.
McCloskey E (2004) Re: generations (Correction concerning a cast member in a recent production of 'Measure for Measure'). TLS-THE TIMES LITERARY SUPPLEMENT(5287), 15-15.
Ralston SH, Coleman R, Fraser WD, Gallagher SJ, Hosking DJ, Iqbal JS, McCloskey E & Sampson D (2003) Medical Management of Hypercalcemia. Calcified Tissue International, 74(1), 1-11.
Ashford RU, Dey A, Kayan K, McCloskey EV & Kanis JA (2003) Oral clodronate as treatment of osteogenesis imperfecta. ARCH DIS CHILD, 88(10), 945-945.
Kayan K, de Takats D, Ashford R, Kanis JA & McCloskey EV (2003) Performance of clinical referral criteria for bone densitometry in patients under 65 years of age assessed by spine bone mineral density.. Postgrad Med J, 79(936), 581-584.
McCloskey EV, Bal S, Tähtelä R, Powles T, Paterson AG, Kanis JA, Ashley S, Tidy A, Atula S & Nevalainen J (2003) 418 Anti-metastatic efficacy of clodronate is associated with a decrease in bone turnover. European Journal of Cancer Supplements, 1(5), S127-S127.
Kayan K, Kanis J & McCloskey E (2003) Osteoporosis management by geriatricians in the UK. Age and Ageing, 32(5), 553-553.
McCloskey EV (2003) Clodronate in the management of breast cancer and multiple myeloma.. Ortop Traumatol Rehabil, 5(2), 227-233.
Vasireddy S, Cliffe J, Charlesworth DK, Jalava T, Kanis JA & McCloskey EV (2003) FRACTURE INCIDENCE IN ELDERLY WOMEN WITH SELF-REPORTED OSTEOARTHRTIS, RHEUMATOID ARTHRITIS OR CURRENT CORTICOSTEROID USE: ANALYSIS FROM THE MRC HIPS STUDY. RHEUMATOLOGY, 42, 112-112.
Sanders DS, Patel D, Stephenson TJ, Ward AM, McCloskey EV, Hadjivassiliou M & Lobo AJ (2003) A primary care cross-sectional study of undiagnosed adult coeliac disease.. Eur J Gastroenterol Hepatol, 15(4), 407-413.
Atula S, Powles T, Paterson A, McCloskey E, Nevalainen J & Kanis J (2003) Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer Patients. Drug Safety, 26(9), 661-671.
Parr RM, Dey A, McCloskey EV, Aras N, Balogh A, Borelli A, Krishnan S, Lobo G, Qin LL, Zhang Y , Cvijetic S et al (2002) Contribution of Calcium and Other Dietary Components to Global Variations in Bone Mineral Density in Young Adults. Food and Nutrition Bulletin, 23(3_suppl1), 180-184.
Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S , Pajunen M et al (2002) Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer. Journal of Clinical Oncology, 20(15), 3219-3224.
Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PHLM, Hamdy NAT, Landman JO, McCloskey EV, Netelenbos JC, Pauwels EKJ, Roos JC , Valentijn RM et al (2002) Daily oral pamidronate in women and men with osteoporosis: A 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J BONE MINER RES, 17(6), 1057-1064.
Van Der Klift M, De Laet CEDH, McCloskey EV, Hofman A & Pols HAP (2002) The incidence of vertebral fractures in men and women: The Rotterdam Study. J BONE MINER RES, 17(6), 1051-1056.
Vasireddy S, Kayan K, Bal SK, Cliffe J, Hinch A, Kanis JA & McCloskey EV (2002) SELF REPORTED RHEUMATOID ARTHRITIS AND CURRENT STEROID USE INCREASE THE RISK OF OSTEOPOROTIC FRACTURES IN ELDERLY WOMEN: A HIPS STUDY INTERIM REPORT. RHEUMATOLOGY, 41, 99-99.
Vasireddy S, Kayan K, Bal SK, Cliffe J, Hinch A, Kanis JA & McCloskey EV (2002) SELF REPORTED OSTEOARTHRITIS IS ASSOCIATED WITH A REDUCED RISK OF OSTEOPOROTIC FRACTURES IN ELDERLY WOMEN: A HIPS STUDY INTERIM REPORT. RHEUMATOLOGY, 41, 100-100.
Sanders DS, Patel D, Stephenson TJ, Ward AM, McCloskey EV, Hadjivassiliou M & Lobo AJ (2002) The relationship of adult coeliac disease with irritable bowel syndrome, iron deficiency anaemia and fatigue: A primary care cross-sectional study. GUT, 50, A18-A18.
McCloskey EV & Kanis JA (2002) Neurological complications of Paget's disease. Clinical Reviews in Bone and Mineral Metabolism, 1(2), 135-143.
Bal SK & McCloskey EV (2002) Menopause and bones. Current Obstetrics and Gynaecology, 12(6), 354-357.
Banffer D, van Hoek B, McCloskey EV, Lamers CBHW & Hamdy NAT (2002) Prevalence of osteoporosis and vertebral fractures and effect of oral bisphosphonates in successful orthotopic liver transplantation. A one-year open study. OSTEOPOROSIS INT, 13, S132-S132.
Banffer D, McCloskey EV, Papapoulos SE & Hamdy NAT (2002) Similar deleterious skeletal effects of intermittent or continuous oral corticosteroids in patients with COPD also using inhalation corticosteroids. OSTEOPOROSIS INT, 13, S131-S131.
van Hogezand RA, Banffer D, McCloskey EV, Zwinderman AM, Papapoulos SE & Hamdy NAT (2002) Low prevalence of osteoporosis and fractures and no significant bone loss at a year's follow-up in well controlled Crohn's disease. OSTEOPOROSIS INT, 13, S132-S132.
van der Klift M, de Laet CEDH, McCloskey EV, Johnell O, Kanis JA, Hofman A & Pols HAP (2002) Risk factors for incident vertebral fractures in men and women: The Rotterdam study. OSTEOPOROSIS INT, 13, S67-S67.
Johnell O, De Laet C, Johansson H, Melton LJ, Eisman J, Reeve J, Tenenhouse A, McCloskey EV & Kanis JA (2002) Oral corticosteroids increase fracture risk independently of BMD. OSTEOPOROSIS INT, 13, S14-S14.
Kayan K, Bal S, Kohler B, Jalava T, Ball A, Cliff J, Charlesworth D, Bostock J, Kanis JA & McCloskey EV (2002) Clinical risk factors for prediction of hip osteoporosis in elderly women. OSTEOPOROSIS INT, 13, S8-S8.
Ashford RU, McCloskey EV, Purohit OP, Ingram CE, Grimer RJ & Coleman RE (2002) Ten-Year Follow-Up of a Patient with Metastatic Ewing's Sarcoma of the Pelvis.. Sarcoma, 6(4), 131-133. View this article in WRRO
Toth E, Meszaros S, Hosszu E, McCloskey EV & Horvath C (2001) Heel ultrasound discriminates osteoporotic males with or without vertebral fractures.. J BONE MINER RES, 16, S523-S523.
van Hogezand RA, Banffer D, Zwinderman AM, McCloskey EV, Papapoulos SE, Lamers CBH & Hamdy NAT (2001) Low prevalence of osteoporosis and fractures and no significant bone loss after one year follow-up in well controlled Crohn's disease.. J BONE MINER RES, 16, S522-S522.
Kayan K, Ashford RU, Dey A, Kohler B, Cliffe J, Hinch A, Ball A, Marples M, Jalava T, Kanis JA & McCloskey EV (2001) BMD independent risk factors for hip fractures in elderly women in England.. J BONE MINER RES, 16, S213-S213.
McCloskey EV, Dunn JA, Kanis JA, MacLennan IC & Drayson MT (2001) Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma.. Br J Haematol, 113(4), 1035-1043.
Ashford RU, Luchetti M, McCloskey EV, Gray RL, Pande KC, Dey A, Kayan K, Ralston SH & Kanis JA (2001) Studies of bone density, quantitative ultrasound, and vertebral fractures in relation to collagen type I alpha 1 alleles in elderly women.. Calcif Tissue Int, 68(6), 348-351.
Kayan K, McCloskey EV, Ashford RU, Dey A & Kanis JA (2001) Sit-to-stand test, a simple predictor of hip and other fractures in older women. BONE, 28(5), S93-S93.
Pande KC, Ashford RU, Dey A, Kayan K, McCloskey EV & Kanis JA (2001) Atypical familial Paget's disease of bone.. Joint Bone Spine, 68(3), 257-261.
McCloskey E, Selby P, de Takats D, Bernard J, Davies M, Robinson J, Francis R, Adams J, Pande K, Beneton M , Jalava T et al (2001) Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone, 28(3), 310-315.
Pande KC, Ashford RU, Dey A, Kayan K, McCloskey EV & Kanis JA (2001) Une maladie osseuse de Paget familiale atypique. Revue du Rhumatisme, 68(5), 439-444.
Powles TJ, Paterson AH, McCloskey E, Ashley S, Tidy VA, Kanis JA & Pylkkänen L (2001) A randomised placebo controlled trial to evaluate the effect of the bisphosphonate, clodronate, on the incidence of metastases and mortality in patients with primary operable breast cancer. Breast Cancer Research and Treatment, 69(3), 209.
Paterson AHG, Powles TJ, Kanis JA, McCloskey EV, Archambault WT, Kurman MR, McCarron T, Pruch JM & Webber DI (2001) Effect of clodronate on time to occurrence of skeletal complications in patients with breast cancer and bone metastases.. BREAST CANCER RES TR, 69(3), 305-305.
McCloskey EV, Guest JF & Kanis JA (2001) The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.. Drugs, 61(9), 1253-1274.
Pande KC, de Takats D, Kanis JA, Edwards V, Slade P & McCloskey EV (2000) Development of a questionnaire (OPQ) to assess patient's knowledge about osteoporosis.. Maturitas, 37(2), 75-81.
Dey A, Parr R, Aras N, Balogh A, Bostock J, Borelli A, Krishnan S, Lobo G, Lin QL, Zhang Y , Cvijetic S et al (2000) Young adult bone mineral density across diverse geographical and racial populations.. J BONE MINER RES, 15, S531-S531.
Ashford R, McGurk C, Ball A, Arnbjerg D, Kanis J & McCloskey EV (2000) Forearm BMD by digital X-ray radiogrammetry: Preliminary comparison of UK and US reference data.. J BONE MINER RES, 15, S531-S531.
De Laet CED, Van der Klift M, McCloskey EV, Kanis JA, Johnell O, Dawson A & Pols HAP (2000) Risk indicators for incident vertebral fractures in men and women.. J BONE MINER RES, 15, S159-S159.
McCloskey EV, Selby P, Davies M, Francis R, Robinson J, Kayan K, Beneton M, Jalava T, Pylkkanen L, Kenrali J & Kanis J (2000) Oral clodronate significantly reduces fracture risk in women with postmenopausal or secondary osteoporosis.. J BONE MINER RES, 15, S227-S227.
Kanis JA & McCloskey EV (2000) Bisphosphonates in multiple myeloma.. Cancer, 88(12 Suppl), 3022-3032.
Cvijetić S, McCloskey E & Koršić M (2000) Vertebral osteophytosis and vertebral deformities in an elderly population sample. Wiener Klinische Wochenschrift, 112(9), 407-412.
Kayan K, de Takats D, Ashford RU, Dey A & McCloskey EV (2000) Clinical referral criteria for bone densitometry in younger women. OSTEOPOROSIS INT, 11, S1-S2.
de Takats D, Richardson A, Kayan K, Ashford RU, Dey A & McCloskey EV (2000) Social and geographical factors influencing local referrals for bone mineral densitometry. OSTEOPOROSIS INT, 11, S1-S1.
Pande KC, Bernard J, McCloskey EV, de Takats D & Kanis JA (2000) Ultrasound velocity and dual-energy X-ray absorptiometry in normal and pagetic bone.. Bone, 26(5), 525-528.
Hosszu E, Ferencz V, Meszaros S, Csupor E, Toth E, Bors K, McCloskey EV & Horvath C (2000) Age-related decrease in bone ultrasonometry in density-adjusted women. OSTEOPOROSIS INT, 11, S124-S124.
Beneton MNC, Robinson J, Dey A, Kayan K, Kanis JA & McCloskey EV (2000) Computing standardised bone mineral density with the Lunar Expert. OSTEOPOROSIS INT, 11, S70-S70.
McCloskey EV, de Takats D, Bernard J, Pande K, Ashford R, Beneton M, Jalava T, Kenraali J, Pylkkanen L & Kanis JA (2000) Comparative predictive ability of skeletal measurements for fragility fracture. OSTEOPOROSIS INT, 11, S100-S100.
Bazarra A, Castro Iglesias A & McCloskey E (2000) Osteoporosis. Hormone replacement therapy and breast cancer. Acta Ginecologica, 57(4), 99-100.
Pande KC, Ashford RU, Dey A, Kayan K, McCloskey EV & Kanis JA (2000) Insufficiency fracture of the calcaneum: an unusual cause of heel pain. The Foot, 10(3), 169-171.
Selby PL, McCloskey EV, Robinson J, Smith IG, Potts B, Beneton MNC & Kanis JA (2000) Is a calculated total hip BMD of clinical use?. OSTEOPOROSIS INT, 11(4), 368-371.
Dey A, McCloskey EV, Taube T, Cox R, Pande KC, Ashford RU, Forster M, de Takats D & Kanis JA (2000) Metacarpal morphometry using a semi-automated technique in the assessment of osteoporosis and vertebral fracture risk.. Osteoporos Int, 11(11), 953-958.
Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Johnell O, Kanis JA, Kellingray S, Leplege A, Liberman UA , McCloskey E et al (1999) Quality of Life in Patients with Vertebral Fractures: Validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Osteoporosis International, 10(2), 150-160.
McCloskey EV, Bone H, Rodan G, McClung M, Wallach S, Lyles KW, Grauer A, Mautelan C, Gutteridge DH, Anderson , Hooper et al (1999) Newer bisphosphonates in the treatment of Paget's disease of bone: Where we are and where we want to go - Discussion. J BONE MINER RES, 14, 74-78.
Diel IJ, Lichinitser MR, Body JJ, Schlosser K, Moecks J, Cavalli F, Dornoff W, Gorbunova VA, McCloskey E, Weiß J & Kanis JA (1999) Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease treated with intravenous ibandronate. European Journal of Cancer, 35, S83-S83.
McCloskey EV, de Takats D, Pande K, Bernard J, Beneton MN, Jalava T, Loyttyniemi E & Kanis JA (1999) Oral clodronate prevents bone loss in elderly women over 3 years of treatment.. J BONE MINER RES, 14, S525-S525.
Forster M, Pande K, de Takats D, McCloskey EV, de Vernijoul MC, Taboulet J, Frenkian M, Frendo JL & Kanis JA (1999) Calcitonin gene receptor polymorphism is not associated with fracture risk factors in a random population sample.. J BONE MINER RES, 14, S231-S231.
de Takats D, McCloskey EV, Bernard J & Kanis JA (1999) Questionnaire survey on current practice in renal osteodystrophy in the United Kingdom.. KIDNEY INT, 55(6), 2569-2569.
de Takats D, Pande K, McCloskey EV, Edwards V & Kanis JA (1999) Early renal and hepatic safety data for a shorter intravenous clodronate regimen in renal impairment.. KIDNEY INT, 55(6), 2595-2595.
de Takats D, Bernard J, McCloskey EV & Kanis JA (1999) Intravenous clodronate 300 mg x 5 days has no deleterious effect on creatinine clearance in mild to moderate renal impairment.. KIDNEY INT, 55(5), 2107-2107.
Bernard J, de Takats D, McCloskey EV, Wilkie M, Brown C, Edwards L, El-Nahas M & Kanis JA (1999) Preliminary comparison of tibial ultrasound velocity with bone mineral density in dialysis patients with marked hyperparathyroidism and with healthy volunteers.. KIDNEY INT, 55(5), 2101-2102.
O'Neill TW, McCloskey EV, Kanis JA, Bhalla AK, Reeve J, Reid DM, Todd C, Woolf AD & Silman AJ (1999) The distribution, determinants, and clinical correlates of vertebral osteophytosis: A population based survey. J RHEUMATOL, 26(4), 842-848.
Kanis JA & McCloskey EV (1999) Effect of calcitonin on vertebral and other fractures.. QJM, 92(3), 143-149.
Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S & Spector T (1999) A high incidence of vertebral fracture in women with breast cancer.. Br J Cancer, 79(7-8), 1179-1181. View this article in WRRO
Bruce NJ, McCloskey EV, Kanis JA & Guest JF (1999) Economic impact of using clodronate in the management of patients with multiple myeloma. BRIT J HAEMATOL, 104(2), 358-364.
(1999) British Association of Surgical Oncology Guidelines: The management of metastatic bone disease in the United Kingdom. European Journal of Surgical Oncology (EJSO), 25(1), 3-23.
Kanis JA, McCloskey EV, de Takats D & Pande K (1999) Clinical assessment of bone mass, quality and architecture.. Osteoporos Int, 9 Suppl 2, S24-S28.
Bishop HM, Cameron DA, Coleman R, Davies AM, Dewar JA, Evans A, Evans A, Harnett AN, McCloskey E, O'Donoghue D , Pullicino V et al (1999) The Guidelines for the management of metastatic bone disease in breast cancer in the United Kingdom. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 25(1), 4-23.
Bazarra A, Castro A, McCloskey E & Talbot JR (1998) How should osteoporosis during the postmenopause be approached?. GINEDIPS, 1(0), 25-27.
Kanis JA & McCloskey EV (1998) Risk factors in osteoporosis.. Maturitas, 30(3), 229-233.
Orme S, Underwood JC, McCloskey E & Hendra TJ (1998) An unusual cause of pulmonary hypertension and right heart failure.. Postgraduate Medical Journal, 74(877), 697-698.
Maggio D, McCloskey EV, Camilli L, Cenci S, Cherubini A, Kanis JA & Senin U (1998) Short-term reproducibility of proximal femur bone mineral density in the elderly. CALCIFIED TISSUE INT, 63(4), 296-299.
McCloskey EV, MacLennan ICM, Drayson MT, Chapman C, Dunn J & Kanis JR (1998) Oral clodronate reduces skeletal morbidity in multiple myeloma. BRIT J HAEMATOL, 102(1), 6-6.
Cohen CB & McCloskey EL (1998) Introduction. Kennedy Institute of Ethics Journal, 8(2), vii-x.
Powles TJ, Ashley S, Tidy VA, Nevantaus A, McCloskey E, Kanis J, Paterson AHG & Rosenqvist K (1998) Oral Clodronate and Reduction in Loss of Bone Mineral Density in Women With Operable Primary Breast Cancer. JNCI: Journal of the National Cancer Institute, 90(9), 704-708.
Bruce NJ, McCloskey EV, Kanis JA & Guest JF (1998) Economic impact of using clodronate in the management of patients with multiple myeloma. BRIT J HAEMATOL, 101, 46-46.
McCloskey EV, MacLennan ICM, Drayson MT, Chapman C, Dunn J, Kanis JA & MRC Working Party Leukaemia Adults (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. BRIT J HAEMATOL, 100(2), 317-325.
McCloskey EV & Libretto SE (1998) Use of Bisphosphonates in the Treatment of Multiple Myeloma. Hematology, 3(4), 291-298.
Brace NJ, McCloskey EV, Kanis JA & Guest JF (1997) PP29. Economic evaluation of the use of prophylactic clodronate to treat multiple myeloma. European Journal of Cancer, 33, S25-S25.
Bruce NJ, McCloskey EV, Kanis JA & Guest JF (1997) Economic evaluation of the use of prophylactic Clodronate to treat multiple myeloma. EUR J CANCER, 33, PP29-PP29.
Kanis JA & McCloskey EV (1997) Clodronate.. Cancer, 80(8 Suppl), 1691-1695.
Kanis JA & McCloskey EV (1997) Bone turnover and biochemical markers in malignancy.. Cancer, 80(8 Suppl), 1538-1545.
Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD , Orgee J et al (1997) Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.. J Bone Miner Res, 12(10), 1700-1707.
Powles TJ, McCloskey E, Paterson AHG, Ashley S, Tidy A & Kanis J (1997) The effect of oral clodronate on bone minerai density in women with primary breast cancer. European Journal of Cancer, 33, S80-S80.
Bernard J, deTakats D, McCloskey EV & Kanis JA (1997) Ultrasound velocity and dexa in normal and pagetic bone.. J BONE MINER RES, 12, T682-T682.
Khan SA, Vasikaran S, McCloskey EV, Benéton MN, Rogers S, Coulton L, Orgee J, Coombes G & Kanis JA (1997) Alendronate in the treatment of Paget's disease of bone.. Bone, 20(3), 263-271.
Nakatsuka K, Sirtori PL, McCloskey EV, Khan SA, Orgee JM, O'Neill TW, Dilsen G & Kanis JA (1997) Preliminary study on relationship between vertebral fracture and aortic calcification in postmenopausal women. Journal of Bone and Mineral Metabolism, 15(4), 218-222.
Kanis JA, McCloskey EV & Beneton MN (1997) Vitamin D and analogues in renal bone disease and implications for osteoporosis.. Osteoporos Int, 7 Suppl 3, S179-S183.
Kanis JA, McCloskey EV, de Takats D, Bernard J & Zhang DM (1997) Treatment of osteoporosis with vitamin D.. Osteoporos Int, 7 Suppl 3, S140-S146.
Kanis JA, Powles T, Paterson AH, McCloskey EV & Ashley S (1996) Clodronate decreases the frequency of skeletal metastases in women with breast cancer.. Bone, 19(6), 663-667.
Khan SA, Brennan P, Newman J, Gray RE, McCloskey EV & Kanis JA (1996) Paget's disease of bone and unvaccinated dogs.. Bone, 19(1), 47-50.
Masud T, Mootoosamy I, McCloskey EV, OSullivan MP, Whitby EP, King D, Matson MB, Doyle DV & Spector TD (1996) Assessment of osteopenia from spine radiographs using two different methods: The Chingford study. BRIT J RADIOL, 69(821), 451-456.
Kanis JA, McCloskey EV & Beneton MN (1996) Clodronate and osteoporosis.. Maturitas, 23 Suppl, S81-S86.
Khan SA, McCloskey EV, Nakatsuka K, Orgee J, Coombes GM & Kanis JA (1996) Duration of response with oral clodronate in Paget's disease of bone.. Bone, 18(2), 185-190.
Khan SA, McCloskey EV, Eyres KS, Nakatsuka K, Sirtori P, Orgee J, Coombes G & Kanis JA (1996) Comparison of three intravenous regimens of clodronate in Paget disease of bone.. J Bone Miner Res, 11(2), 178-182.
Luchetti M, McCloskey E, DeTakats D, Bernard J, Reaney L & Kanis J (1996) Vertebral osteophytosis and bone mass at the hip and forearm in elderly women. Osteoporosis International, 6(S1), 134-134.
McCloskey E, Orgee J, Bernard J, deTakats D, Luchetti M, Beneton M, Charlesworth D & Kanis JA (1996) Vertebral fracture risk. A comparison of ultrasonic and absorptiometric techniques. Osteoporosis International, 6(S1), 217-217.
McCloskey E, Luchetti M, Bernard J, deTakats D, Brazier J, Nicholl J & Kanis J (1996) Bone loss at the hip in elderly women is prevented by oral clodronate — A pilot study. Osteoporosis International, 6(S1), 271-271.
Kanis JA, McCloskey EV, Bernard J, de Takats D & Beneton MNC (1996) Bone measurements with DXA and ultrasound. Osteoporosis International, 6(S1), 89-89.
Orgee JM, Foster H, McCloskey EV, Khan S, Coombes G & Kanis JA (1996) A precise method for the assessment of tibial ultrasound velocity.. Osteoporos Int, 6(1), 1-7.
Kanis JA & McCloskey EV (1996) Evaluation of the risk of hip fracture.. Bone, 18(3 Suppl), 127S-132S.
Vasikaran SD, Khan S, McCloskey EV & Kanis JA (1995) Sustained response to intravenous alendronate in postmenopausal osteoporosis. BONE, 17(6), 517-520.
Paterson AH, Kanis JA, Powles TJ, McCloskey E, Hanson J & Ashley S (1995) Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.. The Canadian journal of oncology, 5 Suppl 1, 54-57.
McCloskey EV, MacLennan ICM, Drayson M, Chapman C, Dunn J & Kanis JA (1995) 775 Effect of clodronate on progression of skeletal disease in multiple myelomatosis. European Journal of Cancer, 31, S162-S162.
O'Doherty DP, McCloskey EV, Vasikaran S, Khan S & Kanis JA (1995) The effects of intravenous alendronate in Paget's disease of bone.. J Bone Miner Res, 10(7), 1094-1100.
Khan SA, Vasikaran S, McCloskey EV & Kanis JA (1995) Determination of the initial retention and rate of elimination of alendronate in postmenopausal osteoporosis. Bone, 16(6), 683-683.
Coombes GM, Nakatsuka K, Sirtori PL, McCloskey EV, O'Neill T & Kanis JA (1995) Relationship between vertebral fracture and aortic calcification in postmenopausal women. Bone, 16(6), 691-692.
McCloskey EV, Sirtori P, Nakatsuka K, Beneton MNC, Khan S & Kanis J (1995) Continuous oral phosphate and intermittent intravenous clodronate in the treatment of postmenopausal osteoporosis — a pilot study. Bone, 16(6), 692-692.
Orgee JM, Taube T, McCloskey EV, Coombes G, Khan S & Kanis JA (1995) Relationship between ultrasound velocity and attenuation in the lower limb and quadriceps strength in elderly women. Bone, 16(6), 691-691.
KANIS JA & MCCLOSKEY EV (1995) EVENTS PER PERSON YEAR - A DECREASE IN MULTIPLE EVENTS MAY BE MISSED. BRIT MED J, 310(6992), 1469-1469.
Laitinen K (1995) Use individual event rate adjustment for follow up time. BMJ, 310(6992), 1469.
O'Rourke N, McCloskey E, Houghton F, Huss H & Kanis JA (1995) Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.. Journal of Clinical Oncology, 13(4), 929-934.
CUMMINGS SR, MELTON LJ, FELSENBERG D, ALLANDER E, BLACK D, COOPER C, DUTTA SN, EASTELL R, EPSTEIN R, GENANT HK , LEIDIGBRUCKNER G et al (1995) ASSESSING VERTEBRAL FRACTURES. JOURNAL OF BONE AND MINERAL RESEARCH, 10(4), 518-523.
Hamdy NAT, McCloskey EV & Kanis JA (1994) Role of bisphosphonates in the medical management of hyperparathyroidism. Acta Chirurgica Austriaca, 26(SUPPL. 112), 6-7.
KANIS JA, OROURKE N & MCCLOSKEY EV (1994) CONSEQUENCES OF NEOPLASIA INDUCED BONE-RESORPTION AND THE USE OF CLODRONATE (REVIEW). INT J ONCOL, 5(4), 713-731.
Vasikaran SD, O'Doherty DP, McCloskey EV, Gertz B, Kahn S & Kanis JA (1994) The effect of alendronate on renal tubular reabsorption of phosphate.. Bone Miner, 27(1), 51-56.
O'Rourke NP, McCloskey EV, Rosini S, Coleman RE & Kanis JA (1994) Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).. Br J Cancer, 69(5), 914-917. View this article in WRRO
Vasikaran SD, McCloskey EV, Kahn S & Kanis JA (1994) Intra-individual variation in fasting urinary calcium- and hydroxyproline-creatinine ratios measured in metabolic bone clinic patients as both outpatients and inpatients.. Ann Clin Biochem, 31 ( Pt 3), 272-276.
Davies KM, McCloskey EV & Kanis JA (1994) Letters. Osteoporosis International, 4(2), 117-119.
MCCLOSKEY EV & KANIS JA (1994) ASSESSING VERTEBRAL DEFORMITIES. OSTEOPOROSIS INT, 4(2), 117-119.
DONNELLY S, DOYLE DV, DENTON A, ROLFE I, MCCLOSKEY EV & SPECTOR TD (1994) BONE-MINERAL DENSITY AND VERTEBRAL COMPRESSION FRACTURE RATES IN ANKYLOSING-SPONDYLITIS. ANN RHEUM DIS, 53(2), 117-121.
Khan S, McCloskey EV, Eyres KS, Fern ED & Kanis JA (1994) Assessment of optimum duration of therapy with oral dichloromethylene diphosphonate (clodronate) in the treatment of Paget's disease.. Semin Arthritis Rheum, 23(4), 271.
Eyres KS, McCloskey EV, Fern ED, Khan S & Kanis JA (1994) Effects of intravenous dichloromethylene bisphosphonate (CL2MBP) in the treatment of Paget's disease of bone.. Semin Arthritis Rheum, 23(4), 270.
O'Rourke N, McCloskey E & Kanis J (1994) WR-2721 and hypocalcemia.. Journal of Clinical Oncology, 12(1), 232-232.
OROURKE NP, MCCLOSKEY EV, NEUGEBAUER G & KANIS JA (1994) RENAL AND NONRENAL CLEARANCE OF CLODRONATE IN PATIENTS WITH MALIGNANCY AND RENAL IMPAIRMENT. DRUG INVEST, 7(1), 26-33.
O'Rourke NP, McCloskey EV & Kanis JA (1994) Tumour induced hypercalcaemia: a case for active treatment.. Clin Oncol (R Coll Radiol), 6(3), 172-176.
Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J & Ashley S (1993) Double-blind trial of oral clodronate in breast cancer patients with bone metastases. Bulletin du cancer, 80(10 Suppl), 50-56.
Kanis JA, Aaron J, Benéton M & McCloskey E (1993) Treatment of osteoporosis. Journal of Bone and Mineral Metabolism, 11(1), S17-S24.
SPECTOR TD, MCCLOSKEY EV, DOYLE DV & KANIS JA (1993) PREVALENCE OF VERTEBRAL FRACTURE IN WOMEN AND THE RELATIONSHIP WITH BONE-DENSITY AND SYMPTOMS - THE CHINGFORD STUDY. J BONE MINER RES, 8(7), 817-822.
Taube T, Beneton MN, Williams JL, McCloskey EV & Kanis JA (1993) Distinction between focally accelerated bone formation and osteomalacia in carcinoma of prostate metastasised to bone.. Br J Urol, 72(1), 98-103.
McCloskey EV, Spector TD, Eyres KS, Fern ED, O'Rourke N, Vasikaran S & Kanis JA (1993) The assessment of vertebral deformity: a method for use in population studies and clinical trials.. Osteoporos Int, 3(3), 138-147.
(1993) BSR Poster Session B. Rheumatology, 32(suppl 1), 108-168.
KANIS JA, MCCLOSKEY EV, OROURKE N, KHAN S, FERN D, EYRES K, SITORI P, TAUBE T, POWLES T & PATERSON A (1993) CLODRONATE IN HYPERCALCEMIA AND OSTEOLYTIC BONE-DISEASE DUE TO BREAST-CANCER. SAUDI MED J, 14(2), 93-97.
O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D & Kanis JA (1993) Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate.. Br J Cancer, 67(3), 560-563. View this article in WRRO
SPECTOR TD, HALL GM, MCCLOSKEY EV & KANIS JA (1993) RISK OF VERTEBRAL FRACTURE IN WOMEN WITH RHEUMATOID-ARTHRITIS. BRIT MED J, 306(6877), 558-558.
Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J & Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.. Journal of Clinical Oncology, 11(1), 59-65.
PATERSON AHG, POWLES TJ, KANIS JA, MCCLOSKEY E, HANSON J & ASHLEY S (1993) DOUBLE-BLIND CONTROLLED TRIAL OF ORAL CLODRONATE IN PATIENTS WITH BONE METASTASES FROM BREAST-CANCER. BULLETIN DU CANCER, 80(10), 50-65.
Kanis JA, McCloskey EV, Sirtori P, Khan S, Fern D, Eyres K, Aaron J & Beneton MN (1993) Rationale for the use of clodronate in osteoporosis.. Osteoporos Int, 3 Suppl 2, S23-S28.
Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M & Kanis JA (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption.. Eur J Haematol, 49(4), 192-198.
EYRES KS, MCCLOSKEY EV, FERN ED, BENETON MNC, ROGERS S, ODOHERTY D & KANIS JA (1992) HAJDU-CHENEY SYNDROME - A REPORT OF 2 CASES. J ORTHOP RHEUMATOL, 5(3), 163-169.
Eyres KS, McCloskey EV, Fern ED, O'Rourke N, Vasikaran S, Risteli J, Risteli I & Kanis JA (1992) Serum type 1 collagen carboxvterminal crosslinked telopeptide (S-1CTP) in Paget's disease of bone and the effect of treatment with bisphosphonates. Bone and Mineral, 17, S29-S29.
McCloskey EV, O'Rourke N, MacLennan I, Chapman C, Beneton M, Greaves M, Preston FE & Kanis JA (1992) Natural history of skeletal disease in multiple myelomatosis and treatment with clodronate. Bone and Mineral, 17, S27-S27.
O'Rourke N, McCloskey E, Eyres K, Vasikaran S & Kanis J (1992) Effective treatment of malignant hypercalcaemia using a single intravenous infusion of clodronate. Bone and Mineral, 17, S28-S28.
Fern ED, Mccloskey EV, Eyres KS, Vasikaran S, Risteli J, Risteli L & Kanis JA (1992) Measurement of carboxy-terminal propeptide (PICP) and carboxy-terminal, pyridinoline-cross-linked telopeptide (1-CTP) in disorders of bone turnover. Bone and Mineral, 17, S21-S21.
Vasikaran SD, Gertz BJ, Sciberras DG, McCloskey EV, O'Rourke N & Kanis JA (1992) Intravenous alendronate therapy in post-menopausal osteoporosis. Bone and Mineral, 17, S25-S25.
Eyres KS, Marshall P, McCloskey E, Douglas DL & Kanis JA (1992) Spontaneous Fractures in a Patient Treated with Low Doses of Etidronic Acid (Disodium Etidronate). Drug Safety, 7(2), 162-165.
Kanis JA & McCloskey EV (1992) Epidemiology of vertebral osteoporosis.. Bone, 13 Suppl 2, S1-10.
Eyres KS, McCloskey EV, Fern ED, Rogers S, Beneton M, Aaron JE & Kanis JA (1992) Osteoporotic fractures: an unusual presentation of haemochromatosis.. Bone, 13(6), 431-433.
Benéton MN, Yates AJ, Rogers S, McCloskey EV & Kanis JA (1991) Stanozolol stimulates remodelling of trabecular bone and net formation of bone at the endocortical surface.. Clin Sci (Lond), 81(4), 543-549.
McCloskey EL (1991) The Spirit of the PSDA. The Hastings Center Report, 21(5), S14-S14.
O'Doherty DP, Bickerstaff DR, McCloskey EV, Eyres KS & Kanis JA (1991) Radiographic healing of osteolytic Paget's disease in the tibia with alendronate. Journal of Orthopaedic Rheumatology, 4(3), 153-157.
Eyres KS, McCloskey EV, O'Doherty DP, Hamdy NAT, Fern ED & Kanis JA (1991) The use of the Mennen clamp-on plate in the management of a pathological fracture. Journal of Orthopaedic Rheumatology, 4(3), 145-151.
Bickerstaff DR, O'Doherty DP, McCloskey EV, Hamdy NA, Mian M & Kanis JA (1991) Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy.. Bone, 12(1), 17-20.
Kanis JA, McCloskey EV, Taube T & O'Rourke N (1991) Rationale for the use of bisphosphonates in bone metastases.. Bone, 12 Suppl 1, S13-S18.
O'Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NA, Beneton MN, Harris S, Mian M & Kanis JA (1990) Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.. J Bone Miner Res, 5(5), 483-491.
McCloskey EV, Murray SA, Charlesworth D, Miller C, Fordham J, Clifford K, Atkins R & Kanis JA (1990) Assessment of broadband ultrasound attenuation in the os calcis in vitro.. Clin Sci (Lond), 78(2), 221-225.
O'Doherty DP, Bickerstaff DR, McCloskey EV, Atkins R, Hamdy NA & Kanis JA (1990) A comparison of the acute effects of subcutaneous and intranasal calcitonin.. Clin Sci (Lond), 78(2), 215-219.
McCloskey EV, Murray SA, Miller C, Charlesworth D, Tindale W, O'Doherty DP, Bickerstaff DR, Hamdy NA & Kanis JA (1990) Broadband ultrasound attenuation in the os calcis: relationship to bone mineral at other skeletal sites.. Clin Sci (Lond), 78(2), 227-233.
KANIS JA, MCCLOSKEY EV & PATERSON AHG (1990) USE OF DIPHOSPHONATES IN HYPERCALCEMIA DUE TO MALIGNANCY. LANCET, 335(8682), 170-171.
McCloskey EV, Murray SA, Charlesworth D, Hamdy NAT & Kanis JA (1990) P21. Broadband ultrasound attenuation of the os calcis in the assessment of osteoporosis. Bone, 11(5), 382-383.
Hamdy NA, McCloskey EV, Brown CB & Kanis JA (1990) Effects of clodronate in severe hyperparathyroid bone disease in chronic renal failure.. Nephron, 56(1), 6-12.
McCloskey EV, Galloway J, Morgan MA & Kanis JA (1989) Pseudohyperphosphataemia in multiple myeloma.. BMJ, 299(6712), 1381-1382.
Hamdy NAT, McCloskey EV, Tindale W, Harris S, Beneton MNC, Boletis J, Brown CB & Kanis JA (1989) P13. The indirect assessment of parathyroid bone disease in renal failure: use of thallium-technetium parathyroid scanning. Bone, 10(6), 478-478.
McCloskey EV, Beneton M, Harris S, Greaves M, Preston FE & Kanis JA (1989) P6. Diphosphonates in multiple myelomatosis. Bone, 10(6), 476-477.
Hamdy NA, McCloskey EV, Naylor VA, Brown CB & Kanis JA (1989) Phosphate binding efficiency of a polyuronic acid in normal subjects.. Nephrol Dial Transplant, 4(9), 829-830.
McCloskey EV, Yates AJ, Gray RE, Hamdy NA, Galloway J & Kanis JA (1988) Diphosphonates and phosphate homoeostasis in man.. Clin Sci (Lond), 74(6), 607-612.
Kanis JA, McCloskey EV, Thavarajah M, Evans D, Hamdy NA, Preston E & Greaves M (1988) Calcium metabolism and myeloma and the treatment of hypercalcemia.. Hematol Oncol, 6(2), 115-117.
JONES PBB, MCCLOSKEY EV & KANIS JA (1987) TRANSIENT TASTE-LOSS DURING TREATMENT WITH ETIDRONATE. LANCET, 2(8559), 637-637.
Jones PBB, Mccloskey EV & Kanis JA (1987) TRANSIENT TASTE-LOSS DURING TREATMENT WITH ETIDRONATE. The Lancet, 330(8559), 637-637.
KANIS JA, GRAY RES & MCCLOSKEY EV (1987) TREATING PAGETS-DISEASE. BRIT MED J, 294(6587), 1612-1613.
KANIS JA, URWIN GH, GRAY RES, BENETON MNC, MCCLOSKEY EV, HAMDY NAT & MURRAY SA (1987) EFFECTS OF INTRAVENOUS ETIDRONATE DISODIUM ON SKELETAL AND CALCIUM-METABOLISM. AM J MED, 82(2A), 55-70.
Jones PBB, McCloskey EV & Kanis JA (1987) Transient taste-loss during treatment with etidronate. Acta Dermato-Venereologica, 67(4), 637.
Hamdy NAT, Gray RES, McCloskey E, Galloway J, Rattenbury JM, Brown CB & Kanis JA (1987) Clodronate in the medical management of hyperparathyroidism. Bone, 8(SUPPl. 1).
McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S & Kanis JA (1987) Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man.. Bone, 8 Suppl 1, S35-S41.
Urwin GH, Yates AJ, Gray RE, Hamdy NA, McCloskey EV, Preston FE, Greaves M, Neil FE & Kanis JA (1987) Treatment of the hypercalcaemia of malignancy with intravenous clodronate.. Bone, 8 Suppl 1, S43-S51.
YATES AJP, MCCLOSKEY EV & KANIS JA (1986) DO ALL DIPHOSPHONATES HAVE HYPERPHOSPHATEMIC EFFECTS IN MAN. BONE, 7(4), 312-312.
Borgström F, Lorentzon M, Johansson H, Harvey NC, McCloskey E, Willems D, Knutsson D & Kanis JA () Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK. Osteoporosis International.
Ye C, Leslie WD, Al-Azazi S, Yan L, Lix LM, Czaykowski P, McCloskey EV, Johansson H, Harvey NC, Kanis JA & Singh H () Fracture Risk Prediction Using the Fracture Risk Assessment Tool in Individuals With Cancer. JAMA Oncology.
Berg K, Dockrell D, Colvin L, Fraser WD, Tang JCY, Aspray T, Dennison E, Divyateja H, Ghouri N, Hanison E , Keen R et al () Causes of Musculoskeletal Pain in Paget’s Disease of Bone. Calcified Tissue International.
Gostage J, Kostenuik P, Goljanek-Whysall K, Bellantuono I, McCloskey E & Bonnet N () Extra-osseous Roles of the RANK-RANKL-OPG Axis with a Focus on Skeletal Muscle. Current Osteoporosis Reports.
Armutcu F & McCloskey E () Insulin resistance, bone health, and fracture risk. Osteoporosis International.
Green O, Raju SA, Shiha MG, Nandi N, Bayley M, McCloskey E & Sanders DS () Clinical utility of the fracture risk assessment tool (FRAX) in biopsy-confirmed coeliac disease. Scandinavian Journal of Gastroenterology, 1-6.
Kanis JA, Harvey NC, Lorentzon M, Liu E, Schini M, Abrahamsen B, Adachi JD, Alokail M, Borgstrom F, Bruyère O , Carey JJ et al () Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk. Osteoporosis International.
Kanis JA, Dawson-Hughes B, Campusano C, Cooper C, Ebeling PR, Halbout P, Harvey NC, McCloskey EV, McClung MR, Reginster J-Y , Saleh Y et al () IOF position on scientists and societies operating in conflict zones. Osteoporosis International.
Westbury LD, Harvey NC, Beaudart C, Bruyère O, Cauley JA, Cawthon P, Cruz-Jentoft AJ, Curtis EM, Ensrud K, Fielding RA , Johansson H et al () Predictive value of sarcopenia components for all-cause mortality: findings from population-based cohorts. Aging Clinical and Experimental Research, 36(1).
McCloskey E, Tan ATH & Schini M () Update on fracture risk assessment in osteoporosis. Current Opinion in Endocrinology, Diabetes & Obesity.
Fuggle NR, Beaudart C, Bruyère O, Abrahamsen B, Al-Daghri N, Burlet N, Chandran M, Rosa MM, Cortet B, Demonceau C , Dere W et al () Evidence-Based Guideline for the management of osteoporosis in men. Nature Reviews Rheumatology.
Gandham A, Gregori G, Johansson L, Johansson H, Harvey NC, Vandenput L, McCloskey E, Kanis JA, Litsne H, Axelsson K & Lorentzon M () Sarcopenia definitions and their association with fracture risk in older Swedish women. Journal of Bone and Mineral Research.
Vandenput L, Johansson H, McCloskey EV, Liu E, Schini M, Åkesson KE, Anderson FA, Azagra R, Bager CL, Beaudart C , Bischoff-Ferrari HA et al () A meta-analysis of previous falls and subsequent fracture risk in cohort studies. Osteoporosis International.
Brown J, Paggiosi MA, Rathbone E, Gregory W, Bertelli G, Din O, McCloskey E, Dodwell D, Cameron D, Eastell R & Coleman R () Adjuvant bisphosphonate therapy and bone health. Journal of Bone and Mineral Research.
Ye C, Schousboe JT, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC, Kanis JA & Leslie WD () FRAX predicts cardiovascular risk in women undergoing osteoporosis screening: the Manitoba BMD registry. Journal of Bone and Mineral Research.
Armutcu F & McCloskey E () Signaling Modifications Associated with Obesity and Dysbiosis and Their Impact on Metabolic Disorders. Journal of Cellular Signaling, 5(2), 57-64.
Richards C, Stevens R, Lix LM, McCloskey EV, Johansson H, Harvey NC, Kanis JA & Leslie WD () Fracture prediction in rheumatoid arthritis: validation of FRAX with bone mineral density for incident major osteoporotic fractures. Rheumatology.
Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA & McCloskey EV () An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. Journal of Endocrinological Investigation.
Leslie WD, Binkley N, Schousboe JT, McCloskey EV, Johansson H, Harvey NC & Kanis JA () Effect of BMI‐Discordant Abdominal Tissue Thickness on Fracture Probability: A Registry‐Based Study. Journal of Bone and Mineral Research.
Ye C, Leslie WD, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC, Lorentzon M & Kanis JA () Adjusting FRAX Estimates of Fracture Probability Based on a Positive Vertebral Fracture Assessment. JAMA Network Open, 6(8), e2329253-e2329253.
Kanis JA, Johansson H, McCloskey EV, Liu E, Åkesson KE, Anderson FA, Azagra R, Bager CL, Beaudart C, Bischoff-Ferrari HA , Biver E et al () Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX. Osteoporosis International.
Jaiswal R, Johansson H, Axelsson KF, Magnusson P, Harvey NC, Vandenput L, McCloskey E, Kanis JA, Litsne H, Johansson L & Lorentzon M () Hemoglobin levels improve fracture risk prediction in addition to FRAX® clinical risk factors and bone mineral density. The Journal of Clinical Endocrinology & Metabolism.
Shevroja E, Reginster J-Y, Lamy O, Al-Daghri N, Chandran M, Demoux-Baiada A-L, Kohlmeier L, Lecart M-P, Messina D, Camargos BM , Payer J et al () Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporosis International.
Moon RJ, Reginster J-Y, Al-Daghri NM, Thiyagarajan JA, Beaudart C, Bruyère O, Burlet N, Chandran M, da Silva MC, Conaghan PG , Dere WH et al () Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Osteoporosis International.
Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, Morin S, Leslie WD & McCloskey EV () Adjusting conventional FRAX estimates of fracture probability according to the number of prior falls in the preceding year. Osteoporosis International.
Gavilanez EL, Luis IN, Mario NG, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, McCloskey EV & Kanis JA () An assessment of intervention thresholds for high fracture risk in Chile. Archives of Osteoporosis, 18(1).
Kanis JA, Harvey NC, Liu E, Vandenput L, Lorentzon M, McCloskey EV, Bouillon R, Abrahamsen B, Rejnmark L, Johansson H , Sikjær T et al () Primary hyperparathyroidism and fracture probability. Osteoporosis International.
Svedbom A, Borgstöm F, Hernlund E, Alekna V, Bianchi ML, Clark P, Diaz-Curiel M, Dimai HP, Jürisson M, Lesnyak O , McCloskey E et al () An experience- and preference-based EQ-5D-3L value set derived using 18 months of longitudinal data in patients who sustained a fracture: results from the ICUROS. Quality of Life Research.
Kanis JA, McCloskey EV, Harvey NC, Cooper C, Rizzoli R, Dawson-Hughes B, Maggi S & Reginster J-Y () The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporosis International.
Kline GA, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC, Kanis JA & Leslie WD () General Comorbidity Indicators Contribute to Fracture Risk Independent of FRAX: Registry-Based Cohort Study. The Journal of Clinical Endocrinology & Metabolism.
Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L & McCloskey EV () Adjusting conventional FRAX estimates of fracture probability according to the number of prior fractures. Osteoporosis International.
Lanz P, Wieczorek M, Sadlon A, de Godoi Rezende Costa Molino C, Abderhalden LA, Schaer DJ, Spahn DR, Freystätter G, Orav EJ, Egli A , Bischoff-Ferrari HA et al () Iron Deficiency and Incident Infections among Community-Dwelling Adults Age 70 Years and Older: Results from the DO-HEALTH Study. The journal of nutrition, health & aging.
Leslie WD, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC & Kanis JA () Effect of Discordant Hip Bone Density on Incident Fracture Risk: A Registry‐Based Cohort Study. Journal of Bone and Mineral Research.
Lorentzon M, Johansson H, Harvey NC, Liu E, Vandenput L, Crandall CJ, Cauley JA, LeBoff MS, McCloskey EV & Kanis JA () Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability—results from the Women’s Health Initiative hormone therapy trials. Osteoporosis International.
McCloskey EV, Chotiyarnwong P, Harvey NC, Lorentzon M, Kanis JA, Prieto-Alhambra D, Abrahamsen B, Adachi JD, Borgström F, Bruyere O , Carey JJ et al () Population screening for fracture risk in postmenopausal women — a logical step in reducing the osteoporotic fracture burden?. Osteoporosis International.
Farzi M, Pozo JM, McCloskey E, Eastell R, Harvey NC, Frangi AF & Wilkinson JM () Quantitating Age‐Related BMD Textural Variation from DXA Region‐Free‐Analysis : A Study of Hip Fracture Prediction in Three Cohorts. Journal of Bone and Mineral Research.
Paskins Z, Babatunde O, Sturrock A, Toh LS, Horne R, Maidment I, McCloskey E, Paskins Z, Armstrong D, Curtis E , Edwards J et al () Supporting patients to get the best from their osteoporosis treatment: a rapid realist review of what works, for whom, and in what circumstance. Osteoporosis International.
Axelsson KF, Wallander M, Johansson H, Harvey NC, Vandenput L, McCloskey E, Liu E, Kanis JA, Litsne H & Lorentzon M () Analysis of Comorbidities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyroidism. JAMA Network Open, 5(6), e2215396-e2215396.
Stahl-Gugger A, de Godoi Rezende Costa Molino C, Wieczorek M, Chocano-Bedoya PO, Abderhalden LA, Schaer DJ, Spahn DR, Orav EJ, Vellas B, da Silva JAP , Kressig RW et al () Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial. Aging Clinical and Experimental Research, 34(9), 2205-2215.
Javaid MK, Harvey NC, McCloskey EV, Kanis JA & Cooper C () Assessment and management of imminent fracture risk in the setting of the fracture liaison service. Osteoporosis International.
Leslie WD, Möller S, Skjødt MK, Yan L, Abrahamsen B, Lix LM, McCloskey EV, Johansson H, Harvey NC, Kanis JA & Rubin KH () FREM predicts 10-year incident fracture risk independent of FRAX® probability: a registry-based cohort study. Osteoporosis International.
Leslie WD, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC & Kanis JA () The Effect of Fracture Recency on Observed 10‐year Fracture Probability: A Registry‐Based Cohort Study. Journal of Bone and Mineral Research.
Bischoff-Ferrari HA, Freystätter G, Vellas B, Dawson-Hughes B, Kressig RW, Kanis JA, Willett WC, Manson JE, Rizzoli R, Theiler R , Hofbauer LC et al () Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. The American Journal of Clinical Nutrition.
Dowling L, McCloskey E, Cuthbertson DJ & Walsh JS () Dynapenic Abdominal Obesity as a Risk Factor for Falls. The Journal of Frailty & Aging.
McCloskey EV, Harvey NC, Johansson H, Lorentzon M, Liu E, Vandenput L, Leslie WD & Kanis JA () Fracture risk assessment by the FRAX model. Climacteric, 1-7.
Povoroznyuk VV, Johansson H, Grygorieva NV, Kanis JA, Musiіenko АS, Lorentzon M, Harvey NC, McCloskey EV & Liu E () Ukrainian FRAX version in the male osteoporosis management. PAIN, JOINTS, SPINE, 11(2), 53-61.
Soriano-Arroquia A, Gostage J, Bardell D, McCloskey E, Bellantuono I, Clegg P, McDonagh B & Goljanek-Whysall K () miR-24:Prdx6 interactions regulate oxidative stress and viability of myogenic progenitors during ageing.
Larsson BAM, Johansson L, Mellström D, Johansson H, Axelsson KF, Harvey N, Vandenput L, McCloskey E, Liu E, Sundh D , Kanis JA et al () One leg standing time predicts fracture risk in older women independent of clinical risk factors and BMD. Osteoporosis International.
Povoroznyuk V, Grygorieva N, Kanis JA, Johansson H & McCloskey EV () Ukrainian frax: criteria for diagnostics and treatment of osteoporosis. PAIN, JOINTS, SPINE, 9(4), 212-221.
Povoroznуuk VV, Grуgorieva NV, Prostenko VV, Kanis JA, Johansson H & McCloskey EV () Информативность алгоритма FRAX® в оценке риска остеопоротических переломов у женщин украинской популяции. Likarska sprava(5-6), 79-87.
Povorozniuk V, Grigoryeva N, Korzh M, Strafun S, Kanis J, McCloskey E, Vaida V, Klymovytsky F, Vlasenko R & Forosenko V () Еpidemiology of proximal femur fractures in ukraine: results of two retrospective studies. ORTHOPAEDICS, TRAUMATOLOGY and PROSTHETICS, 0(4), 68-74.
Povoroznуuk VV, Grуgorieva NV, Kanis JA, McCloskey EV & Johansson H () Ukrainian Version of FRAX: from Creation to Validation. PAIN. JOINTS. SPINE, 0(3.23), 5-14.
Povoroznyuk VV, Grygorieva NV, Korzh MO, Strafun SS, Vaida VM, Klymovytsky FV, Vlasenko RO, Forosenko VS, Kanis JA, Johansson H & McCloskey EV () EPIDEMIOLOGY OF THE PROXIMAL FEMUR FRACTURES IN UKRAINE: RESULTS OF STOP-STUDY (SYSTEM OF REGISTRATION OF OSTEOPOROTIC FRACTURES IN UKRAINIAN POPULATION). TRAUMA, 17(5), 14-20.
Horvath C, Meszaros S, Acs O, Hosszu E, Nemeth J, Csupor E, Szathmari M, Acs N & McCloskey EV () Idiopathic hypercalcaemia in pregnancy not due to PTHrP: suggestion for another pathomechanism by genetic defect of 24-hydroxylase. Endocrine Abstracts.
Zayed MG () Unilateral compressive optic neuropathy due to skull hyperostosis secondary to nutritional vitamin A deficiency. Clinical Cases in Mineral and Bone Metabolism.
Lesnyak OM, Yershova OB, Belova KY, Gladkova EN, Sinitsyna OS, Ganert OA, Romanova MA, Hodyrev VN, Johanson H, McCloskey EV & Kanis JA () EPIDEMIOLOGY OF OSTEOPOROTIC FRACTURES IN THE RUSSIAN FEDERATION AND THE RUSSIAN MODEL OF FRAX. Osteoporosis and Bone Diseases, 17(3), 3-8.
Naylor K, Paggiosi M, Gossiel F, McCloskey E, Peel N, Walsh J & Eastell R () Determinants of bone turnover marker response to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Bone Abstracts.
Gossiel F, Hoyle C, McCloskey E, Walsh J, Peel N & Eastell R () The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal women with rsteoporosis: The TRIO study. Bone Abstracts.
Gossiel F, Naylor K, McCloskey E, Peel N, Walsh J, Paggiosi M & Eastell R () The effect of bisphosphonate treatment on sclerostin levels in postmenopausal osteoporosis: the TRIO study. Bone Abstracts.
Zheng H-F, Tobias JH, Duncan E, Evans DM, Eriksson J, Paternoster L, Yerges-Armstrong LM, Lehtimäki T, Bergström U, Kähönen M , Leo PJ et al () WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk. PLoS Genetics, 8(7), e1002745-e1002745. View this article in WRRO
Barker ME, McCloskey E, Saha S, Gossiel F, Charlesworth D, Powers HJ & Blumsohn A () Serum Retinoids and β-Carotene as Predictors of Hip and Other Fractures in Elderly Women. Journal of Bone and Mineral Research, 20(6), 913-920.
McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L , Kenraali J et al () Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double-Blind, Placebo-Controlled 3-Year Study. Journal of Bone and Mineral Research, 19(5), 728-736.
Jalava T, Sarna S, Pylkkänen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J & McCloskey E () Association Between Vertebral Fracture and Increased Mortality in Osteoporotic Patients. Journal of Bone and Mineral Research, 18(7), 1254-1260.
Patel S, Kwan JTC, McCloskey E, McGee G, Thomas G, Johnson D, Wills R, Ogunremi L & Barron J () Prevalence and Causes of Low Bone Density and Fractures in Kidney Transplant Patients*. Journal of Bone and Mineral Research, 16(10), 1863-1870.
Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L & McCloskey EV () The effect on subsequent fracture risk of age, sex, and prior fracture site by recency of prior fracture. Osteoporosis International.

Chapters

Harvey NC, McCloskey EV, Rizzoli R, Kanis JA, Cooper C & Reginster J-Y (2024) Osteoporosis: Treatment gaps and health economics, Reference Module in Biomedical Sciences Elsevier
Kanis JA, Harvey NC, Johansson H, Lorentzon M, Liu E, Leslie WD & McCloskey EV (2022) FRAX, Senior Trauma Patients (pp. 89-99). Springer International Publishing
McCloskey EV (2019) Evaluation of Fracture Risk, Pocket Reference to Osteoporosis (pp. 21-29). Springer International Publishing
Harvey NCW, McCloskey EV, Rizzoli R, Kanis JA, Cooper C & Reginster J-Y (2019) Osteoporosis: Treatment Gaps and Health Economics, Encyclopedia of Endocrine Diseases (pp. 288-295). Elsevier
Kanis JA, McCloskey EV, Harvey NC & Leslie WD (2018) FRAX (pp. 331-339). Wiley
McCloskey EV, Leslie WD & Kanis JA (2018) Assessment of fracture risk, Osteoporosis: a lifecourse epidemiology approach to skeletal health (pp. 163-176). CRC Press
Kanis JA, Odén A, Johansson H & McCloskey EV (2013) Fracture Risk Assessment: The Development and Application of FRAX, Osteoporosis: Fourth Edition (pp. 1611-1637).
Kanis JA, Odén A, Johansson H & McCloskey EV (2013) Fracture Risk Assessment, Osteoporosis (pp. 1611-1637). Elsevier
Adler RA, Anderson DE, Arabi A, Arnett TR, Bachrach LK, Ballane G, Baran D, Barnes GL, Baron R, Bauer DC , Bauman WA et al (2013) Contributors, Osteoporosis (pp. xix-xxiii). Elsevier
Adler RA, Allen MR, Amin S, Antoniucci DM, Araujo AB, Armas LAG, Baroncelli GI, Bertelloni S, Bhasin S, Bilezikian JP , Binkley NC et al (2010) Contributors, Osteoporosis in Men (pp. ix-xii). Elsevier
Kanis JA, McCloskey EV, Johansson H & Oden A (2010) Diagnostic Thresholds for Osteoporosis in Men, Osteoporosis in Men (pp. 605-611). Elsevier
(2004) Related Disorders, Multiple Myeloma and Related Disorders (pp. 367-367). CRC Press
Kanis JA, McCloskey EV, O’Doherty D, Hamdy NAT, Bickerstaff D, Beneton M & Thavarajah M (1991) Treatment of Paget’s Disease with the New Bisphosphonates, Paget’s Disease of Bone (pp. 112-134). Springer US
Kanis JA, McCloskey EV, Eyres KS, O’Doherty DV & Aaron J (1990) Screening Techniques in the Evaluation of Osteoporosis, HRT and Osteoporosis (pp. 135-147). Springer London
Kanis JA & McCloskey EV () The Use of Clodronate in Disorders of Calcium and Skeletal Metabolism1, Calcium Metabolism (pp. 89-136). S. Karger AG

Conference proceedings papers

Johansson H, Messina OD, Vidal M, Neira LFV, Liu E, Lorentzon M, Vandenput L, Schini M, Harvey NC, Mccloskey E & Kanis JA (2023) A SURROGATE FRAX MODEL FOR PERU. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S269-S269)
Ye C, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC, Kanis JA & Leslie WD (2023) Performance of FRAX in Men with Prostate Cancer: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 255-256)
McCloskey EV (2023) SHOULD THE PUNISHMENT FIT THE CRIME? OSTEOPOROSIS TREATMENT IN RELATION TO FRACTURE RISK. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S39-S39)
Ye C, Leslie WD, Al-Azazi S, Yan L, Lix LM, Czaykowski P, McCloskey EV, Harvey NC, Johansson H, Kanis JA & Singh H (2023) FRAX Underestimates Major Osteoporotic Fracture Risk in Cancer Survivors: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 76-76)
McCloskey EV, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, Leslie WD, Schini M & Kanis JA (2023) FRAXPLUS-POST HOC EXPLORATION OF IMPACT OF ADDITIONAL RISK FACTOR INFORMATION ON FRAX PROBABILITY CALCULATIONS. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S52-S52)
Vandenput L, Lorentzon M, Harvey NC, Liu E, Mccloskey EV, Kanis JA, Abrahamsen B, Rejnmark L & Johansson H (2023) EFFECTS OF PARATHYROIDECTOMY ON RISK OF FRACTURE BY SEVERITY OF PRIMARY HYPERPARATHYROIDISM: A DANISH REGISTER STUDY. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S46-S46)
McCloskey EV (2023) COMPARATIVE EFFECTIVENESS AND CARDIOVASCULAR SAFETY OF ABALOPARATIDE AND TERIPARATIDE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN REAL WORLD USE. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S581-S582)
Harvey NC, Liu E, Vandenput L, Lorentzon M, Mccloskey EV, Kanis JA, Abrahamsen B, Rejnmark L & Johansson H (2023) DIFFERENTIAL EFFECTS ON RISK OF FRACTURE AND DEATH BY SEVERITY OF PRIMARY HYPERPARATHYROIDISM: A DANISH REGISTER STUDY. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S64-S65)
Vandenput L, Lorentzon M, Harvey NC, Liu E, Mccloskey EV, Kanis JA, Abrahamsen B, Rejnmark L & Johansson H (2023) EFFECTS OF PARATHYROIDECTOMY ON RISK OF FRACTURE BY SEVERITY OF PRIMARY HYPERPARATHYROIDISM: A DANISH REGISTER STUDY. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S331-S331)
Kanis JA, Vandenput L, Lorentzon M, Harvey NC, Liu E, McCloskey EV & Johansson H (2023) OSTEOPOROSIS IN MEN: SCREENING, DIAGNOSIS AND IDENTIFICATION OF PATIENTS TO BE TREATED. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S76-S76)
Gandham A, Gregori G, Johansson L, Johansson H, Harvey C, Vandenput L, Mccloskey E, Kanis J, Litsne H, Axelsson K & Lorentzon M (2023) SARCOPENIA DEFINITIONS AND THEIR ASSOCIATION WITH FRACTURE RISK IN OLDER SWEDISH WOMEN. THE SAHLGRENSKA UNIVERSITY HOSPITAL PROSPECTIVE EVALUATION OF RISK OF BONE FRACTURES (SUPERB) STUDY. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 35 (pp S59-S59)
Bhatia P, Shreef H, Johansson H, Harvey N, Lorentzon M, Kanis J & McCloskey E (2022) Fracture Risk in Parkinson's Disease - the Role of Bone Density, Falls Risk and Muscle Strength. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 67-67)
Leslie W, Morin S, Lix L, McCloskey E, Johansson H, Harvey N & Kanis J (2022) The Effect of Recent Fracture on 10-year Fracture Probability: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 194-194)
Leslie W, Morin S, Lix L, McCloskey E, Johansson H, Harvey N & Kanis J (2022) Discordance in Hip DXA Subregions Affects Incident Fracture Risk Independent of Fracture Probability: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 27-27)
McCloskey E, Harvey NC, Lorentzon M, Vandenput L, Liu E, Kanis JA & Johansson H (2022) CONCOMITANT PPI USE NEGATES ORAL BISPHOSPHONATE ANTI-FRACTURE EFFICACY: A POST HOC ANALYSIS FROM A RANDOMIZED CONTROLLED TRIAL OF CLODRONATE. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 34(SUPPL 1) (pp S41-S41)
Leslie W, Morin S, Lix L, McCloskey E, Johansson H, Harvey N & Kanis J (2022) Discordance in Hip DXA Subregions Affects Incident Fracture Risk Independent of Fracture Probability: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 247-247)
Johansson L, Johansson H, Harvey N, Liu E, Leslie W, Vandenput L, Mccloskey E, Kanis J & Lorentzon M (2022) IMPROVED FRACTURE RISK PREDICTION BY ADDING VFA-IDENTIFIED VERTEBRAL FRACTURE DATA TO BMD BY DXA AND CLINICAL RISK FACTORS USED IN FRAX. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 34(SUPPL 1) (pp S42-S43)
McCloskey E (2022) ADDED VALUE OF THE NEW VERSION OF THE FRAX (R) ALGORITHM. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 34(SUPPL 1) (pp S37-S38)
Leslie W, Moller S, Skjodt M, Yan L, Abrahamsen B, Lix L, McCloskey E, Johansson H, Harvey N, Kanis J & Rubin K (2022) FREM Affects Incident 10-year Fracture Risk Independent of FRAX (R) Probability: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 305-306)
Vandenput L, Johansson H, Mccloskey EV, Liu E, Harvey NC, Lorentzon M, Leslie WD & Kanis JA (2022) UPDATE OF THE FRACTURE RISK PREDICTION TOOL FRAX: A SYSTEMATIC REVIEW OF POTENTIAL COHORTS AND ANALYSIS PLAN. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 34(SUPPL 1) (pp S256-S256)
Harvey NC, Liu E, Vandenput L, Lorentzon M, Mccloskey EV, Kanis JA, Abrahamsen B, Rejnmark L & Johansson H (2022) PRIMARY HYPERPARATHYROIDISM, BONE MINERAL DENSITY AND INCIDENT FRACTURE RISK: A DANISH REGISTER STUDY. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 34(SUPPL 1) (pp S43-S43)
Gupta A, Maslen C, Vindlacheruvu M, Abel R, Bhattacharya P, Bromiley P, Clark E, Compston J, Crabtree N, Gregory J , Kairki E et al (2022) Digital Health Interventions for Osteoporosis and Post-Fragility Fracture Care. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 37 (pp 184-184)
Johansson H, Abdulla N, Alsaed OS, Lutf A, Alam F, Abdulmomen I, Al Emadi S, Harvey N, Liu E, Vandenput L , Lorentzon M et al (2022) EPIDEMIOLOGY OF HIP FRACTURE IN QATAR AND DEVELOPMENT OF A COUNTRY SPECIFIC FRAX MODEL. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 34(SUPPL 1) (pp S235-S235)
Johansson H, Poiana C, Barbu C, Pascanu I, Gasparik AI, Dobre R, Harvey N, Liu E, Vandenput L, Lorentzon M , Mc Closkey E et al (2022) CHANGES IN HIP FRACTURE INCIDENCE IN ROMANIA AND IMPLICATIONS FOR FRAX. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 34(SUPPL 1) (pp S235-S236)
Johansson H, Harvey N, Liu E, Vandenput L, Leslie W, Lorentzon M, Mc Closkey E & Kanis J (2022) FRAXPLUS. AGING CLINICAL AND EXPERIMENTAL RESEARCH, Vol. 34(SUPPL 1) (pp S236-S237)
Zheng Z, Johansson H, Harvey NC, Lorentzon M, Kanis JA & McCloskey EV (2021) MIGHT NSAID USE INTERACT WITH BISPHOSPHONATE EFFICACY? EXPLORATORY ANALYSIS FROM THE CLODRONATE HIP STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S56-S56)
Povoroznyuk V, Johansson H, Grygorieva N, Lorentzon M, Musienko A, Harvey NC, McCloskey EV, Liu E & Kanis JA (2021) FRAX BASED OSTEOPOROSIS MANAGEMENT PATHWAY FOR UKRAINIAN MEN. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S278-S278)
McCloskey EV (2021) THE EFFECTIVENESS WORKING GROUP OF THE ROYAL OSTEOPOROSIS SOCIETY OSTEOPOROSIS AND BONE RESEARCH ACADEMY. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S74-S75)
Lorentzon M, McCloskey EV, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Liu E, Vandenput L, Leslie W & Kanis JA (2021) RECENT SENTINEL FRACTURES AND SUBSEQUENT FRACTURE PROBABILITIES OVER TWO, FIVE AND 10-YEAR TIMEFRAMES. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S41-S41)
Leroy S, Saunders-Hastings P, Eusebi P, Taieb V, Abrahamsen B, McCloskey EV, Fujiwara S, Libanati C & Moayyeri A (2021) TREATMENT GAP AMONG PATIENTS WITH PRIMARY OSTEOPOROSIS: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S189-S190)
McCloskey EV, Harvey NC, Johansson H, Lorentzon M, Liu E, Vandenput L & Kanis JA (2021) IDENTIFICATION OF PATIENTS AT LOW, HIGH AND VERY HIGH RISK OF OSTEOPOROTIC FRACTURES IN THE UK USING FRAX. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S54-S55)
McCloskey EV (2021) SCREENING FOR HIGH FRAC TUR E RISK IN PRIMARY CARE. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S91-S92)
Axelsson KF, Wallander M, Johansson H, Harvey NC, Vandenput L, McCloskey EV, Enwu L, Kanis JA, Litsne H & Lorentzon M (2021) PARATHYROIDECTOMY IS ASSOCIATED WITH REDUCED RISK OF FRACTURE AND CARDIOVASCULAR EVENTS IN PATIENTS DIAGNOSED WITH PRIMARY HYPERPARATHYROIDISM - A NATIONAL, RETROSPECTIVE COHORT STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S47-S47)
Johansson H, Pandey D, Liu E, Lorentzon M, Vandenput L, Harvey NC, McCloskey EV & Kanis JA (2021) A SURROGATE FRAX MODEL FOR NEPAL. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S383-S383)
Johansson H, Hailu S, Liu E, Lorentzon M, Vandenput L, Harvey NC, McCloskey EV & Kanis JA (2021) A SURROGATE FRAX MODEL FOR ETHIOPIA. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S380-S380)
Bhattia P, Shreef H, Johansson H, Lorentzon M, Harvey NC, Kanis JA & McCloskey EV (2021) FRACTURE RISK IN PARKINSON'S DISEASE: DRIVEN BY LOW BONE STRENGTH, MUSCLE WEAKNESS OR FALLS?. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S42-S43)
Johansson H, Saleh Y, Liu E, Lorentzon M, Vandenput L, Harvey NC, McCloskey EV & Kanis JA (2021) EPIDEMIOLOGY OF HIP FRACTURES IN SAUDI ARABIA: DEVELOPMENT OF A COUNTRY SPECIFIC FRAX MODEL. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S383-S384)
Johansson H, Liu E, Lorentzon M, Vandenput L, Harvey NC, McCloskey EV, Paruk F, Ferrand R, Ndhlovu C, Dela S , Gregson C et al (2021) A SURROGATE FRAX MODEL IN ZIMBABWE. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S381-S382)
Povoroznyuk V, Johansson H, Grygorieva N, Lorentzon M, Musienko A, Harvey NC, McCloskey EV, Liu E & Kanis JA (2021) FRAX BASED OSTEOPOROSIS MANAGEMENT PATHWAY FOR UKRAINIAN MEN. OSTEOPOROSIS INTERNATIONAL, Vol. 32(SUPPL 1) (pp S86-S86)
Leslie W, Morin S, Lix L, McCloskey E, Johansson H, Harvey N & Kanis J (2020) Adjusting Fracture Probability for Prior Falls: A Registry-Based Cohort Study.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 35 (pp 316-316)
McCloskey E, Harvey N, Johansson H, Lorentzon M, Vandenput L, Liu E & Kanis J (2020) Global impact of COVID-19 on osteoporosis management: A retrospective, longitudinal descriptive analysis of access to online MAX fracture risk assessments.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 35 (pp 212-212)
Leslie W, Morin S, Lix L, McCloskey E, Johansson H, Harvey N & Kanis J (2020) General Comorbidity Indicators Contribute to Fracture Risk Independent of FRAX: A Registry-Based Cohort Study.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 35 (pp 197-197)
Abrahamsen B, Rubio JB, Langdahl B, Ferrari S, De Ferrari G & McCloskey E (2020) BUILDING A STRONGER FUTURE FOR POSTMENOPAUSAL WOMEN WITH SEVERE OSTEOPOROSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S623-S623)
Lorentzon M, Johansson H, Harvey N, Liu E, Vandenput L, Crandall C, McCloskey E & Kanis J (2020) Hormone therapy reduces the risk of fracture regardless of baseline FRAX probability or prior falls - results from the Women's Health Initiative hormone therapy trials. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 35 (pp 249-249)
Leslie W, Morin S, Lix L, McCloskey E, Johansson H, Harvey N & Kanis J (2020) Adjusting Fracture Probability for the Effects of Recent Fracture: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 35 (pp 199-199)
Almog Y, Rai A, Mishra A, Moulaison A, Powell R, Weinberg K, Hamilton C, Oates M, McCloskey E & Cummings SR (2020) Crystal Bone: Personalized, Shot term Fracture Risk Prediction With Natural Language Processing, Methods. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 35 (pp 200-200)
Ferrari S, Diez-Perez A, Ojeda C & McCloskey EV (2020) A CHRONIC DISEASE: GOING BEYOND TODAY WITH OSTEOPOROSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S625-S625)
McCloskey EV (2020) ALGORITHM FOR THE ASSESSMENT OF ANTI-OSTEOPOROSIS TREATMENTS BY BONE TURNOVER MARKERS. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S66-S67)
Lorentzon M, Branco J, Brandi ML, Bruyere O, Chapurlat R, Cooper C, Cortet B, Diez-Perez A, Ferrari S, Gasparik A , Herrman M et al (2020) CLINICAL APPLICATION OF BONE TURNOVER MARKERS IN POST-MENOPAUSAL OSTEOPOROSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S65-S66)
Johansson H, Kanis JA, Harvey NC, Gudnason V, Sigurdson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L, Leslie WD & McCloskey EV (2020) Comparison of Short:Term and 10-year Probabilities to Characterise Fracture Risk After a Recent Sentinel Fracture. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 35 (pp 198-198)
Kanis JA, Harvey NC, Mccloskey EV, Bruyere O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N , Campusano C et al (2020) ESCEO-IOF ALGORITHM FOR THE MANAGEMENT OF PATIENTS AT LOW/HIGH/VERY HIGH RISK OF FRACTURE. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S33-S33)
McCloskey EV (2020) DIFFERENCES IN CLINICAL GUIDELINES. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S37-S37)
Borgstrom F, Norton NV, Karlsson L, Ortsater G, Harvey NC, Mccloskey EV & Kanis JA (2020) DISABILITY-ADJUSTED LIFE YEARS RELATED TO FRAGILITY FRACTURES. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S320-S321)
Povoroznyuk V, Grygorieva N, Musienko A, Johansson H, Lorentzon M, Harvey N-C, Mccloskey E-V, Liu E & Kanis J-A (2020) FRAX BASED INTERVENTION THRESHOLDS FOR UKRAINE. OSTEOPOROSIS INTERNATIONAL, Vol. 31(SUPPL 1) (pp S480-S480)
Harvey N, Orwoll E, Cauley J, Kwok T, Karlsson M, Rosengren B, Ribom E, Cawthon P, Ensrud K, Liu E , Ward K et al (2020) pQCT Muscle Density Predicts Hip Fractures Independent of FRAX, Falls and BMD in the Osteoporotic Fractures in Men (MrOS) Study: a Meta-Analysis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 35 (pp 159-159)
Leslie W, Moller S, Skjodt M, Yan L, Abrahamsen B, Lix L, McCloskey E, Johansson H, Harvey N, Kanis J & Rubin K (2020) External Validation of in 74,828 Patients from Manitoba, Canada: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 35 (pp 202-202)
Parsons CM, Harvey N, Shepstone L, Kanis JA, Lenaghan E, Clarke S, Fordham R, Gittoes N, Harvey I, Holland R , Redmond NM et al (2020) Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporosis International, Vol. 31(1) (pp 67-75)
Söreskog E, Borgström F, Shepstone L, Clarke S, Cooper C, Harvey I, Harvey NC, Howe A, Johansson H, Marshall T , O’Neill TW et al (2020) Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. Osteoporosis International, Vol. 31(8) (pp 1499-1506)
Brown JE, Handforth C, Walsh J, Pezaro C, Sydes MR, Clarke NW, James ND & McCloskey E (2019) 857P - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial. Annals of Oncology, Vol. 30(Suppl 5) (pp v334-v335). Barcelona, Spain, 27 September 2019 - 1 October 2019.
Forgetta V, Forest M, Bhatnagar S, Morris JA, Greenwood CMT, Richards B, Keller-Baruch J, Durand A, Pineau J, Nethander M , Kemp J et al (2019) Genetic Risk Scores to Improve Osteoporosis Screening: Validation in External Cohorts. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 210-210)
Johansson H, Siggeirsdottir K, Harvey NC, Mccloskey EV, Gudnason V, Sigurdsson G, Lorentzon M, Liu E & Kanis JA (2019) ADJUSTING FRAX FOR IMMINENT RISK. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S166-S167)
Borgstrom F, Norton N, Karlsson L, Ortsater G, Harvey NC, McCloskey EV & Kanis JA (2019) BURDEN OF FRAGILITY FRACTURES IN 6 EUROPEAN COUNTRIES. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S686-S686)
Harvey NC, Kanis JA, Liu E, Cooper C, Lorentzon M, Crandall C, Johansson H & McCloskey EV (2019) APPENDICULAR LEAN MASS DOES NOT PREDICT INCIDENT FRACTURES INDEPENDENTLY OF BMD: RESULTS FROM THE WOMEN'S HEALTH INITIATIVE (WHI) COHORT. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S356-S357)
Chotiyarnwong P & McCloskey EV (2019) FRAX (R) TOOL WEBSITE USAGE IN THAILAND. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S374-S374)
Lorentzon M, Johansson H, Harvey NC, Liu E, Crandall J, McCloskey EV & Kanis JA (2019) HORMONE THERAPY REDUCES THE RISK OF FRACTURE IN FALLERS AND IN NON-FALLERS: RESULTS FROM THE WOMEN'S HEALTH INITIATIVE HORMONE THERAPY TRIALS. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S163-S163)
McCloskey EV, Roux C, Papapoulos S & Borgermans L (2019) IMPROVING OSTEOPOROSIS CARE - GETTING CLOSER TO THE PATIENT. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S782-S782)
Zakroyeva AG, Lesnyak OM, Cazac V, Groppa L, Russu E, Rotaru L, Chislari L, Johansson H, Harvey NC, McCloskey EV & Kanis JA (2019) EPIDEMIOLOGY OF OSTEOPOROTIC NONVERTEBRAL FRACTURES IN MOLDOVA. POPULATION-BASED LONGITUDINAL STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S450-S451)
McCloskey EV, Eastell R, Mcclung M, Pannacciulli N, Wang C, Yue S & Cummings SR (2019) A POOLED ANALYSIS OF FALL INCIDENCE FROM PLACEBO-CONTROLLED TRIALS OF DENOSUMAB. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S179-S180)
Johansson H, Matijevic R, Harhaji V, McCloskey EV, Harvey NC, Lorentzon M, Liu E & Kanis JA (2019) TEN-YEAR FRACTURE PROBABILITY IN SERBIA ACCORDING TO AGE AND OTHER FRAX MODELS IN THE REGION. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S489-S490)
McCloskey EV, Rathi J, Heijmans S, Blagden M, Koukakis R, Stad R, O'Kelly J & Papapoulos S (2019) OSTEOPOROSIS (OP) DIAGNOSIS AND TREATMENT OF WOMEN AGED >= 70 YEARS IN PRIMARY CARE: RESULTS FROM A LARGE EUROPEAN CROSS-SECTIONAL STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S685-S686)
Johansson H, Adib G, McCloskey EV, Harvey NC, Lorentzon M, Liu E & Kanis JA (2019) TEN-YEAR FRACTURE PROBABILITY IN SYRIA USING A SURROGATE MODEL. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S489-S489)
Johansson H, Gavilanez EL, Grijalva MN, McCloskey EV, Harvey NC, Lorentzon M, Liu E & Kanis JA (2019) SECULAR CHANGES IN HIP FRACTURE INCIDENCE IN ECUADOR AND IMPLICATIONS FOR FRAX. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S490-S491)
Johansson H, Harvey C, Oden A, Orwoll E, Kwok T, Karlsson M, Rosengren B, Ribom E, Cawthon P, Ensrud K , Cooper C et al (2019) DO DEFINITIONS OF SARCOPENIA PREDICT FRACTURE RISK INDEPENDENT OF FRAX, FALLS AND BMD? A META-ANALYSIS OF THE OSTEOPOROTIC FRACTURES IN MEN (MROS) STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S52-S52)
Stone B, Dockrell D & McCloskey E (2019) FRAX is a good predictor of bone mineral density in people living with HIV of black ethnicity and/or low fracture risk. HIV MEDICINE, Vol. 20 (pp 39-40)
Lorentzen M, Johansson H, Harvey NC, Liu E, Crandall CJ, McCloskey EV & Kanis J (2019) Hormone therapy decreases the risk of fracture both in fallers and non-fallers - data from the combined Women's Health Initiative Hormone Therapy Trials. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 363-363)
Koromani F, Oei L, Trajanoska K, Schoufour J, Muka T, Franco O, Ikram A, Zillikens C, Uitterlinden A, Krestin G , Oei E et al (2019) Type 2 Diabetes Mellitus and the risk of osteoporotic vertebral fractures: a meta-analysis of summary and individual participant data from 852,705 individuals. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 102-102)
McCloskey E, Rathi J, Heijmans S, Blagden M, Koukakis R, Stad R, O'Kelly J & Papapoulos S (2019) Osteoporosis (OP) diagnosis and treatment of women aged >= 70 years in primary care: results from a large Europeal cross-sectional study. SWISS MEDICAL WEEKLY (pp 10S-10S)
McCloskey E, Lorentzon M, Johansson H, Kanis J & Harvey N (2019) A POST HOC ANALYSIS OF ROMOSOZUMAB EFFICACY AND BASELINE FRACTURE RISK - GREATER REDUCTION IN FRACTURE OUTCOMES IN PATIENTS AT HIGHER RISK. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 112-112)
Leslie W, Lix L, Schousboe J, Morin S, Martineau P, Johansson H, Kanis J, McCloskey E & Harvey N (2019) Subsequent Fracture Risk Following Traumatic versus Non-traumatic Fracture: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 53-53)
Leslie W, Lix L, Schousboe J, Morin S, Martineau P, Johansson H, Kanis J, McCloskey E & Harvey N (2019) Measured Height Loss Predicts Incident Clinical Fractures Independently from FRAX: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 100-100)
Johansson H, Liu E, Kanis JA, Siggeirsdottir K, Gudnason V, Sigurdson G, Harvey NC, McCloskey E & Lorentzon M (2019) Potential Impact of Recent Clinical Vertebral Fracture on FRAX 10year Probability. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 155-155)
Leslie W, Schousboe J, Morin S, Martineau P, Lix L, Johansson H, McCloskey E, Harvey N & Kanis J (2019) Loss in DXA-Estimated Total Body Lean Mass but not Fat Mass Predicts Incident Major Osteoporotic Fracture and Hip Fracture Independently from FRAX: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 21-21)
Svedbom A, Borgstrom F, Hernlund E, Alekna V, Bianchi ML, Clark P, Curiel DM, Dimai HP, Jurisson M, Olga L , McCloskey E et al (2019) EXPERIENCE AND PREFERENCE-BASED EQ-5D-3L VALUE SET DERIVED FROM LONGITUDINAL DATA: RESULTS FROM THE INTERNATIONAL COSTS AND UTILITIES OF OSTEOPOROTIC FRACTURES STUDY (ICUROS). VALUE IN HEALTH, Vol. 22 (pp S705-S706)
Bauer J, Cruz-Jentoft AJ, Bauer JM, Cruz-Jentoft AJ, Fielding RA, Kanis JA, Reginster J-Y, Bruyere O, Cesari M, Chapurlat R , Al-Daghri N et al (2019) OSTEOSARCOPENIC OBESITY: ENOUGH EVIDENCE FOR A DISTINCT ENTITY?. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S191-S192)
McCloskey E (2019) WHEN AND WHY USE A BONE-FORMING AGENT?. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S157-S157)
Povoroznyuk V, Grygorieva N, Korzh M, Strafun S, Vayda V, Klymovytsky F, Vlasenko R, Forosenko V, Kanis JA, Johansson H & Mccloskey E (2019) EPIDEMIOLOGY OF HIP FRACTURES IN UKRAINE: RESULTS OF STOP-STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 30 (pp S83-S83)
Harvey N, Cooper C, Kanis JA, Liu E, Lorentzon M, Bea JW, Carbone L, Feliciano EMC, Laddu DR, Schnatz PF , Shadyab AH et al (2019) DXA appendicular lean mass, FRAX, BMD and incident fractures: Findings from the Women's Health Initiative (WHI). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 34 (pp 155-155)
Borgstrom F, Jonsson E, Harvey N, Shepstone L, Lenaghan E, Clarke S, Gittoes N, Harvey I, Holland R, Heawood A , Redmond N et al (2018) Cost-effectiveness Evaluation of a Screening Programme for Fracture Risk in UK. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 398-399)
Ugur A, Gossiel F, Naylor K, Walsh J, Peel N, Mccloskey E & Eastell R (2018) Apparent Response Rate by PINP to Oral Bisphosphonates in Clinical Practice and Clinical Trial Settings. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 319-319)
Forgetta V, Keller-Baruch J, Forest M, Durand A, Bhatnagar S, Kemp J, Morris J, Kanis J, Kiel D, Mccloskey E , Johansson H et al (2018) Genomic Prediction of Osteoporosis Using 426,000 Individuals from UK Biobank. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 39-39)
Harvey NC, Oden A, Orwoll E, Lapidus J, Kwok T, Karlsson M, Rosengren B, Ljunggren O, Coopers C, Cawthon PM , Kanis JA et al (2018) PHYSICAL PERFORMANCE OR FUNCTION, BUT NOT APPENDICULAR LEAN MASS, PREDICT INCIDENT FRACTURES INDEPENDENTLY OF FRAX PROBABILITY AND BMD: RESULTS FROM THE OSTEOPOROTIC FRACTURES IN MEN (MROS) COHORT. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp S69-S70)
Aram P, Trela-Larsen L, Sayers A, Hills AF, Blom AW, McCloskey EV, Kadirkamanathan V & Wilkinson JM (2018) An evaluation of survival modelling approaches for personalised risk prediction after hip replacement for osteoarthritis. Osteoarthritis and Cartilage, Vol. 26(Supplement 1) (pp S281-S281). Liverpool, United Kingdom, 26 April 2018 - 29 April 2018.
Ferrari S, McCloskey E, Bouxsein M, De Schepper J & Reginster J-Y (2018) AGN1 LOCAL OSTEO-ENHANCEMENT PROCEDURE (LOEP): AN EMERGING, MINIMALLY-INVASIVE SURGICAL TREATMENT TO ADDRESS OSTEOPOROSIS-RELATED BONE LOSS IN PROXIMAL FEMURS. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp S568-S569)
Farzi M, Pozo JM, McCloskey E, Eastell R, Wilkinson JM & Frangi AF (2018) Spatio-Temporal Atlas of Bone Mineral Density Ageing (pp 720-728)
Mccloskey E, Johansson H, Harvey N, Compston J, Cooper C & Kanis J (2018) Inappropriate Use of Cost-effectiveness Thresholds as Intervention Thresholds - Potential for Overtreatment of Low Risk Individuals. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 108-108)
Harvey N, Oden A, Orwoll E, Kwok T, Karlsson M, Rosengren B, Ribom E, Cawthon P, Ensrud K, Cooper C , Kanis J et al (2018) Definitions of sarcopenia as predictors of fracture risk independent of FRAX, falls and BMD: A meta-analysis of the Osteoporotic Fractures in Men (MrOS) Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 13-14)
McCloskey E, Harvey N, Johansson H, Shepstone L, Lenaghan E, Cooper C & Kanis J (2018) WOMEN IDENTIFIED AT HIGH RISK OF HIP FRACTURE BASED ON FRAX ARE RESPONSIVE TO APPROPRIATE OSTEOPOROSIS MANAGEMENT: ANALYSIS FROM THE SCOOP STUDY OF POPULATION SCREENING. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp 613-614)
McCloskey E, Johansson H, Oden A, Harvey N, Compston J, Cooper C & Kanis JA (2018) DANGER OF OVERTREATMENT OF OSTEOPOROSIS WITH INAPPROPRIATE USE OF INTERVENTION THRESHOLDS DERIVED BY COST-EFFECTIVENESS ANALYSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp S73-S73)
Johansson H, Kanis JA, Oden A, Harvey NC, Gudnason V, Sanders K, Sigurdsson G, Siggeirsdottir K, Fitzpatrick L, Lorentzon M , Borgstrom F et al (2018) Comparing Utility Loss Due to Fractures, in Cohorts With and Without a Previous Fracture. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 392-393)
Leslie W, Morin S, Lix L, Mccloskey E, Johansson H, Harvey N & Kanis J (2018) Fracture Risk Assessment in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 47-48)
Lorentzon M, Johansson H, Harvey NC, Oden A, Sanders K, Borgstrom F, Svedbom A, Mccloskey E & Kanis J (2018) Treatment gap following clinical vertebral fracture in the International Cost and Utility Related to Osteoporosis Fractures Study (ICUROS). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 33 (pp 115-115)
Johansson H, Azizieh F, Al Ali N, Thamer A, Harvey N, Mccloskey E & Kanis J (2018) INTERVENTION THRESHOLD BASED ON FRAX AND BMD. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp S504-S504)
Johansson H, Seeman E, Siggeirsdottir K, Harvey N, Oden A, Gudnason V, Lorentzon M, Mccloskey E, Sanders K, Sigurdsson G & Kanis J (2018) A MISSED OPPORTUNITY: WHAT PROPORTION OF FRACTURE PATIENTS HAVE HAD A PRIOR FRACTURE?. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp S534-S534)
McCloskey E (2018) AN UPDATE ON RISK ASSESSMENT AND FRACTURE PREVENTION IN EUROPEAN NATIONS. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp S119-S120)
Johansson H, Kanis I, Oden A, Harvey N, Gudnason V, Sanders K, Sigurdsson G, Siggeirsdottir K, Fitzpanick L, Lorentzon M , Borgstrom F et al (2018) UTILITY LOSS AFTER A SENTINEL FRACTURE. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp S72-S73)
McCloskey E (2018) INFLAMMATION AND MUSCULOSKELETAL AGING. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp S45-S45)
Johansson H, Siggeirsdottir K, Harvey N, Oden A, Gudnason V, Mccloskey E, Sigurdsson G & Kanis J (2018) IMPACT OF RECENT FRACTURE ON 10-YEAR PROBABILITY OF FRACTURE. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp S478-S478)
Johansson H, Oden A, Harvey N, Sanders K, Borgstrom F, Svedbom A, Lorentzon M, Mccloskey E & Kanis J (2018) TREATMENT GAP FOLLOWING HIP FRACTURE IN THE INTERNATIONAL COST AND UTILITY RELATED TO OSTEOPOROSIS FRACTURES STUDY (ICUROS). OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp S534-S534)
Parsons C, Harvey N, Shepstone L, Kanis J, Lenaghan E, Clarke S, Fordham R, Gittoes N, Harvey I, Holland R , Heawood A et al (2018) SYSTEMATIC SCREENING USING FRAX LEADS TO INCREASED USE OF, AND ADHERENCE TO, ANTI-OSTEOPOROSIS MEDICATIONS: THE UK SCOOP TRIAL. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp 613-613)
Sahakyan S, Lesnyak O, Zakroyeva A, Bilezikian J, Hutchings N, Babalyan V, Galstyan R, Lebedev A, Johansson H, Harvey NC , Mccloskey E et al (2018) EPIDEMIOLOGY OF FRACTURES IN ARMENIA: DEVELOPMENT OF A COUNTRY-SPECIFIC FRAX MODEL AND COMPARISON TO ITS SURROGATE. OSTEOPOROSIS INTERNATIONAL, Vol. 29 (pp S423-S423)
Gossiel F, Flintham L, Naylor K, Walsh J, Peel N, McCloskey E & Eastell R (2017) Offset of Effect of Oral Bisphosphonates on Tartrate-Resistant Acid Phosphatase in Postmenopausal Osteoporosis: the TRIO Study.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 32 (pp S379-S379)
Cooper C, Parsons C, Harvey NC, Shepstone L, Kanis JA, Lenaghan E, Clarke S, Fordham R, Gittoes N, Harvey I , Holland R et al (2017) Effect of fracture risk assessment on anti-osteoporosis medication use and adherence: Findings from the SCOOP Trial.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 32 (pp S108-S108)
Harvey NC, Oden A, Orwoll E, Lapidus J, Kwok T, Karlsson M, Rosengren B, Ljunggren O, Cooper C, Kanis JA , Ohlsson C et al (2017) MOBILITY RELATED RISK FACTORS PREDICT INCIDENT FRACTURES INDEPENDENTLY OF FRAX: THE OSTEOPOROTIC FRACTURES IN MEN (MROS) STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 28 (pp S61-S61)
McCloskey EV (2017) SKELETAL DETERMINANTS OF FRACTURE RISK - CAN WE DO BETTER?. OSTEOPOROSIS INTERNATIONAL, Vol. 28 (pp S118-S118)
McCloskey EV (2017) WHEN IS IT TIME TO STOP OSTEOPOROSIS TREATMENT?. OSTEOPOROSIS INTERNATIONAL, Vol. 28 (pp S46-S47)
McCloskey EV, Harvey NC, Johansson H, Shepstone L, Lenaghan E, Cooper C & Kanis JA (2017) WOMEN IDENTIFIED AT HIGH RISK BASED ON FRAX HIP FRACTURE PROBABILITY ARE RESPONSIVE TO APPROPRIATE OSTEOPOROSIS MANAGEMENT: ANALYSIS FROM THE SCOOP STUDY OF POPULATION SCREENING. OSTEOPOROSIS INTERNATIONAL, Vol. 28 (pp S60-S60)
Johansson H, McCloskey E, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick LA & Kanis JA (2017) THE EFFICACY OF ABALOPARATIDE-SC IS INDEPENDENT OF BASELINE BMD. OSTEOPOROSIS INTERNATIONAL, Vol. 28 (pp S519-S519)
Harvey N, Oden A, Orwoll E, Lapidus J, Kwok T, Karlsson M, Rosengren B, Ljunggren S, Cooper C, Cawthon P , Kanis J et al (2017) Measures of physical performance or function, but not appendicular lean mass, predict new fractures independently of FRAX probability: Findings from MrOS.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 32 (pp S30-S30)
McCloskey E, Harvey N, Johansson H, Shepstone L, Lenaghan E, Cooper C & Kanis J (2017) Women Identified at High Risk of Hip Fracture based on FRAX are Responsive to Appropriate Osteoporosis Management: Results from the SCOOP Study of Population Screening.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 32 (pp S30-S30)
Harvey NC, Oden A, Orwoll E, Lapidus J, Kwok T, Karlsson M, Rosengren B, Ljunggren O, Cooper C, McCloskey E , Kanis JA et al (2017) PRIOR FALLS PREDICT INCIDENT FRACTURES INDEPENDENTLY OF FRAX: THE OSTEOPOROTIC FRACTURES IN MEN (MROS) STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 28 (pp S259-S259)
Leslie W, Majumdar S, Morin S, Lix L, Johannson H, Oden A, McCloskey E & Kanis J (2017) FRAX for Fracture Prediction Shorter and Longer Than Ten Years: The Manitoba BMD Registry.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 32 (pp S29-S29)
Martineau P, Leslie W, Johannson H, Oden A, McCloskey E, Kanis J & Hans D (2017) In Which Patient Populations Does Lumbar Spine Trabecular Bone Score (TBS) Have the Largest Effect on Fracture Prediction?.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 32 (pp S244-S244)
Johansson H, Siggeirsdottir K, Harvey NC, Oden A, Gudnason V, McCloskey E, Sigurdsson G & Kanis JA (2017) Risk of Hip Fracture After Recent Fracture - Comparison of Sentinel Fracture Sites (Reykjavik Study).. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 32 (pp S251-S251)
Leslie W, Shevroja E, Johansson H, Oden A, McCloskey E, Kanis J & Hans D (2017) "Risk-Equivalent" T-score Adjustment Using Lumbar Spine Trabecular Bone Score (TBS): The Manitoba BMD Registry. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 32 (pp S93-S93)
Johansson H, McCloskey E, Oden A, Harvey NC, Black DM, Cauley J & Kanis JA (2017) THE EFFECT OF ALENDRONATE ON VERTEBRAL FRACTURE RISK IS INDEPENDENT OF BASELINE FRAX FRACTURE PROBABILITY: A POST HOC ANALYSIS OF THE FIT STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 28 (pp S619-S619)
Povoroznyuk VV, Grygorieva NV, Korzh MO, Strafun SS, Vaida VM, Klymovytsky FV, Vlasenko RO, Forosenko VS, Kanis JA, Johansson H & McCloskey E (2017) EPIDEMIOLOGY OF HIP FRACTURES IN UKRAINE: RESULTS OF STOP-STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 28 (pp S570-S570)
McCloskey E (2017) TREATMENT BASED ON FRACTURE RISK - HEALTH ECONOMIC IMPLICATIONS. OSTEOPOROSIS INTERNATIONAL, Vol. 28 (pp S101-S101)
Johansson H, Siggeirsdottir K, Harvey NC, Oden A, Gudnason V, McCloskey E, Sigurdsson G & Kanis JA (2017) IMMINENT RISK OF HIP FRACTURE AFTER RECENT ( SENTINEL) FRACTURE - COMPARISON OF SENTINEL FRACTURE SITES (REYKJAVIK STUDY). OSTEOPOROSIS INTERNATIONAL, Vol. 28 (pp S61-S62)
McCloskey E, Fitzpatrick LA, Hu M & Kanis JA (2017) ABALOPARATIDE-SC DECREASES VERTEBRAL, NONVERTEBRAL, MAJOR OSTEOPOROTIC, AND WRIST FRACTURES IN A SUBSET OF POSTMENO-PAUSAL WOMEN AT HIGH RISK OF FRACTURE BY FRAX SCORE. OSTEOPOROSIS INTERNATIONAL, Vol. 28 (pp S49-S50)
Koromani F, Oei L, Muka T, Shevroja E, Schoufour J, Franco O, Zillikens C, Mc Closkey E, Leslie W, Lamy O , Oei E et al (2017) Type 2 Diabetes Is Associated With Lower Prevalence Of Vertebral Fractures: A Meta-Analysis of Prospective Studies. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 32 (pp S95-S96)
McCloskey E, Lenaghan E, Clarke S, Fordham R, Gittoes N, Harvey I, Holland R, Howe A, Marshal T, Peters T , Kanis J et al (2016) SCREENING BASED ON FRAX FRACTURE RISK ASSESSMENT REDUCES THE INCIDENCE OF HIP FRACTURES IN OLDER COMMUNITY-DWELLING WOMEN - RESULTS FROM THE SCOOP STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp 624-624)
McCloskey E, Chiu S, Lenaghan E, Shepstone L, Birrell F & Harvey N (2016) IMPACT OF FALLS ON FRACTURES AND MORTALITY - AN OPPORTUNITY FOR INTERVENTION AND ENHANCEMENT OF FRACTURE PREDICTION?. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp 617-617)
McCloskey EV (2016) WHAT IS THE PROFILE OF PATIENTS AT IMMINENT HIGH RISK OF FRACTURE?. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S692-S692)
McCloskey EV (2016) TREAT-TO-TARGET IN OSTEOPOROSIS AND OTHER CHRONIC DISORDERS: OPPORTUNITIES AND CHALLENGES. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S696-S696)
Kanis JA, Harvey N, Johansson H, McCloskey EV & Oden A (2016) TOWARDS AN OPERATIONAL DEFINITION OF SARCOPENIA. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S688-S689)
Brown J, Dakin P, Hadji P, McClung M, Miller P, Reginster J-Y, Wagman R, Wang A & McCloskey E (2016) Can we use Bone Turnover Markers as Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? An Analysis from the DECIDE and STAND Clinical Trials. JOURNAL OF RHEUMATOLOGY, Vol. 43(6) (pp 1208-1209)
McCloskey E, Harvey NC, Oden A, Jiang H, Modin S, Fitzpatrick LA, Kanis JA & Johansson H (2016) EFFECT OF INVESTIGATIONAL TREATMENT ABALOPARATIDE FOR PREVENTION OF MAJOR OSTEOPOROTIC FRACTURE OR ANY FRACTURE IS NOT ALTERED BY BASELINE FRACTURE PROBABILITY. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S44-S45)
Shepstone L, Lenaghan E, Clarke S, Fordham R, Gittoes N, Harvey I, Holland R, Howe A, Marshall T, McCloskey E , Peters T et al (2016) A RANDOMIZED CONTROLLED TRIAL OF SCREENING IN THE COMMUNITY TO REDUCE FRACTURES IN OLDER WOMEN IN THE UK (THE SCOOP STUDY). OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S42-S43)
Farzi M, Pozo JM, McCloskey EV, Wilkinson JM & Frangi AF (2016) Automatic Quality Control for Population Imaging: A Generic Unsupervised Approach (pp 291-299)
McCloskey E, Compston JE, Cooper C, Harvey NC, Johansson H, Oden A & Kanis JA (2016) IMPACT OF FRACTURE RISK ASSESSMENT TOOLS ON PROPORTIONS OF WOMEN WITHOUT PRIOR FRACTURE IDENTIFIED AT RISK AND TREATED - LESSONS FROM THE SIGN GUIDANCE. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S382-S383)
Johansson H, Siggeirsdottir K, Harvey N, Oden A, Gudnason V, McCloskey E, Sigurdsson G & Kanis J (2016) IMMINENT MAJOR OSTEOPOROTIC AND CLINICAL VERTEBRAL FRACTURE RISK AFTER FRACTURE (REYKJAVIK STUDY). OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S699-S700)
Kanis JA, Harvey N, Johansson H, McCloskey E & Oden A (2016) FRAX IN THE WORLD TODAY. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S563-S563)
McCloskey E (2016) FRAX IN EUROPE - DEVELOPMENT AND THE NEXT STEPS. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S564-S565)
McCloskey E, Johansson H, Harvey NC, Compston JE & Kanis JA (2016) ONLINE USAGE OF FRAX FRACTURE RISK ASSESSMENT AND NATIONAL OSTEOPOROSIS GUIDELINE GROUP GUIDANCE BY UK CLINICAL PRACTITIONERS. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S345-S345)
Svedbom A, Hernlund E, Alekna V, Bianchi M-L, Clark P, Diaz-Curiel M, Dimai H-P, Lesnyak OM, McCloskey E, Sanders KM , Silverman SL et al (2016) QUALITY OF LIFE UP TO 18 MONTHS AFTER DISTAL FOREARM FRACTURE: RESULTS FROM THE ICUROS. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S61-S62)
Johansson H, Oden A, Karlsson M, Lorentzon M, Kanis JA, Rosengren B, Mellstrom D, Ljunggren O, OhIsson C, Harvey NC & McCloskey E (2016) FEMORAL NECK BMD IS STILL THE PREFERRED SITE IN THE ASSESSMENT OF HIP FRACTURE IN ELDERLY MEN (10-YEAR FOLLOW-UP OF MROS SWEDEN). OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S58-S59)
Johansson H, Vala CH, Oden A, Lorentzon M, McCloskey E, Kanis JA, Lohmander S, Karrholm J & Mellstrom D (2016) SWEDISH FARMERS HAVE LOWER RISK FOR HIP FRACTURE THAN EXPECTED FROM ECONOMIC STATUS, EDUCATION AND LOCATION. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S56-S57)
Harvey NC, Johansson H, Siggeirsdottir K, Oden A, Gudnason V, McCloskey E, Sigurdsson G & Kanis JA (2016) IMMINENT RISK OF MAJOR OSTEOPOROTIC FRACTURE AFTER FRACTURE (REYKJAVIK STUDY). OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S59-S59)
McCloskey E (2016) OFFSET OF FRACTURE RISK AFTER TREATMENT CESSATION, A BASE FOR TRANSIENT TREATMENT INTERRUPTION. OSTEOPOROSIS INTERNATIONAL, Vol. 27 (pp S33-S34)
Brown JP, Dakin P, Hadji P, McClung MR, Miller PD, Reginster J-Y, Wagman RB, Wang A & McCloskey E (2015) Can We Use Bone Turnover Markers As Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? an Analysis from Two Phase 3 Clinical Trials. ARTHRITIS & RHEUMATOLOGY, Vol. 67
Reginster J-Y, Cooper C, Rizzoli R, Kanis JA, Appelboom G, Bautmans I, Bischoff-Ferrari HA, Boers M, Brandi ML, Bruyere O , Cherubini A et al (2015) RECOMMENDATIONS FOR THE REGISTRATION OF DRUGS TO TREAT SARCOPENIA. OSTEOPOROSIS INTERNATIONAL, Vol. 26 (pp S62-S62)
Harvey NC, Oden A, Johansson H, Burge R, Mitlak B, Kanis JA & McCloskey EV (2015) EFFICACY OF TERIPARATIDE FOR PREVENTION OF VERTEBRAL AND NONVERTEBRAL FRACTURE IS NOT ALTERED BY BASELINE FRACTURE PROBABILITY. OSTEOPOROSIS INTERNATIONAL, Vol. 26 (pp S203-S204)
Leslie WD, Lix LM, Morin SN, Johansson H, Oden A, McCloskey EV & Kanis JA (2015) HIP AXIS LENGTH IS A FRAX AND BONE DENSITY INDEPENDENT RISK FACTOR FOR HIP FRACTURE IN MEN AND WOMEN. OSTEOPOROSIS INTERNATIONAL, Vol. 26 (pp S50-S51)
Harvey NC, Johansson H, Oden A, Karlsson MK, Rosengren B, Ljunggren O, Cooper C, McCloskey EV, Kanis JA, Ohlsson C & Mellstrom D (2015) THE PREDICTIVE VALUE OF PAST FALLS FOR INCIDENT FALLS DECREASES, BUT THAT OF FRAX REMAINS STABLE, WITH INCREASING FOLLOW-UP TIME: FINDINGS FROM MROS SWEDEN. OSTEOPOROSIS INTERNATIONAL, Vol. 26 (pp S143-S143)
Johansson H, McCloskey EV, Kanis JA, Harvey NC & Oden A (2015) WORLDWIDE BURDEN OF HIGH FRACTURE PROBABILITY. OSTEOPOROSIS INTERNATIONAL, Vol. 26 (pp S151-S152)
Johansson H, Harvey NC, Oden A, McCloskey EV, Kanis JA, Nicholson G & Sanders KM (2015) FRAX PREDICTS INCIDENT FALLS IN ELDERLY WOMEN: FINDINGS FROM AUSTRALIA. OSTEOPOROSIS INTERNATIONAL, Vol. 26 (pp S152-S152)
Kanis JA, Oden A, Harvey NC, Leslie WD, Hans D, Johansson H, Barkmann R, Boutroy S, Brown JP, Chapurlat RD , Elders P et al (2015) A META-ANALYSIS OF TRABECULAR BONE SCORE IN FRACTURE RISK PREDICTION AND ITS INTERACTION WITH FRAX. OSTEOPOROSIS INTERNATIONAL, Vol. 26 (pp S46-S46)
Johansson H, Harvey NC, Oden A, Karlsson MK, Rosengren B, Ljunggren O, Cooper C, McCloskey EV, Kanis JA, Ohlsson C & Mellstrom D (2015) WANING LONG-TERM PREDICTIVE VALUE OF FALLS HISTORY FOR INCIDENT FRACTURE: MROS SWEDEN. OSTEOPOROSIS INTERNATIONAL, Vol. 26 (pp S42-S42)
Akesson K, Harvey NC, Oden A, McCloskey EV, Kanis JA & Johansson H (2015) WANING LONG-TERM PREDICTIVE VALUE OF SERUM CTX FOR INCIDENT FRACTURE (OPRA COHORT). OSTEOPOROSIS INTERNATIONAL, Vol. 26 (pp S364-S364)
Harvey NC, Kanis JA, Johansson H, Oden A, Cooper A, Cooper C, Francis RM, Reid DM, Selby P, Compston JE & McCloskey E (2015) FRAX-BASED ASSESSMENT AND INTERVENTION THRESHOLDS: AN EXPLORATION OF THRESHOLDS IN WOMEN AGED 50 YEARS AND OLDER IN THE UK. OSTEOPOROSIS INTERNATIONAL, Vol. 26 (pp S54-S54)
McCloskey EV, Kanis JA, Johansson H, Harvey N, Oden A & Compston J (2014) ASSESSMENT AND INTERVENTION THRESHOLDS IN THE UK - AN EXPLORATION OF ALTERNATIVE NOGG THRESHOLDS IN OLDER POSTMENOPAUSAL WOMEN. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S673-S674)
McCloskey EV, Johansson H, Oden A, Kanis JA, Morris HA, Cooper C & Vasikaran S (2014) A META-ANALYSIS OF REFERENCE MARKERS OF BONE TURNOVER FOR PREDICTION OF FRACTURE. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S314-S315)
Johansson H, Leslic WD, Kanis JA, Lamy O, Oden A, Mccloskey EV & Hans D (2014) DERIVATION OF A LUMBAR SPINE TRABECULAR BONE SCORE (TBS) ADJUSTMENT RATIO FOR FRAX: THE MANITOBA BMD COHORT. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S408-S409)
Kanis JA, Johansson H, Oden A, McCloskey EV, Cooper C, Rizzoli R & Reginster J-Y (2014) A META-ANALYSIS OF THE EFFECT OF STRONTIUM RANELATE ON THE RISK OF VERTEBRAL AND NON-VERTEBRAL FRACTURE IN POSTMENOPAUSAL OSTEOPOROSIS: THE IMPACT OF SEVERE OSTEOPOROSIS AND CONTRAINDICATIONS. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S120-S121)
McCloskey EV, Oden A, Nakamura T, Kuroda T, Eto M, Shiraki M, Sugimoto T, Tanaka S, Kanis JA & Johansson H (2014) EFFICACY OF TERIPARATIDE ON THE RISK OF VERTEBRAL FRACTURE AND THE INTERACTION WITH FRAX. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S324-S324)
Oden A, McCloskey EV, Johansson H & Kanis JA (2014) DECLINING HIP FRACTURE RISK IN SWEDEN. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S318-S319)
Svedbom A, Wintzell V, Alekna V, Tamulaitiene M, Bianchi ML, Clark P, Diaz-Curiel M, Dimai HP, Lesnyak O, McCloskey EV , Sanders KM et al (2014) HOSPITALIZED AND NONHOSPUIALIZED VERTEBRAL FRACTURES: COMPARISON OF PATIENT DEMOGRAPHICS AND HEALTH RELATED QUALITY OF LIFE IMPLICATIONS. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S109-S110)
Johansson H, Oden A, McCloskey EV, Kanis JA, Karlsson M, Lorenton M & Mellstrtom D (2014) WHICH FRAX MODEL IS APPROPRIATE FOR SWEDISH IMMIGRANTS?. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S122-S122)
Grigorie D, Sucaliuc A, Johansson H, Kanis JA & Mccloskey EV (2014) WAYS TO REDUCE OSTEOPOROSIS TREATMENT GAP IN ROMANIA. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S229-S230)
McCloskey EV, Kanis JA, Oden A, Bauer DC, Glueer CC, Hans D, Kaptoge SK, Khaw KT, Krieg MA, Kwok A , Lau E et al (2014) QUANTITATIVE ULTRASOUND (QUS) IS ASSOCIATED WITH FRACTURE RISK: A META-ANALYSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S108-S108)
Johansson H, Siggeirsdottir K, Aspelund T, Gudmundsson E, Mogensen B, Jonsson BY, Gudnason V, McCloskey EV, Sigurdsson G & Kanis JA (2014) THE INCIDENCE OF A FIRST MAJOR OSTEOPOROTIC FRACTURE IN ICELAND AND IMPLICATIONS FOR FRAX. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S316-S316)
Chakhtoura M, Cheung AM, Kanis JA, Leslie WD, McCloskey EV, Mcclung M & El-Hajj Fuleihan G (2014) FRAX BASED GUIDELINES: IS A UNIVERSAL MODEL APPROPRIATE?. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S121-S122)
McCloskey EV (2014) GOAL ORIENTED TREATMENT IN OSTEOPOROSIS: LESSONS FROM OTHER DISEASES AREAS. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S144-S144)
McCloskey EV (2014) PREVENTION OF BONE METASTASES. OSTEOPOROSIS INTERNATIONAL, Vol. 25 (pp S152-S152)
Harvey N, Johansson H, Oden A, Bauer D, Glueer C-C, Hans D, Kaptoge S, Krieg M-A, Kwok T, Marin F , Moayyeri A et al (2014) Performance Characteristics of Heel Quantitative Ultrasound (QUS) for the Assessment of Fracture Risk; an Individual-level Meta-analysis.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S177-S177)
Kanis J, Oden A, Johansson H, Burge R, Mitlak B & McCloskey E (2014) FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S321-S321)
Johansson H, Oden A, Lorentzon M, McCloskey E, Harvey N, Kanis J, Karlsson M & Mellstrom D (2014) Is the Swedish FRAX Model Appropriate for Immigrants to Sweden?.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S305-S305)
McCloskey E, Johansson H, Oden A, Harvey N, Compston J & Kanis J (2014) Assessment and Intervention Thresholds for FRAX probabilities in the UK - An Evaluation of adjusting Thresholds in Older Postmenopausal Women.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 29 (pp S46-S46)
Kanis JA, Johansson H, Oden A & McCloskey EV (2013) COUNTRY, CULTURE & RISK IN ASIA-PACIFIC. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S515-S515)
Chan D-C, McCloskey EV, Lin K-P, Wen C-J, Tsou H-H, Lim LC, Hwang J-S, Tsai K-S & Yang R-S (2013) COST-EFFECTIVE FRAX PROBABILITY THRESHOLDS FOR ALENDRONIC ACID USE IN TAIWAN. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S587-S588)
Johansson H, Leslie WD, Kanis JA, Lamy O, Oden A, McCloskey EV & Hans D (2013) DERIVATION OFA LUMBAR SPINE TRABECULAR BONE SCORE (TBS) ADJUSTMENT RATIO FOR FRAX: THE MANITOBA BMD COHORT. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S624-S625)
Leslie WD, Johansson H, Kanis JA, Lamy O, Oden A, McCloskey EV & Hans D (2013) LUMBAR SPINE TEXTURE FROM TBS ENHANCES FRACTURE RISK ASSESSMENT IN CLINICAL PRACTICE: THE MANITOBA BMD COHORT. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S555-S556)
McGowan B, Silke C, Doherty J, Johannsen H, McCloskey E, Kanis J & Whelan B (2013) Development of the FRAX model for Ireland. IRISH JOURNAL OF MEDICAL SCIENCE, Vol. 182 (pp S103-S103)
Brennan S, Leslie W, Lix L, Johansson H, Oden A, McCloskey E & Kanis J (2013) Is lower income associated with an increased likelihood of qualification for treatment for osteoporosis in Canadian women?. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
Brennan S, Leslie W, Lix L, Johansson H, Oden A, McCloskey E & Kanis J (2013) The Performance of FRAX (R) According to Different Levels of Socioeconomic Status. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
Hans D, Kanis JA, Johansson H, Oden A, McCloskey E & Leslie WD (2013) LUMBAR SPINE TRABECULAR BONE SCORE (TBS) IS A FRAX INDEPENDENT RISK FACTOR FOR FRACTURE: THE MANITOBA BMD COHORT. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S308-S308)
Johansson H, Kanis JA, Oden A & McCloskey E (2013) MILD MORPHOMETRIC VERTEBRAL FRACTURES PREDICT VERTEBRAL FRACTURES BUT NOT NONVERTEBRAL FRACTURES. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S310-S311)
Johansson H, Oden A, McCloskey E & Kanis JA (2013) THE WORLDWIDE BURDEN OF HIP FRACTURES AND THE IMPACT OF OSTEOPOROSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S270-S270)
Mellstrom D, Johansson H, Oden A, Karlsson M, McCloskey E & Kanis JA (2013) BONE AREA OF THE RADIUS CONTRIBUTES TO HIP FRACTURE RISK INDEPENDENTLY OF BMD. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S268-S269)
Johansson H, Oden A, Mccloskey E & Kanis JA (2013) THE EFFECT OF LATITUDE AND SEASONAL VARIATION ON THE RISK OF HIP FRACTURE IN SWEDEN. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S46-S47)
McCloskey E (2013) ASSESSMENT OF OSTEOPOROSIS: EUROPEAN GUIDANCE FOR THE DIAGNOSIS, ASSESSMENT AND TREATMENT OF OSTEOPOROSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S80-S81)
Johansson H, Oden A, Karlsson M, Ljunggren O, Mccloskey E, Kanis JA, Ohlsson C & Mellstrom D (2013) ADIPONECTIN AND 10-YEAR PROBABILITY OF FRACTURE IN ELDERLY MEN: MR OS SWEDEN. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S47-S47)
McCloskey E (2013) SECONDARY PREVENTION: A CALL TO ACTION. OSTEOPOROSIS INTERNATIONAL, Vol. 24 (pp S28-S29)
Ivergard M, Wintzell V, Tanko LB, Barghout V, Svedbom A, Alekna V, Bianchi ML, Clark P, Diaz Curiel M, Dimai HP , Juerisson M et al (2013) The Quality Of Life and Resource Use Related To Hip Fractures Based On Data From The International Costs and Utilities Related To Osteoporotic Fractures Study.. ARTHRITIS AND RHEUMATISM, Vol. 65 (pp S520-S520)
Krakauer AH, Blundell M, Scanlan T, Wechsler M, Mccloskey E, Yu J & Patricelli GL (2013) Successful Sage-grouse Show Greater Laterality in Social Behaviors. INTEGRATIVE AND COMPARATIVE BIOLOGY, Vol. 53 (pp E313-E313)
Johansson H, Oden A, Karlsson M, Rosengren B, Ljunggren O, McCloskey E, Kanis J, Ohlsson C & Mellstrom D (2013) FRAX (R) Predicts Future Falls in Elderly Men. MrOs Sweden. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
Leslie W, Kanis J, Lamy O, Johansson H, Oden A, McCloskey E & Hans D (2013) Lumbar Spine Trabecular Bone Score (TBS) combined with FRAX improves fracture prediction: The Manitoba BMD Cohort. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
Leslie W, Lix L, Morin S, Majumdar S, Johansson H, McCloskey E, Oden A & Kanis J (2013) Can Changes in FRAX Probability Be Used to "Treat-to-Target"? A Clinical Feasibility Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
Johansson H, Oden A, Karlsson M, McCloskey E, Kanis J, Ohlsson C & Mellstrom D (2013) Could Fracture Risk Assessment in Elderly Men Be Improved by Adiponectin? Mr Os Sweden. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
McCloskey E, Oden A, Kanis J & Johansson H (2013) Markers of Bone Turnover for Prediction of Fracture: a Meta-analysis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
Leslie W, Orwoll E, Nielson C, Morin S, Majumdar S, Johansson H, McCloskey E, Oden A & Kanis J (2013) Total Body Lean Mass and Fat Mass Differentially Affect Hip BMD and Strength Index in Women and Men But Are Not FRAX Independent Risk Factors for Fracture: A Large Clinical Cohort Study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 28
Udall W, Eastell R, McCloskey E, Paggiossi M & Yang L (2012) STRUCTURE ANALYSIS OF THE HIP QCT SCANS AND HIP FRACTURE RISK IN OLDER WOMEN. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S579-S579)
Johansson⁎ H, Kanis JA, Odén A, McCloskey E, Leslie WD, Eisman JA, Fujiwara S, Gluer CC, Kroger H, La Croix AZ , Lau E et al (2012) Adjustment of FRAX for women according to BMD at the lumbar spine. Bone, Vol. 50 (pp S52-S53)
Zheng⁎ H-F, Duncan E, Eriksson J, Bergström U, Yerges-Armstrong L, Leo P, Vandenput L, Nicholson G, Ladouceur M, Prince R , Leslie W et al (2012) The 7Q31 locus, containing WNT16, is associated with bone mineral density, osteoporotic fracture and bone strength. Bone, Vol. 50 (pp S33-S34)
Kanis JA, Johansson H, Oden A & McCloskey EV (2012) FRAX: WHERE ARE WE NOW?. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S54-S54)
McCloskey EV (2012) CURRENT CONTROVERSIES IN PRIMARY AND SECONDARY FRACTURE PREVENTION. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S53-S53)
McCloskey EV, Kanis JA, Oden A, Johansson H, Diez-Perez A, Jaeisman JA, Nguyen TV, Center JR, Hans D, Krieg M-A & Prior JC (2012) A META-ANALYSIS OF THE ASSOCIATION BETWEEN FALLS AND HIP FRACTURE RISK. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S80-S81)
Johansson H, Kanis JA, Oden A, McCloskey E, Chapurlat RD, Christiansen C, Cummings SR, Diez-Perez A, Eisman JA, Fujiwara S , Gluer CC et al (2012) HIGH BODY MASS INDEX, ADJUSTED FOR BMD, IS A RISK FACTOR FOR FRACTURE IN WOMEN. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S311-S312)
Johansson H, Kanis JA, Oden A, McCloskey E, Leslie WD, Eisman JA, Fujiwara S, Gluer CC, Kroger H, LaCroix AZ , Lau E et al (2012) IMPACT OF LUMBAR SPINE BMD ON FRAX IN WOMEN. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S65-S66)
Zheng H-F, Duncan E, Eriksson J, Bergstrom U, Yerges-Armstrong LM, Leo PJ, Vandenput L, Nicholson G, Ladouceur M, Prince RL , Leslie WD et al (2012) WNT16 IS ASSOCIATED WITH BONE MINERAL DENSITY, OSTEOPOROTIC FRACTURE AND BONE STRENGTH: A LARGE-SCALE META-ANALYSIS OF GENOMEWIDE ASSOCIATION STUDIES. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S402-S403)
Harvey NC, Cushnaghan J, Lawrence W, Ntani G, Collins K, Lenaghan L, Shepstone L, McCloskey E, Kanis J & Cooper C (2012) IS ANXIETY ASSOCIATED WITH FRACTURE RISK AND ADHERENCE TO TREATMENT? FINDINGS FROM THE MRC SCOOP TRIAL. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S200-S200)
Kanis J, Compston J, Cooper C, Hernlund E, Ivergard M, Johansson H, McCloskey E, Oden A, Stenmark J, Svedbom A & Jonsson B (2012) THE ECONOMIC BURDEN OF FRACTURES IN THE EUROPEAN UNION IN 2010. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S57-S57)
Harvey N, Cushnaghan J, Lawrence W, Ntani G, Collins K, Lenaghan L, Shepstone L, McCloskey E, Kanis J & Cooper C (2012) ANXIETY, FRACTURE RISK AND ADHERENCE TO TREATMENT: THE MRC SCOOP TRIAL. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S531-S531)
McCloskey E, Johansson H, Oden A & Kanis JA (2012) PITFALLS IN THE VALIDATION OF FRACTURE RISK ASSESSMENT TOOLS. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S302-S303)
McCloskey E, Johansson H, Oden A, Kanis JA & Leslie WD (2012) FRAX (R) WITHOUT BMD. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S305-S305)
Kanis JA, Johansson H, Oden A & McCloskey E (2012) EVIDENCE BASED EVALUATION OF CLINICAL RISK FACTORS USED IN THE ASSESSMENT OF FRACTURE RISK. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S309-S310)
Johansson H, Oden A, Lerner UH, Jutberger H, Lorentzon M, Barrett-Connor E, Karlsson MK, Ljunggren O, Smith U, McCloskey E , Kanis JA et al (2012) HIGH SERUM ADIPONECTIN PREDICTS INCIDENT FRACTURES IN ELDERLY MEN: MR OS SWEDEN. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S306-S307)
Oden A, Johansson H, McCloskey E & Kanis JA (2012) LIMITATIONS OF AREA UNDER THE ROC CURVE. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S196-S196)
Johansson H, Oden A, McCloskey E & Kanis JA (2012) COMPARING OUTPUTS OF THE FRAX AND GARVAN FRACTURE RISK ASSESSMENT TOOLS. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S306-S306)
Jakob FJ, Palacios S, Audran M, Brandi ML, Broll J, Hamdy N & McCloskey E (2012) FINAL RESULTS OF A 3 YEARS PROSPECTIVE OBSERVATIONAL COHORT STUDY OF PATIENTS TREATED WITH STRONTIUM RANELATE. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S73-S73)
Kanis JA, Oden A, McCloskey E, Johansson H, Wahl DA & Cooper C (2012) A SYSTEMATIC REVIEW OF HIP FRACTURE INCIDENCE AND PROBABILITY OF FRACTURE WORLDWIDE. OSTEOPOROSIS INTERNATIONAL, Vol. 23 (pp S308-S308)
Neilly E, Gregory JS, Yoshida K, McCloskey E, Reid DM & Barr RJ (2011) 388 CAN LOW RESOLUTION DUAL ENERGY X-RAY ABSORPTIOMETRY IMAGES BE USED TO GRADE OSTEOARTHRITIS SEVERITY?. Osteoarthritis and Cartilage, Vol. 19 (pp S179-S179)
Gregson C, Poole K, Steel S, Ayuk J, McCloskey E, Fraser W & Tobias J (2011) Elevated sclerostin levels in individuals with high bone mass. Bone, Vol. 48 (pp S71-S72)
Breart G, Jacob FJ, Palacios S, Audran M, Brandi ML, Broll J, Hamdy NA & McCloskey EV (2011) NEW INTERIM ANALYSIS OF A PROSPECTIVE OBSERVATIONAL COHORT STUDY OF PATIENTS (N=13,069) TREATED WITH STRONTIUM RANELATE. OSTEOPOROSIS INTERNATIONAL, Vol. 22 (pp 269-270)
McCloskey EV, Oden A, Johansson H & Kanis JA (2011) FRAX (R) 2 YEARS AFTER ITS LAUNCH. OSTEOPOROSIS INTERNATIONAL, Vol. 22 (pp 94-94)
McCloskey E, Lewiecki M, Kanis J, Johansson H, Oden A, Austin M, Siris E, Wang A, Libanati C, Chapurlat R & Lorenc R (2011) DENOSUMAB REDUCES THE RISK OF CLINICAL OSTEOPOROTIC FRACTURES IN POSTMENOPAUSAL WOMEN, PARTICULARLY IN THOSE WITH MODERATE TO HIGH FRACTURE RISK AS ASSESSED WITH FRAX (R). OSTEOPOROSIS INTERNATIONAL, Vol. 22 (pp 103-103)
McCloskey E (2011) Care of the elderly: Preventing osteoporotic fractures in older people. Practitioner, Vol. 255(1736) (pp 19-22)
Strom O, Borgstrom F, Kanis J, Compston J, Cooper C, Stenmark J, McCloskey E, Oden A, Johansson H, Olson M & Jonsson B (2011) THE BURDEN OF FRACTURES IN FRANCE, GERMANY, ITALY, SPAIN, SWEDEN, AND THE UK. OSTEOPOROSIS INTERNATIONAL, Vol. 22 (pp 97-97)
Johansson H, Clark P, Carlos F, Olden A, McCloskey E & Kanis J (2011) Increasing Age and Sex Specific Rates of Hip Fracture in Mexico. Projections for 2050. JOURNAL OF RHEUMATOLOGY, Vol. 38(6) (pp 1197-1197)
McCloskey E (2011) KEEPING UP TO DATE: CLINICAL DECISION MAKING - WHAT IS THE EVIDENCE? OSTEOPOROSIS. RHEUMATOLOGY, Vol. 50 (pp 3-3)
McCloskey E, Johansson H, Compston J, Oden A & Kanis J (2011) A COMPARISON OF CASE-FINDING STRATEGIES FOR THE MANAGEMENT OF OSTEOPOROSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 22 (pp 270-270)
Johansson H, Oden A, McCloskey EV & Kanis JA (2010) GUIDANCE FOR THE ADJUSTMENT OF FRAX (R) ACCORDING TO THE DOSE OF GLUCOCORTICOIDS. OSTEOPOROSIS INTERNATIONAL, Vol. 21 (pp S771-S772)
Johansson H, Oden A, Kanis JA, McCloskey EV, Lorentzon M, Ljunggren O, Karlsson MK, Tivesten A, Barrett-Connor E, Ohlsson C & Mellstrom D (2010) LOW VITAMIN D IS RELATED TO INCREASED RISK OF DEATH IN ELDERLY MEN: MROS SWEDEN. OSTEOPOROSIS INTERNATIONAL, Vol. 21 (pp S772-S772)
Gauthier A, Kanis J, Martin M, Compston J, Borgstrom F, Cooper C & McCloskey E (2010) DEVELOPMENT AND VALIDATION OF AN EPIDEMIOLOGICAL MODEL TO ESTIMATE THE BURDEN OF POST-MENOPAUSAL OSTEOPOROSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 21 (pp 20-20)
Johansson H, McCloskey E, Oden A, Kanis J, Lorentzon M, Ljunggren O, Karlsson MK, Orwoll E, Tivesten A, Ohlsson C & Mellstrom D (2010) THE PATTERN OF MORTALITY ASSOCIATED WITH BONE MINERAL DENSITY IN ELDERLY MEN - MROS SWEDEN. OSTEOPOROSIS INTERNATIONAL, Vol. 21 (pp 101-102)
McCloskey E, Kanis J, Johansson H & Oden A (2010) FRAX (R) AND THE EFFECT OF RALOXIFENE ON VERTEBRAL AND NON-VERTEBRAL FRACTURE. OSTEOPOROSIS INTERNATIONAL, Vol. 21 (pp 22-22)
Johansson H, Oden A, Kanis J, Borgstrom F, Strom O, Mellstrom D & McCloskey E (2010) A TRANSLATIONAL APPROACH TO CLINICAL GUIDELINE DEVELOPMENT WITH FRAX (R) BASED ON THE GUIDELINES FOR SWEDEN. OSTEOPOROSIS INTERNATIONAL, Vol. 21 (pp 331-331)
McCloskey E, Johansson H, Oden A, Chines A & Kanis J (2010) BAZEDOXIFENE REDUCES NON-VERTEBRAL FRACTURES IN PATIENTS AT HIGH PROBABILITY OF FRACTURE. OSTEOPOROSIS INTERNATIONAL, Vol. 21 (pp 205-206)
McCloskey E, Johansson H, Oden A, Compston J & Kanis J (2010) A COMPARISON OF CASE-FINDING STRATEGIES FOR THE MANAGEMENT OF OSTEOPOROSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 21 (pp 330-330)
McCloskey E, Johansson H, Chines A, Oden A & Kanis J (2010) Bazedoxifene reduces non-vertebral fractures in patients at high probability of fracture. Bone, Vol. 46 (pp S26-S26)
Breart G, Jakob FJ, Palacios S, Audran M, Brandi ML, Broll J, Hamdy NA & McCloskey EV (2010) NEW INTERIM ANALYSIS OF A PROSPECTIVE OBSERVATIONAL COHORT STUDY OF PATIENTS TREATED WITH STRONTIUM RANELATE. OSTEOPOROSIS INTERNATIONAL, Vol. 21 (pp 166-166)
Clark⁎ EM, Hutchinson A, McCloskey E, Stone M, Martin J, Bhalla A & Tobias J (2009) Novel analysis of Margolis diagram allows identification of underlying vertebral fracture. Bone, Vol. 44 (pp S375-S376)
Yang L, Chen L, Rotter JM, Eastell R, McCloskey EV & Chen J (2009) To buckle or not to buckle: A finite element modelling of the proximal femur. BONE, Vol. 44(2) (pp S382-S383)
McCloskey EV (2009) The benefits of combining cohorts for mega-analysis. BONE, Vol. 44(2) (pp S205-S205)
Clark E, Hutchinson A, McCloskey E, Stone M, Martin J, Bhalla A & Tobias J (2009) NOVEL ANALYSIS OF MARGOLIS DIAGRAM ALLOWS IDENTIFICATION OF UNDERLYING VERTEBRAL FRACTURE. OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp S269-S269)
Clark E, Hutchinson A, McCloskey E, Stone M, Martin J, Bhalla A & Tobias J (2009) NOVEL ANALYSIS OF MARGOLIS PAIN DIAGRAM ALLOWS IDENTIFICATION OF UNDERLYING VERTEBRAL FRACTURE. RHEUMATOLOGY, Vol. 48 (pp I12-I12)
Aloumanis K, Eastell R & McCloskey EV (2009) The effect of a history of thyroid disease in skeletal and muscle health and the risk of fractures in elderly women. EUR J CLIN INVEST, Vol. 39 (pp 3-3)
Compston J, McCloskey E & Kanis J (2009) ASSESSMENT AND INTERVENTION THRESHOLDS FOR THE UK USING FRAX (R). OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp S281-S281)
McCloskey E, Johansson H, Oden A & Kanis J (2009) IMPACT OF VARYING BMD RESOURCES ON PREDICTION OF HIP FRACTURE USING FRAX. OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp S266-S266)
Johansson H, Kanis JA, Oden A, Johnell O & McCloskey E (2009) IMPACT OF VARYING BMD RESOURCES ON PREDICTION OF HIP FRACTURE USING FRAX. OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp S200-S200)
McCloskey E, Johansson H, Oden A & Kanis JA (2009) BAZEDOXIFENE REDUCES ALL CLINICAL FRACTURES AND MORPHOMETRIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN AT INCREASED FRACTURE RISK ASSESSED BY FRAX. OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp S199-S200)
Epstein S & McCloskey E (2009) EFFICACY OF ONCE-MONTHLY ORAL BISPHOSPHONATES (IBANDRONATE AND RISEDRONATE) IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS. OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp 146-146)
Breart G, Audran M, Brandi ML, Broell J, Hamdy N, Jakob F, McCloskey E & Palacios S (2009) GOOD SAFETY AND PERSISTENCE OF STRONTIUM RANELATE IN A PROSPECTIVE OBSERVATIONAL COHORT STUDY. OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp 94-94)
McCloskey E (2009) FRAX (R): WHAT IT IS AND WHAT IT ISN'T. OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp 183-183)
McCloskey E, Johansson H, Oden A, Johnell O & Kanis JA (2009) IMPACT OF VARYING BMD RESOURCES ON PREDICTION OF HIP FRACTURE USING FRAX (R). OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp 32-32)
McCloskey E, Johansson H, Oden A & Kanis JA (2009) BAZEDOXIFENE REDUCES ALL CLINICAL FRACTURES AND MORPHOMETRIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN AT INCREASED FRACTURE RISK ASSESSED WITH FRAX (R). OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp 16-17)
Strom O, Coelho J, Borgstrom F, Mccloskey E, Oden A, Johansson H & Kanis J (2009) COST-EFFECTIVENESS OF BAZEDOXIFENE IN THE UK AND SWEDEN INCORPORATING THE FRAX (R)-ALGORITHM. OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp 13-13)
Compston J, McCloskey E, Johansson H, Strom O, Borgstrom F, Oden A & Kanis JA (2009) CASE FINDING FOR THE MANAGEMENT OF OSTEOPOROSIS WITH FRAX® - ASSESSMENT AND INTERVENTION THRESHOLDS FOR THE UK. OSTEOPOROSIS INTERNATIONAL, Vol. 20 (pp 19-19)
Yang L, Peel N, Clowes J, McCloskey EV & Eastell R (2008) Use of DXA-based structural engineering models of the proximal femur to predict hip fracture. CALCIFIED TISSUE INT, Vol. 83(1) (pp 5-6)
Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T , McCloskey EV et al (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, Vol. 93(3) (pp 852-860)
McCloskey E, Johansson H, Oden A & Kanis JA (2008) Impact of Varying BMD Resources on Prediction of Hip Fracture using FRAX (TM). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 23 (pp S305-S305)
Compston JE, McCloskey E, Johansson H, Strom O, Borgstrorn F, Oden A & Kanis J (2008) Case Finding for the Management of Osteoporosis with FRAX - Assessment and Intervention Thresholds for the UK. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 23 (pp S82-S82)
Stroem O, Borgstroem F, McCloskey E, Anders O, Johansson H & Kanis JA (2008) Incorporating FRAX (TM) Algorithms in Models of Cost-effectiveness. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 23 (pp S8-S8)
Johansson H, Kayan K, Oden A, Kanis JA & McCloskey E (2008) Can fall risk be incorporated into fracture risk assessment algorithms?: A pilot study of responsiveness to bisphosphonates. CALCIFIED TISSUE INTERNATIONAL, Vol. 83(1) (pp 18-18)
Johansson H, Oden A, Kayan K, Kanis J & McCloskey E (2008) Can fall risk be incorporated into fracture risk assessment algorithms: A pilot study of responsiveness to bisphosphonates. CALCIFIED TISSUE INTERNATIONAL, Vol. 82 (pp S54-S54)
McCloskey E, Johansson H, Oden A, Aropuu S, Jalava T & Kanis J (2008) Efficacy of clodronate on fracture risk in women selected by 10-year fracture probability. OSTEOPOROSIS INTERNATIONAL, Vol. 19(11) (pp 1675-1675)
McCloskey E (2008) Vertebral deformities in men: How many are osteoporotic?. OSTEOPOROSIS INTERNATIONAL, Vol. 19(11) (pp 1664-1664)
Yan L, Peel N, Clowes J, McCloskey EV & Eastell R (2007) Use of DXA-Based structural engineering models of the proximal femur to predict hip fracture. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22 (pp S116-S116)
Schousboe JT, Taylor BC, Kiel DP, Ensrud KE, Wilson KE & McCloskey EV (2007) Abdominal Aortic Calcification (AAC) on Vertebral Fracture Assessment (VFA) images predicts incident myocardial infarction and stroke independent of clinical cardiovascular disease risk factors. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22 (pp S22-S22)
McCloskey E, Hannon R, Clack G, Miyamoto A & Eastell R (2007) Interaction between body mass index and bone turnover during aromatase inhibition: Evidence from the Letrozole (L), Exemestane (E), and Anastrozole (A) Pharmacodynamics (LEAP) trial. BONE, Vol. 40(6) (pp S161-S162)
Hadji P, Nickelsen T, Marin F, Farrerons J, McCloskey EV, Audran M, Boonen S, Anastasilakis A, Barker C & Obermaier-Pietsch GB (2007) Bone mineral density response to 2 years of continuous treatment with teriparatide: Final results from the EUROFORS study. OSTEOPOROSIS INTERNATIONAL, Vol. 18 (pp S7-S7)
McCloskey E, Johansson H, Oden A, Aropuu S, Jalava T & Kanis J (2007) Efficacy of clodronate on fracture risk in women selected by 10-year fracture probability. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22 (pp S17-S17)
McCloskey E (2007) Assessment of absolute fracture risk. ANNALS OF THE RHEUMATIC DISEASES, Vol. 66 (pp 29-29)
McCloskey E, Johansson H, Oden A & Kanis JA (2007) Comparison of European and WHO strategies for the identification of women at risk of hip fracture. OSTEOPOROSIS INTERNATIONAL, Vol. 18 (pp S23-S23)
McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A & Eastell R (2007) Interaction between body mass index and bone turnover during aromatase inhibition: Evidence from the letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial. JOURNAL OF CLINICAL ONCOLOGY, Vol. 25(18)
Bolton CE, Pettit RJ, Stone MD, McCloskey EV, Ionescu AA, Edwards PH, Evans WD & Shale DJ (2006) Bone thinning: Prevalent in COPD but early detection allows treatment opportunity before vertebral fracture occurs. THORAX, Vol. 61 (pp II83-II83)
Tobias JH, Hutchinson AP, Hunt LP, McCloskey EV, Stone MD, Martin JC, Thompson PW, Palferman TG & Bhalla AK (2006) Use of clinical risk factors to identify postmenopausal women with vertebral fractures.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S275-S275)
McCloskey E, Beneton M, Charlesworth D, Orgee J, Pande K, Kersh L, Cliffe J, Peel N, Aropuu S, Jalava T & Kanis J (2006) Offset of effect of bisphosphonates on fracture incidence - Evidence from a prospective controlled trial of clodronate.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S71-S71)
McCloskey E, Hannon R, Lakner G, Clack G, Finkelman RD & Eastell R (2006) The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial: A direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S71-S71)
Yang L, McCloskey EV & Eastell R (2006) A DXA-based composite beam model of the proximal femur for stress estimation. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1161-1161)
McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A & Eastell R (2006) The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial: A direct comparison of bone biochemical measurements between aromatase inhibitors (AIS) in healthy postmenopausal women. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1160-1160)
McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A & Eastell R (2006) The letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial: A direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 24(18) (pp 16S-16S)
Johnell O, Kanis JA, Johansson A, Oden A, Delmas PD, Eisman JA, Fujiwara S, Gluer C, Kroger H, McCloskey EV , Mellstrom D et al (2006) A comparison of bone mineral measurements for fracture prediction: A meta-analysis. OSTEOPOROSIS INTERNATIONAL, Vol. 17 (pp S162-S162)
Johnell O, Kanis JA, Johansson H, Oden A, Delmas PD, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Melton LJ , Pols H et al (2006) Prior clinical vertebral fractures are a particularly strong predictor of hip fracture: A meta-analysis. OSTEOPOROSIS INTERNATIONAL, Vol. 17 (pp S131-S131)
Tobias J, Hutchinson A, Hunt L, McCloskey E, Bhalla A & Stone M (2006) (Poster prize nominee - highly commended) - Use of clinical risk factors to identify postmenopausal women with vertebral fractures. OSTEOPOROSIS INTERNATIONAL, Vol. 17 (pp 408-409)
Kanis JA, Johnell O, Johansson H, Oden A, Delmas PD, Eisman JA, Fujiwara S, Gluer C, Kroger H, McCloskey EV , Melstrom D et al (2006) A comparison of bone mineral measurements for fracture prediction: A meta-analysis. OSTEOPOROSIS INTERNATIONAL, Vol. 17 (pp S9-S9)
McCloskey E, Hannon R, Lakner G, Clack G, Miyamoto A, Finkelman R & Eastell R (2006) Complete data from the letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamic (PD) 'LEAP' trial: direct comparison of safety parameters between aromatase inhibitors (Als) in healthy postmenopausal women.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S111-S111)
Obermayer-Pietsch B, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Anastasilakis A & McCloskey E (2006) Response of BMD to 24 months of teriparatide (rhPTH 1-34) in patients with and without prior antiresorptive treatment: Final results from the EUROFORS study.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S43-S43)
McCloskey E, deTakats D, Beneton M, Cliffe J, Reaney L, McGurk C, Charlesworth D, Jalava T & Kanis J (2006) Mild primary hyperparathyroidism is associated with low BMD, but not fracture risk, quality of life or mortality in community dwelling elderly women. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1149-1149)
McCloskey E (2006) Using risk factors for the diagnosis and treatment of osteoporosis. OSTEOPOROSIS INTERNATIONAL, Vol. 17 (pp S113-S114)
(2006) A DXA-based composite beam model of the proximal femur for stress estimation. CALCIFIED TISSUE INTERNATIONAL, Vol. 78 (pp S165-S165)
Yang L, McCloskey EV & Eastell R (2005) The cross section geometry of the femoral neck.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S65-S65)
Johnell O, Kanis JA, Oden A, Johansson H, Gluer C, Fujiwara S, McCloskey EV, Melton LJ & Delmas P (2005) A comparison of total hip BMD as a predictor of fracture risk: A meta-analysis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S4-S4)
McCloskey EV, Paterson AHG & Powles TJ (2005) Effects of oral clodronate (BONEFOS (R)) therapy on bone turnover and skeletal metastases in women with primary breast cancer.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S21-S21)
McCloskey E, Eastell R, Hannon RA, Lakner G, Miyamoto A & Clack G (2005) Initial results from the LEAP Study: the first direct comparison of safety parameters between aromatase inhibitors (AIs) in healthy postmenopausal women. BREAST CANCER RESEARCH AND TREATMENT, Vol. 94 (pp S101-S102)
McCloskey E, Powles T & Paterson A (2005) Skeletal protective effect of clodronate in primary breast cancer-bone mass, bone turnover, and skeletal-related events (SRE's). EJC SUPPLEMENTS, Vol. 3(2) (pp 97-97)
McCloskey E, deTakats D, Orgee J, Aropuu S, Jalava T, Cliffe J, Reaney L, McGurk C, Charlesworth D & Kanis JA (2005) Characteristics associated with non-persistence during daily therapy - Experience from the placebo wing of a community-based clinical trial.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S282-S282)
McCloskey E, Charlesworth D, Bostock J, Eastaugh J, Bonnet N, Beneton M, Jalava T & Kanis J (2005) Utility of MXA for detecting prevalent fractures - Experience from a large epidemiological study. BONE, Vol. 36 (pp S116-S116)
McCloskey E, Paterson AHG & Powles TJ (2005) Oral clodronate maintains bone mass in women with primary breast cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 23(16) (pp 12S-12S)
McCloskey E (2005) Vertebral deformities in men: How many are osteoporotic?. OSTEOPOROSIS INTERNATIONAL, Vol. 16(5) (pp S6-S7)
McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Beneton M, Charlesworth D, Rosnell J & Kanis J (2004) Early offset of the action of clodronate after 3 years of treatment in osteoporosis. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S55-S56)
Kanis JA, Johansson H, Oden A, De Laet C, Johnell O, Eisman JA, McCloskey EV, Mellstom D, Pols H, Reeve J , Silman A et al (2004) A meta-analysis of milk intake and fracture risk. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S429-S429)
Johnell O, Kanis JA, Johansson H, Oden A, De Laet C, Eisman JA, McCloskey EV, McCloskey EV, Mellstrom D, Melton LJ , Pols HAP et al (2004) A family history of fracture and fracture risk: A meta-analysis.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S91-S91)
Barker ME, McCloskey EV, Saha S, Gossiel F, Powers HJ & Blumsohn A (2004) Plasma retinol and retinyl esters as predictors of incident osteoporotic fracture in elderly women.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S6-S6)
Brown JE, McCloskey E, Dewar JA, Body JJ, Cameron DA, Purohit OPK, Harnett A, Tahtela R, Kurkilahti M & Coleman RE (2004) A double blind, parallel, placebo controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 743S-743S)
McCloskey EV, Vasireddy S, Cliffe J, Reaney L, Charlesworth D, McGurk C, Jalava T, Beneton MNC & Kanis JA (2004) Fractures and all-cause mortality in a population sample of elderly women; Observations from the MRC HIP study. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(6) (pp 1032-1032)
Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D , Melton LJ et al (2004) Smoking and fracture risk: A meta-analysis. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S10-S10)
Vasireddy S, Cliffe J, Reaney L, Charlesworth D, McGurk C, Jalava T, Beneton MNC, Kanis JA & McCloskey EV (2004) Fractures and all-cause mortality in a population sample of elderly women: Observations from the MRC HIP study. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S9-S9)
Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Garnero P, Fujiwara S, Kroger H , McCloskey EV et al (2004) A meta-analysis of BMD as a predictor of fracture risk. OSTEOPOROSIS INTERNATIONAL, Vol. 15 (pp S5-S5)
McCloskey E, de Takats D, Beneton M, Cliffe J, Reaney L, McGurk C, Charlesworth D, Jalava T & Kanis J (2004) Mild primary hyperparathyroidism is associated with low BMD but not fracture risk, quality of life or mortality in community dwelling elderly women.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19 (pp S102-S102)
Powles T, Paterson A, McCloskey E, Kurkilahti M & Kanis J (2004) Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 9S-9S)
Vasireddy S, Kayan K, Jalava T, McGurk C, Reaney L, Kanis J & McCloskey E (2004) EFFECT OF MEDICAL RISK FACTORS, MUSCLE STRENGTH AND FALLS HISTORY ON FRACTURE INCIDENCE. RHEUMATOLOGY, Vol. 43 (pp 56-56)
Powles T, McCloskey E & Paterson A (2004) Oral clodronate (BONEFOS (R)) reduces skeletal complications and mortality in breast cancer patients with bone metastases: retrospective analysis of patients from a randomized, placebo-controlled trial. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S131-S131)
Bal S, McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Dey A, Ashford R, deTakats D , Beneton M et al (2003) Offset of the action of Clodronate (Bonefos (R)) after 3 years of treatment in women with osteoporosis.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S159-S159)
Csupor E, Toth E, Ferencz V, Szucs J, Lakatos P, Horanyi J, Perner F, McCloskey EV & Horvath C (2003) Does the location of the parathyroid adenoma influence kidney stone formation in primary hyperparathyroidism?. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S391-S391)
Kanis JA, Oden A, Johansson H, De Laet C, McCloskey EV, Kayan K, Jalava T, Oglesby A & Johnell O (2003) The use of BMD for therapeutic decision making.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S57-S57)
McCloskey E, Jalava T, Oden A, Johansson H, Kayan K, Beneton M, Brazier J, Nicholl J, Richards A, Cliffe J , Reaney L et al (2003) The efficacy of clodronate (Bonefos (R)) to reduce the incidence of osteoporotic fractures in elderly women is independent of the underlying BMD.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S92-S92)
Vasireddy S, Bal SK, Reaney L, Kanis JA & McCloskey EV (2003) Semi-automated metacarpal morphometry (metacarpal cortical index) predicts fracture risk in elderly women. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18(7) (pp 1374-1374)
Pande KC, Pande SK, DeTakats D & McCloskey EV (2003) The use of plain radiograph of the calcaneum for evaluation of osteoporosis?. BONE, Vol. 32(5) (pp S179-S179)
Kanis JA, Oden A, Johansson H, De Laet C, McCloskey EV, Kayan K, Jalava T & Johnell O (2003) Optimisation of case finding with bone mineral density. BONE, Vol. 32(5) (pp S142-S142)
Kanis JA, Delmas P, Reeve J, Garnero P, Tenenhouse A, Melton JL, Oden A, McCloskey EV, Pols H & De Laet C (2003) A meta-analysis of previous fracture and fracture risk. BONE, Vol. 32(5) (pp S84-S84)
Bal SK, Powles T, Paterson S, Kanis JA, Ashley S, Tidy A, Beneton M, Atula S, Nevalainen J, Pylkkanen L & McCloskey EV (2003) Adjuvant clodronate therapy in primary operable breast cancer - Duration and offset of effects on bone mineral density. OSTEOPOROSIS INTERNATIONAL, Vol. 14 (pp S10-S10)
Sanders DS, Patel D, Khan FB, Westbrook RH, Webber CV, Ward AM, Lobo AJ & McCloskey EV (2003) The prevalence of unrecognised adult coeliac disease in patients with reduced bone mineral density: A case finding approach. GUT, Vol. 52 (pp A38-A38)
Vasireddy S, Haigh C, Adams JE, Jalava T, McCloskey E & Grp VOTS (2003) Digital X-ray radiogrammetry (DXR) of the metacarpals in the prediction of vertebral fracture and monitoring bone density in a study of Clodronate therapy. OSTEOPOROSIS INTERNATIONAL, Vol. 14 (pp S6-S6)
McCloskey E, Jalava T, Vasireddy S, Bal S, Beneton M, Charlesworth D, Kanis J & Blumsohn A (2003) Relative importance of BMD, markers of bone turnover, height and body weight as predictors of hip fracture - A prospective case-control study.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S84-S84)
Vasireddy S, Bal S, Reaney L, McGurk C, Kanis J & McCloskey E (2003) Metacarpal BMD and cortical index are significant predictors of hip fracture.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S65-S65)
De Laet CED, Johansson H, Johnell O, Kanis J, McCloskey EV, Mellstrom D, Melton LJ, Oden A, Delmas P, Garnero P , Oglesby A et al (2003) A meta-analysis of body mass index (BMI) as a predictor of fracture risk. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S21-S21)
Bal SK, Tahtela R, Paterson A, Powles T, Atula S, Kanis J, Vasireddy S, Nevalainen J & McCloskey E (2003) Biochemical markers of bone turnover are associated with risk of bone metastases in women with primary operable breast cancer. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18(7) (pp 1362-1362)
Bal SK, Kayan K, Richards A, Vasireddy S, Cliffe J, Hinch A, McGurk C, Jalava T, Beneton M, Kanis JA & McCloskey EV (2002) Maternal hip fracture and current smoking are not associated with hip fracture risk in elderly women in the UK.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 17 (pp S462-S462)
Toth E, Meszaros S, Ferencz V, Csupor E, Bors K, McCloskey EV & Horvath C (2002) Nasal calcitonin increases spinal bone density in male osteoporosis without vertebral deformity.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 17 (pp S275-S275)
Horvath C, Hosszu E, Meszaros S, Ferencz V, Bors K & McCloskey EV (2002) Senile defect in the renal activation of vitamin D.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 17 (pp S277-S277)
Vasireddy S, Haigh C, Reaney L, Adams J, Selby PL, Bal SK, Ashford R, Charlesworth D, Kanis JA, Jalava T , Beneton M et al (2002) Digital X-ray radiogrammetry indices,particularly MCI, can predict vertebral fracture risk in osteoporotic women.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 17 (pp S186-S186)
Haigh C, Reaney L, Adams J, Davies M, Selby PL, Robinson J, Francis R, Dey A, Kanis JA, Bostock J , Horvath C et al (2002) Digital X-ray radiogrammetry indices are sensitive to clodronate treatment in women with osteoporosis.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 17 (pp S231-S231)
McCloskey E, Kanis J, Paterson A, Powles T, Beneton M, Tahtela R, Atula S & Nevalainen J (2002) Serum PINP, an index of bone turnover, but not bone mineral density, may be predictive of bone metastases in women with primary operable breast cancer.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 76 (pp S142-S142)
Adams JE, Haigh C, Reaney L, Davies M, Javala T & McCloskey E (2002) Changes can be monitored by digital X-ray radiogrammetry (DXR) in women on clodronate treatment for osteoporosis. RADIOLOGY, Vol. 225 (pp 419-419)
Powles T, McCloskey E, Paterson A, Kanis J, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S , Pajunen M et al (2002) Clodronate decreases the incidence of skeletal metastases in primary breast cancer - A randomised, placebo-controlled study.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 17 (pp S185-S185)
Atula S, Kants J, McCloskey E, Paterson A, Pylkkanen L, Nevalamen J & Powles T (2002) Safety profile of oral clodronate during long-term use in breast cancer patients. BONE, Vol. 30(3) (pp 46S-46S)
Ashford RU, Dey A, Kayan K, Delaney H, Nissen DS, Ambjerg D, Reaney L, McGurk C & McCloskey E (2001) Digital X-ray Radiogrammetry predicts hip fracture in elderly women.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 16 (pp S194-S194)
Ashford RU, Powles T, Paterson S, Beneton M, Kanis J, Spector T, Pylkkanen L, Nevalainen J & McCloskey E (2001) BMD at diagnosis of primary operable breast doesn't influence the incidence of skeletal metastases.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 16 (pp S455-S455)
Kayan K, Ashford RU, Dey A, Charlesworth D, Bostock J & McCloskey EV (2001) HIP axis length a predictor of HIP fracture in elderly women in England. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 16(6) (pp 1182-1182)
Patel S, Kwan JTC, McCloskey E, McGee G, Thomas G, Johnson D, Wills R, Ogunremi L & Barron J (2000) Prevalence and causes of low bone density and fractures in kidney transplant patients.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 15 (pp S571-S571)
Jalava T, Mawer B, Sarna S, Pylkkanen L, Kanis JA & McCloskey E (2000) Health and vitamin D status in osteoporotic patients with and without vertebral fracture. OSTEOPOROSIS INTERNATIONAL, Vol. 11 (pp S97-S97)
Kanis JA, McCloskey EV, de Takats D & Pande K (1999) Clinical assessment of bone mass, quality and architecture. OSTEOPOROSIS INTERNATIONAL, Vol. 9 (pp 24-28)
deTakats D, McCloskey E, Bernard J, Orgee J, Coombes G, Khan S, Nicholl J, Brazier J, Beneton M, Charlesworth D & Kanis J (1997) Effects of clodronate on hip BMD in community-dwelling women: Randomised trial: 1 year results.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 12 (pp S490-S490)
McCloskey EV, Gray RL, Kanis JA, Luchetti M, diGiovine F & Ralston SH (1997) COLIA1 Sp1 polymorphism and bone mass in elderly women. J BONE MINER RES, Vol. 12 (pp S547-S547)
Powles TJ, McCloskey E, Paterson AHG, Ashley S, Tidy A & Kanis J (1997) The effect of oral clodronate on bone mineral density in women with primary breast cancer. EUROPEAN JOURNAL OF CANCER, Vol. 33 (pp 344-344)
Paterson AHG, Kanis JA, Powles T, McCloskey EV & Ashley S (1997) Clodronate as an adjuvant to hormone and chemotherapy in patients with breast cancer. ADJUVANT THERAPY OF CANCER VIII, Vol. 8 (pp 153-162)
McCloskey EV, McLennan I, Chapman K, Grayson M & Kanis JA (1996) Vertebral fracture, loss of height and treatment with clodronate in myeloma.. J BONE MINER RES, Vol. 11 (pp T732-T732)
Beneton MNC, deTakats BJ, McCloskey EV & Kanis JA (1996) Image-based ultrasound attenuation assessment of the heel.. J BONE MINER RES, Vol. 11 (pp S611-S611)
Kanis JA, McCloskey EV, MacLennan I, Drayson M, Chapman C & Dunn J (1996) Effect of clodronate on the natural history of myelomatosis. BRIT J HAEMATOL, Vol. 93 (pp 1136-1136)
Kanis JA, McCloskey EV, Beneton MNC, Bernard J & deTakats D (1996) Bone measurements with DXA and ultrasound: Diagnostic and prognostic use. OSTEOPOROSIS 1996, Vol. 1118 (pp 181-190)
Bernard J, McCloskey E, deTakats D, Luchetti M, Parry A, Beneton M & Kanis JA (1996) Tibial ultrasound velocity and skeletal status in the normal population.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 11 (pp S632-S632)
deTakats D, McCloskey E, Bernard J, Beneton M, Charlesworth D & Kanis JA (1996) Comparison of normative data for skeletal assessment at the spine, hip and forearm.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 11 (pp S588-S588)
McCloskey EV, MacLennan ICM, Drayson M, Chapman C, Dunn J & Kanis JA (1995) Effect of clodronate on progression of skeletal disease in multiple myelomatosis. EUR J CANCER, Vol. 31A (pp 775-775)
Paterson AHG, McCloskey EV, Ashley S, Powles T & Kanis JA (1995) Effect of oral clodronate in women with recurrent breast cancer in the absence of skeletal metastases. EUR J CANCER, Vol. 31A (pp 368-368)
KANIS JA, POWLES TJ, PATERSON AHG, MCCLOSKEY EV & ASHLEY S (1995) CLODRONATE DECREASES THE FREQUENCY OF SKELETAL METASTASES IN WOMEN WITH BREAST-CANCER. J BONE MINER RES, Vol. 10 (pp S194-S194)
TAUBE T, MCCLOSKEY E, KHAN S, ORGEE J, COOMBES G, PHILLIPS R & KANIS J (1995) PHYSICAL RISK-FACTORS FOR HIP FRACTURE IN ELDERLY WOMEN IN THE COMMUNITY AND NURSING-HOMES. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 10 (pp S362-S362)
COOMBES G, MCCLOSKEY E, ORGEE J, KHAN S, BENETON M, CHARLESWORTH D & KANIS J (1995) A COMPARISON OF RADIOGRAPHIC VERTEBRAL MORPHOMETRY AND MXA IN ESTABLISHED VERTEBRAL OSTEOPOROSIS. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 10 (pp S473-S473)
MCCLOSKEY E, KHAN S, ORGEE J, COOMBES G, TAUBE T, PHILLIPS R, BRAZIER J, NICHOLL J & KANIS J (1995) ORAL CLODRONATE PREVENTS BONE LOSS AT THE HIP IN ELDERLY WOMEN - A PILOT-STUDY. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 10 (pp S356-S356)
ORGEE J, MCCLOSKEY E, KHAN S, COOMBES G, BENETON M, CHARLESWORTH D & KANIS J (1995) SKELETAL STATUS OF ELDERLY WOMEN WITH AND WITHOUT VERTEBRAL DEFORMITY. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 10 (pp S473-S473)
KHAN S, BRENNAN P, NEWMAN G, GRAY R, MCCLOSKEY E & KANIS J (1995) PAGETS-DISEASE OF BONE AND UNVACCINATED DOGS. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 10 (pp S404-S404)
MCCLOSKEY E, DOYLE D, KANIS J & SPECTOR TD (1995) INCIDENCE OF VERTEBRAL DEFORMITY IN POSTMENOPAUSAL WOMEN - THE CHINGFORD-STUDY. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 10 (pp S260-S260)
REEVE J, LUNT M, FELSENBERG D, BENEVOLENSKAYA L, CANNATA J, DEQUEKER J, DODENHOF C, FALCH J, MCCLOSKEY E, MASARYK P , POLS H et al (1995) VARIATIONS IN VERTEBRAL DEFORMITY PREVALENCE IN EUROPE ARE STATISTICALLY DEPENDENT ON POPULATION DIFFERENCES IN BONE-DENSITY - THE EVOS-STUDY. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 10 (pp S260-S260)
KHAN S, MCCLOSKEY EV, SIRTORI P, NAKATSUKA K, FOSTER H & KANIS JA (1993) THE EFFECT OF ORAL ALENDRONATE IN THE TREATMENT OF PAGETS-DISEASE OF THE BONE. J BONE MINER RES, Vol. 8 (pp S286-S286)
MCCLOSKEY EV, ASHLEY S, PATERSON AHG, POWLES T & KANIS JA (1993) COMPLIANCE AND EFFICACY OF CLODRONATE IN METASTATIC SKELETAL DISEASE IN BREAST-CANCER. J BONE MINER RES, Vol. 8 (pp S286-S286)
MCCLOSKEY EV, ORGEE J, FOSTER H & KANIS JA (1993) RISK-FACTORS IN SENILE OSTEOPOROSIS. RECENT ADVANCES IN AGING SCIENCE, VOLS I AND II (pp 1145-1150)
Kanis JA, Aaron J, Beneton M & McCloskey E (1992) Treatment of established osteoporosis. European Journal of Internal Medicine, Supplement, Vol. 3(1) (pp 125-133)
SPECTOR TD, HALL GM & MCCLOSKEY EV (1992) THE PREVALENCE OF VERTEBRAL FRACTURES IN FEMALES WITH RHEUMATOID-ARTHRITIS. ARTHRITIS RHEUM, Vol. 35(9) (pp S130-S130)
MCCLOSKEY EV, ASHLEY S, PATERSON AHG, POWLES T & KANIS JA (1992) ORAL CLODRONATE REDUCES SKELETAL MORBIDITY IN METASTATIC BREAST-CANCER. J BONE MINER RES, Vol. 7 (pp S152-S152)
MCCLOSKEY EV, SPECTOR TD, EYRES KS, OROURKE N, FERN DE & KANIS JA (1992) RELATIONSHIP BETWEEN CRITERIA FOR VERTEBRAL DEFORMITY AND BONE MASS IN A POPULATION STUDY. J BONE MINER RES, Vol. 7 (pp S137-S137)
KHAN S, EYRES KS, MCCLOSKEY EV, FERN ED, OROUKE N & KANIS JA (1992) EFFECTS OF ORAL DICHLOROMETHYLENE DIPHOSPHONATE (CL2MDP) IN THE TREATMENT OF PAGETS-DISEASE OF BONE. J BONE MINER RES, Vol. 7 (pp S293-S293)
EYRES KS, FERN ED, MCCLOSKEY EV, KHAN S & KANIS JA (1992) EFFECTS OF INTRAVENOUS DICHLOROMETHYLENE DIPHOSPHONATE (CL2MDP) IN THE TREATMENT OF PAGETS-DISEASE OF BONE. J BONE MINER RES, Vol. 7 (pp S292-S292)
MCCLOSKEY EV, SPECTOR TD, EYRES KS, OROURKE N, FERN DE, MACLENNAN I & KANIS JA (1992) ASSESSMENT OF VERTEBRAL DEFORMITY - VALIDATION OF A NEW METHOD WITH HIGH SPECIFICITY. J BONE MINER RES, Vol. 7 (pp S185-S185)
SPECTOR TD, HALL GM & MCCLOSKEY EV (1992) THE PREVALENCE OF VERTEBRAL FRACTURES IN FEMALES WITH RHEUMATOID-ARTHRITIS. BRIT J RHEUMATOL, Vol. 31 (pp 94-94)
PATERSON AHG, ERNST DS, POWLES TJ, ASHLEY S, MCCLOSKEY EV & KANIS JA (1991) TREATMENT OF SKELETAL DISEASE IN BREAST-CANCER WITH CLODRONATE. BONE, Vol. 12 (pp S25-S30)
KANIS JA, MCCLOSKEY EV, OROURKE N, PRESTON E, GREAVES M, EYRES K & VASIKARAN S (1991) BISPHOSPHONATES IN THE MANAGEMENT OF HYPERCALCEMIA OF MALIGNANCY. TUMOUR INDUCED HYPERCALCAEMIA AND ITS MANAGEMENT, Vol. 176 (pp 59-70)
KANIS JA, MCCLOSKEY EV, EYRES KS, OROURKE N & AARON J (1991) DIAGNOSTIC METHODOLOGY IN THE EVALUATION OF OSTEOPOROSIS. REHABILITATION MEDICINE /, Vol. 928 (pp 79-94)
GRAY RES, YATES AJP, SMITH R, MURRAY S, RUSSELL RGG, MCCLOSKEY E & KANIS JA (1986) OPTIMIZING TREATMENT OF PAGETS-DISEASE OF BONE. CALCIFIED TISSUE INTERNATIONAL, Vol. 39 (pp A75-A75)
URWIN GH, PERCIVAL RC, GRAY RES, MURRAY S, HAMDY NAT, GALLOWAY J, GUILLANDCUMMING DF, MCCLOSKEY EV, WILLIAMS JL & KANIS JA (1986) CALCIUM AND PHOSPHATE HOMEOSTASIS IN DISSEMINATED PROSTATIC-CANCER - EVIDENCE FOR SECONDARY HYPERPARATHYROIDISM. CALCIFIED TISSUE INT, Vol. 39 (pp A107-A107)
Gossiel F, McCloskey E, Walsh J, Naylor K, Peel N & Eastell R () The response of fibroblast growth factor-23 to teriparatide in postmenopausal osteoporosis. Bone Abstracts

Datasets

Montefiori E, Kalkman B, Mazza C, Paggiosi M, McCloskey E & Henson W Data for paper "MRI-based anatomical characterisation of lower-limb muscles in older women".
Tai ZA, Montefiori E, Veen BV, Paggiosi M, McCloskey E, Viceconti M, Mazza C & Li X Femoral neck strain prediction during level walking using a combined musculoskeletal and finite element model approach.

Preprints

Axelsson KF, Wallander M, Johansson H, Harvey NC, Vandenput L, McCloskey E, Liu E, Kanis JA, Litsne H & Lorentzon M () Clinical Characteristics and Outcomes in Patients with Hospital-Based Diagnosis of Primary Hyperparathyroidism – a National Retrospective Cohort Study.
Almog YA, Rai A, Zhang P, Moulaison A, Powell R, Mishra A, Weinberg K, Hamilton C, Oates M, McCloskey E & Cummings SR () Deep Learning With Electronic Health Records for Short-Term Fracture Risk Identification: Crystal Bone Algorithm Development and Validation (Preprint), JMIR Publications Inc..
Forgetta V, Keller-Baruch J, Forest M, Durand A, Bhatnagar S, Kemp J, Morris JA, Kanis JA, Kiel DP, McCloskey EV , Rivadeneira F et al () Machine Learning to Predict Osteoporotic Fracture Risk from Genotypes, Cold Spring Harbor Laboratory.

Research group

Current Collaborators

Prof T Skerry
Prof M Brown

Postgraduate Students

Lucy Harris

Teaching activities: I am the educational lead and teaching coordinator for Musculoskeletal Medicine across the various phases of the undergraduate curriculum at the University of Sheffield, as well as teaching on postgraduate courses (e.g. MSc in Molecular Medicine, Molecular and Cellular Basis of Disease module).

Professional activities and memberships

I am currently secretary of the Bone Research Society, chair of the American Society for Bone and Mineral Research Ancillary Program Committee and a member of the National Specialty Group for Musculoskeletal Diseases.

I also chair the Implementation Committee of the National Osteoporosis Guidance Group.

School of Medicine and Population Health

School of Medicine and Population Health

Professor Eugene McCloskey

Current Projects

Featured publications

Journal articles

All publications

Journal articles

Chapters

Conference proceedings papers

Datasets

Preprints

Current Collaborators

Postgraduate Students

Links